Methods for editing single nucleotide polymorphisms using a programmable base editor system
A programmable adenosine base editor is used to precisely correct Mecp2 gene mutations in Rett syndrome, addressing the limitations of current gene therapy methods by avoiding overexpression risks and achieving targeted mutation reversal.
Patent Information
- Application Number
- JP2021513765
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-13
- Filing Date
- 2019-05-11
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2039-05-11
AI Technical Summary
Current gene therapy approaches for Rett syndrome, such as delivering functional Mecp2 using recombinant adeno-associated virus (rAAV), face challenges in precisely correcting mutations and inducing off-target edits, risking Mecp2 duplication syndrome phenotype due to heterogeneous mutations and X-linked mosaic expression.
Employing a programmable adenosine base editor (ABE) to precisely correct single nucleotide polymorphisms in the Mecp2 gene, converting A·T to G·C to reverse prevalent mutations causing Rett syndrome, thereby avoiding overexpression risks.
Precise correction of Mecp2 gene mutations in Rett syndrome, potentially reversing pathogenic mutations without inducing Mecp2 overexpression, offering a targeted therapeutic approach.
Smart Images

Figure 0007596259000039 
Figure 0007596259000040 
Figure 0007596259000041
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims priority to and the benefit of U.S. Provisional Patent Application No. 62 / 670,558, filed May 11, 2018, U.S. Provisional Patent Application No. 62 / 780,838, filed December 17, 2018, and U.S. Provisional Patent Application No. 62 / 817,986, filed March 13, 2019, each of which is incorporated herein by reference in its entirety. [Background technology]
[0002] Rett syndrome (RTT or RETT) is caused by a heterogeneous group of mutations in methyl-CpG-binding protein 2 (Mecp2) in the central nervous system (CNS) that impair or abolish the ability of its encoded protein to modify chromatin and transcriptional states. Gene therapy to deliver functional Mecp2 or RNA editing to repair endogenous Mecp2 mRNA transcripts, if delivered broadly throughout the CNS, offer promising approaches for therapeutic intervention. However, both approaches must overcome significant challenges to achieve therapeutic efficacy. Mecp2 gene therapy requires strict control of the gene dosage delivered per cell or risk mimicking the phenotype of Mecp2 duplication syndrome. RNA editing platforms are unable to precisely correct the most prevalent Mecp2 mutations, which account for over 45% of RTT diagnoses, and also induce undirected off-target editing with high efficiency.
[0003] The Mecp2 gene mutations that cause Rett syndrome are highly heterogeneous. As a result, the preferred strategy for treatment has been the delivery of wild-type Mecp2 delivered by recombinant adeno-associated virus (rAAV). Because this strategy is agnostic to the causative mutation in each individual, a successful gene therapy approach could provide a treatment option for a large portion of the RTT patient population. However, to date, this strategy has met with limited success. RTT patients are almost always heterozygous females, and random X-chromosome inactivation results in characteristic X-linked mosaic expression of wild-type and mutant Mecp2 within the central nervous system (CNS). Therefore, rAAV delivery and expression of wild-type Mecp2 in neurons that already express wild-type Mecp2 may partially mimic the phenotype of Mecp2 duplication syndrome. Consistent with this, the high transduction efficiency in the CNS of RTT model mice resulted in Mecp2 expression that was nearly twice as high as that seen in wild-type mice.
[0004] Thus, there is a need for novel compositions and methods for treating patients with Rett Syndrome.
[0005] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference. Unless otherwise indicated, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety. Summary of the Invention
[0006] As described below, the present invention features compositions and methods for precisely correcting pathogenic amino acids using programmable nucleobase editors. In particular, the compositions and methods of the present invention are useful for treating Rett syndrome (RTT). That is, the present invention provides compositions and methods for treating Rett syndrome that use adenosine (A) base editors (ABEs) to precisely correct single nucleotide polymorphisms in the endogenous Mecp2 gene to correct deleterious mutations (e.g., R133C, T158M, R255*, R270*, and R306C).
[0007] In one aspect, the invention provides a method of editing an MECP2 polynucleotide comprising a single nucleotide polymorphism (SNP) associated with Rett syndrome (RTT), the method comprising contacting the MECP2 polynucleotide with a base editor complexed with one or more guide polynucleotides, wherein the base editor comprises a polynucleotide-programmable DNA-binding domain and an adenosine deaminase domain, and wherein one or more of the guide polynucleotides targets the base editor to result in an A·T to G·C modification of the SNP associated with RTT.
[0008] In another aspect, the invention provides a cell produced by introducing a base editor, or a polynucleotide encoding a base editor, into a cell or a precursor thereof, wherein the base editor comprises a polynucleotide-programmable DNA-binding domain and an adenosine deaminase domain, and one or more guide polynucleotides that target the base editor to result in an A·T to G·C modification of an RTT-associated SNP.
[0009] In another aspect, the invention provides a method of treating RTT in a subject, the method comprising administering to the subject a base editor or a polynucleotide encoding a base editor, wherein the base editor comprises a polynucleotide-programmable DNA-binding domain and an adenosine deaminase domain, and one or more guide polynucleotides that target the base editor to result in an A·T to G·C modification of a SNP associated with RTT.
[0010] In another aspect, the invention provides (i) modified (engineered) SpCas9 comprising one or more of the amino acid substitutions L1111R, D1135V, G1218R, E1219F, A1322R, R1335V, T1337R, and L1111, D1135L, S1136R, G1218S, E1219V, D1332A, R1335Q, T1337, T1337L, T1337Q, T1337I, T1337V, T1337F, and T1337M, or their corresponding amino acid substitutions, and (ii) a base editor comprising an adenosine deaminase.
[0011] In another aspect, the invention provides (i) a modified SpCas9 that comprises one or more of the amino acid substitutions D1135L, S1136R, G1218S, E1219V, A1322R, R1335Q, and T1337, and L1111R, G1218R, E1219F, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, and T1337M, or their corresponding amino acid substitutions, and (ii) a base editor that comprises an adenosine deaminase.
[0012] In various embodiments, the contacting step is in a cell, a eukaryotic cell, a mammalian cell, or a human cell. In various embodiments, the cell is in vivo or ex vivo. In various embodiments, the modification is one or more of R106W, R168*, R133C, T158M, R255*, R270*, and R306C. In various embodiments, the A·T to G·C modification in the RTT-associated SNP changes a cysteine to an arginine, a methionine to a threonine, or a stop codon to an arginine in a methyl-CpG-binding protein 2 (MeCP2) polypeptide. In various embodiments, the RTT-associated SNP results in expression of a Mecp2 polypeptide containing an arginine at amino acid position 168, 133, 255, 270, or 306, or a threonine at position 158. In various embodiments, the polynucleotide-programmable DNA-binding domain is Streptococcus pyogenes Cas9 (SpCas9) or a variant thereof. In various embodiments, the polynucleotide-programmable DNA-binding domain comprises a modified SpCas9 with altered protospacer adjacent motif (PAM) specificity. In various embodiments, the altered PAM has specificity for the nucleic acid sequence 5'-NGT-3'. In various embodiments, the modified SpCas9 has the amino acid substitutions L1111R, D1135V, G1218R, E1219F, A1322R, R1335V, T1337R, and L1111, D1135L, S1136R, G1218S, E1219V, D1332A, D1332S, D1332T, D1332V, Contains one or more of D1332L, D1332K, D1332R, R1335Q, T1337, T1337L, T1337Q, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337H, T1337Q, and T1337M, or their corresponding amino acid substitutions.In various embodiments, the modified SpCas9 comprises one or more of the amino acid substitutions D1135L, S1136R, G1218S, E1219V, A1322R, R1335Q, and T1337, as well as L1111R, G1218R, E1219F, D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, D1332R, T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, and T1337M, or the corresponding amino acid substitutions. In various embodiments, the polynucleotide-programmable DNA-binding domain is a nuclease-inactive or nickase variant. In various embodiments, the nickase variant comprises the amino acid substitution D10A or its corresponding amino acid substitution. In various embodiments, the adenosine deaminase domain can deaminate adenosine in deoxyribonucleic acid (DNA). In various embodiments, the adenosine deaminase is a modified (altered) adenosine deaminase that does not occur in nature. In various embodiments, the adenosine deaminase is TadA deaminase. In various embodiments, the TadA deaminase is TadA*7.10. In various embodiments, the one or more guide RNAs comprise a CRISPR RNA (crRNA) and a transcoding small RNA (tracrRNA), wherein the crRNA comprises a nucleic acid sequence complementary to a Mecp2 nucleic acid sequence containing a SNP associated with RTT. In various embodiments, the base editor is complexed with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to a Mecp2 nucleic acid sequence comprising a SNP associated with RTT. In various embodiments, the cell is a neuron. In various embodiments, the neuron expresses a Mecp2 polypeptide. In various embodiments, the cell is from a subject with RTT.
[0013] The features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings. [Brief explanation of the drawings]
[0014] [Figure 1]
[0033] Figure 12 is a graph showing the percentage of accurate correction of the R255X RTT mutation using base editor variants with specificity for the NGT PAM.
[0015] [Figure 2]
[0033] Figure 12 is a graph showing the percentage of accurate correction of the R255X RTT mutation using base editor variants with specificity for the NGT PAM.
[0016] [Figure 3] 10 is a graph showing PAM variant optimization with the amino acid substitution T1337L. Figure 11 shows the percentage of accurate correction of the R255X RTT mutation using base editor variants with specificity for the NGT PAM.
[0017] [Figure 4]
[0023] Figure 12 is a graph showing the percentage of accurate correction of the R255X RTT mutation by PAM base editor variants with specificity for NGT PAMs generated by shuffling mutations from other characterized PAM variants. T1337Q was identified as important for editing efficiency.
[0018] [Figure 5] 12A-C are graphs showing the change in base editing efficiency when T1337 and D1332 are substituted with other amino acids. The percentage of accurate correction of the R255X RTT mutation using base editor variants with specificity for the NGT PAM is shown.
[0019] [Figure 6]
[0023] Figure 1 shows the importance of E1219V and R1335Q for base editing activity associated with T1337. Percentage of accurate correction of the R255X RTT mutation using base editor variants with specificity for the NGT PAM is shown.
[0020] [Figure 7]
[0023] Figure 12 is a graph showing the percentage of accurate correction of the R255X RTT mutation using PAM variant base editors with specificity for the NGT PAM variants listed in Table 8 and Table 9.
[0021] [Figure 8]
[0023] Figure 12 is a graph showing the percentage of accurate correction of the R255X RTT mutation using PAM variant base editors with specificity for the NGT PAM variants listed in Table 8 and Table 9.
[0022] [Figure 9]
[0023] Figure 11 is a graph showing the percentage of accurate correction of the R255X RTT mutation using PAM variant base editors with specificity for the NGT PAM variants listed in Table 10. DETAILED DESCRIPTION OF THE INVENTION
[0023] Described herein are compositions and methods that provide base editing and base editing systems that precisely correct one or more mutations in the methyl-CpG binding protein 2 (Mecp2) gene, which are causally linked to Rett syndrome (RTT), a progressive neurodevelopmental disorder and its symptoms. RTT is an X-linked dominant disorder that primarily affects females. It is associated with mutations in the Mecp2 gene in 96% of affected individuals and is characterized by apparently normal early development, followed by regression with loss of fine motor skills and effective communication, fixed movements, and apraxia or complete loss of gait. Additional clinical features in affected individuals include abnormally slowed head growth rate after birth, periodic breathing, gastrointestinal dysfunction, epilepsy, and scoliosis.
[0024] The most prevalent mutation causing RTT is a cytidine-to-thymidine (C→T) transition, resulting in a C·G to T·A base pair substitution. This substitution can be reversed to a wild-type, non-pathogenic genomic sequence by an adenosine base editor (ABE), which catalyzes an A·T to G·C substitution. By extension, highly prevalent mutations causing RTT are potential targets for reversing to a wild-type sequence using ABEs without the risk of inducing overexpression of the Mecp2 gene, as can occur with gene therapy. Thus, A·T to G·C DNA base editing has the potential to precisely correct one or more of the most prevalent RTT-causing mutations in the Mecp2 gene.
[0025] The following description and examples will explain the embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein and may therefore vary. Those skilled in the art will understand that there are numerous variations and modifications to the present disclosure that fall within its scope.
[0026] The headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0027] Although various features of the present disclosure may be described in the context of a single embodiment, these features may also be provided separately or in any suitable combination. Conversely, although the present disclosure may for clarity be described herein in the context of separate embodiments, the present disclosure may also be implemented in a single embodiment.
[0028] definition Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. The following references provide common definitions for many of the terms used in this invention to one of skill in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991).
[0029] In this application, the use of the singular includes the plural unless specifically stated otherwise. It should be noted that as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless stated otherwise. Furthermore, the use of the term "including" and other forms such as "include," "includes," and "included" is not limiting.
[0030] As used in this specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive and open-ended and do not exclude additional, unrecited elements or method steps. It is intended that any embodiment discussed herein can be implemented with respect to any method or composition of the disclosure, and vice versa. Furthermore, the compositions of the disclosure can be used to achieve the methods of the disclosure.
[0031] The terms "about" or "approximately" mean within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within one or more standard deviations per practice of the art. Alternatively, "about" can mean within 20%, 10%, 5%, or 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold of a value. When a particular value is described in this application and claims, unless otherwise stated, the term "about" should be assumed to mean within an acceptable error range for that particular value.
[0032] Ranges provided herein are understood to be shorthand for all of the values within that range. For example, the range 1 to 50 is understood to include any number, combination of numbers, or subrange in the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0033] References in the specification to "some embodiments," "one embodiment," "an embodiment," or "another embodiment" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least some embodiments of the disclosure, but not necessarily in all embodiments.
[0034] "Adenosine deaminase" refers to a polypeptide or fragment thereof capable of catalyzing the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine to inosine or deoxyadenosine to deoxyinosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). The adenosine deaminases provided herein (e.g., engineered adenosine deaminases, evolved adenosine deaminases) can be from any organism, such as bacteria.
[0035] By "agent" is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragment thereof.
[0036] "Ameliorate" means to reduce, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
[0037] "Alteration" means a change (increase or decrease) in the expression level or activity of a gene or polypeptide as detected by standard art-known methods such as those described herein. As used herein, alteration includes a 10% change in expression level, preferably a 25% change in expression level, more preferably a 40% change, and most preferably a 50% or greater change.
[0038] "Analog" refers to a molecule that is not identical but has similar functional or structural characteristics. For example, a polypeptide analog retains the biological activity of a corresponding naturally occurring polypeptide, but has certain biochemical modifications that enhance the function of the analog relative to the naturally occurring polypeptide. Such biochemical modifications can, for example, increase the analog's protease resistance, membrane permeability, or half-life without altering ligand binding. Analogs can include unnatural amino acids.
[0039] "Administering," as used herein, means providing one or more compositions described herein to a patient or subject. By way of example and without limitation, administration, e.g., injection, of a composition can be performed by intravenous (iv), subcutaneous (sc), intradermal (id), intraperitoneal (ip), or intramuscular (im) injection. One or more such routes can be employed. Parenteral administration can be, for example, by bolus injection or gradual perfusion over time. Alternatively, or concurrently, administration can be via the oral route.
[0040] "Cytidine deaminase" refers to a polypeptide or fragment thereof capable of catalyzing a deamination reaction that converts an amino group to a carbonyl group. In one embodiment, a cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine. PmCDA1 derived from Petromyzon marinus (Petromyzon marinus cytidine deaminase 1, "PmCDA1"), AID (activity-induced cytidine deaminase, AICDA) derived from mammals (e.g., human, pig, cow, horse, monkey, etc.), and APOBEC are exemplary cytidine deaminases.
[0041] "Methyl-CpG binding protein 2 (Mecp2) protein" refers to a polypeptide or fragment thereof having at least about 95% amino acid sequence identity to NCBI Accession No. NP_004983. In certain embodiments, the Mecp2 protein comprises one or more modifications relative to the following reference sequence: In certain embodiments, the Mecp2 protein associated with RTT comprises one or more mutations selected from R106W, R168*, R133C, T158M, R255*, R270*, and R306C. Exemplary Mecp2 amino acid sequences are provided below. 1 mvagmlglre eksedqdlqg lkdkplkfkk vkkdkkeeke gkhepvqpsa hhsaepaeag 61 kaetsegsgs apavpeasas pkqrrsiird rgpmyddptl pegwtrklkq rksgrsagky 121 dvylinpqgk afrskvelia yfekvgdtsl dpndfdftvt grgspsrreq kppkkpkspk 181 apgtgrgrgr pkgsgttrpk aatsegvqvk rvlekspgkl lvkmpfqtsp ggkaegggat 241 tstqvmvikr pgrkrkaead pqaipkkrgr kpgsvvaaaa aeakkkavke ssirsvqetv 301 lpikkrktre tvsievkevv kpllvstlge ksgkglktck spgrkskess pkgrsssass 361 ppkkehhhhh hhsespkapv pllpplpppp pepessedpt sppepqdlss svckeekmpr 421 ggslesdgcp kepaktqpav ataataaeky khrgegerkd ivsssmprpn reepvdsrtp 481 vtervs
[0042] "Mecp2 polynucleotide" refers to a nucleic acid molecule encoding a Mecp2 protein or a fragment thereof. Exemplary Mecp2 polynucleotide sequences, available at NCBI Accession No. NM_004992, are provided below. In certain embodiments, Mecp2 polynucleotides comprise one or more modifications relative to the following reference sequences: In certain embodiments, Mecp2 polynucleotides associated with RTT comprise one or more mutations selected from 316C>T, 397C>T, 473C>T, 763C>T, 808C>T, and 916C>T. 1 ccggcgtcgg cggcgcgcgc gctccctcct ctcggagaga gggctgtggt aaaagccgtc 61 cggaaaatgg ccgccgccgc cgccgccgcg ccgagcggag gaggaggagg aggcgaggag 121 gagagactgc tccataaaaa tacagactca ccagttcctg ctttgatgtg acatgtgact 181 ccccagaata caccttgctt ctgtagacca gctccaacag gattccatgg tagctgggat 241 gttagggctc agggaagaaa agtcagaaga ccaggacctc cagggcctca aggacaaacc 301 cctcaagttt aaaaaggtga agaaagataa gaaagaagag aaagagggca agcatgagcc 361 cgtgcagcca tcagcccacc actctgctga gcccgcagag gcaggcaaag cagagacatc 421 agaagggtca ggctccgccc cggctgtgcc ggaagcttct gcctccccca aacagcggcg 481 ctccatcatc cgtgaccggg gacccatgta tgatgacccc accctgcctg aaggctggac 541 acggaagctt aagcaaagga aatctggccg ctctgctggg aagtatgatg tgtatttgat 601 caatccccag ggaaaagcct ttcgctctaa agtggagttg attgcgtact tcgaaaaggt 661 aggcgacaca tccctggacc ctaatgattt tgacttcacg gtaactggga gagggagccc 721 ctcccggcga gagcagaaac cacctaagaa gcccaaatct cccaaagctc caggaactgg 781 cagaggccgg ggacgcccca aagggagcgg caccacgaga cccaaggcgg ccacgtcaga 841 gggtgtgcag gtgaaaaggg tcctggagaa aagtcctggg aagctccttg tcaagatgcc 901 ttttcaaact tcgccagggg gcaaggctga ggggggtggg gccaccacat ccacccaggt 961 catggtgatc aaacgccccg gcaggaagcg aaaagctgag gccgaccctc aggccattcc 1021 caagaaacgg ggccgaaagc cggggagatgt ggtggcagcc gctgccgccg aggccaaaaa 1081 gaaagccgtg aaggagtctt ctatccgatc tgtgcaggag accgtactcc ccatcaagaa 1141 gcgcaagacc cgggagacgg tcagcatcga ggtcaaggaa gtggtgaagc ccctgctggt 1201 gtccaccctc ggtgagaaga gcgggaaagg actgaagacc tgtaagagcc ctgggcggaa 1261 aagcaaggag agcagcccca aggggcgcag cagcagcgcc tcctcacccc ccaagaagga 1321 gcaccaccac catcaccacc actcagagtc cccaaaggcc cccgtgccac tgctcccacc 1381 cctgccccca cctccacctg agcccgagag ctccgaggac cccaccagcc cccctgagcc 1441 ccaggacttg agcagcagcg tctgcaaaga ggagaagatg cccagaggag gctcactgga 1501 gagcgacggc tgccccaagg agccagctaa gactcagccc gcggttgcca ccgccgccac 1561 ggccgcagaa aagtacaaac accgagggga gggagagcgc aaagacattg tttcatcctc 1621 catgccaagg ccaaacagag aggagcctgt ggacagccgg acgccccgtga ccgagagagt 1681 tagctgactt tacacggagc ggattgcaaa gcaaaccaac aagaataaag gcagctgttg 1741 tctcttctcc ttatgggtag ggctctgaca aagcttcccg attaactgaa ataaaaaata 1801 tttttttttc tttcagtaaa cttagagttt cgtggcttca gggtgggagt agttggagca 1861 ttggggatgt ttttcttacc gacaagcaca gtcaggttga agacctaacc agggccagaa 1921 gtagctttgc acttttctaa actaggctcc ttcaacaagg cttgctgcag atactactga 1981 ccagacaagc tgttgaccag gcacctcccc tcccgcccaa acctttcccc catgtggtcg 2041 ttagagacag agcgacagag cagttgagag gacactcccg ttttcggtgc catcagtgcc 2101 ccgtctacag ctcccccagc tccccccacc tcccccactc ccaaccacgt tgggacaggg 2161 aggtgtgagg caggagagac agttggattc tttagagaag atggatatga ccagtggcta 2221 tggcctgtgc gatcccaccc gtggtggctc aagtctggcc ccacaccagc cccaatccaa 2281 aactggcaag gacgcttcac aggacaggaa agtggcacct gtctgctcca gctctggcat 2341 ggctaggagg ggggagtccc ttgaactact gggtgtagac tggcctgaac cacaggagag 2401 gatggcccag ggtgaggtgg catggtccat tctcaaggga cgtcctccaa cgggtggcgc 2461 tagaggccat ggaggcagta ggacaaggtg caggcaggct ggcctggggt caggccggggc 2521 agagcacagc ggggtgagag ggattcctaa tcactcagag cagtctgtga cttagtggac 2581 agggggggg gcaaagggggg agggggg aatgttcttc cagttacttt ccaattctcc 2641 tttagggaca gcttagaatt atttgcacta ttgagtcttc atgttcccac ttcaaaacaa 2701 acagatgctc tgagagcaaa ctggcttgaa ttggtgacat ttagtccctc aagccaccag 2761 atgtgacagt gttgagaact acctggattt gtatatatac ctgcgcttgt tttaaagtgg 2821 gctcagcaca tagggttccc acgaagctcc gaaactctaa gtgtttgctg caattttata 2881 aggacttcct gattggtttc tcttctcccc ttccattct gccttttgtt catttcatcc 2941 tttcacttct ttcccttcct ccgtcctcct ccttcctagt tcatcccttc tcttccaggc 3001 agccgcggtg cccaaccaca cttgtcggct ccagtcccca gaactctgcc tgccctttgt 3061 cctcctgctg ccgtaccag ccccaccctg ttttgagccc tgaggaggcc ttgggctctg 3121 ctgagtccga cctggcctgt ctgtgaagag caagagagca gcaaggtctt gctctcctag 3181 gtagccccct cttccctggt aagaaaaagc aaaaggcatt tcccaccctg aacaacgagc 3241 cttttcaccc ttctactcta gagaagtgga ctggaggagc tgggcccgat ttggtagttg 3301 aggaaagcac agaggcctcc tgtggcctgc cagtcatcga gtggcccaac aggggctcca 3361 tgccagccga ccttgacctc actcagaagt ccagagtcta gcgtagtgca gcagggcagt 3421 agcggtacca atgcagaact cccaagaccc gagctgggac cagtacctgg gtccccagcc 3481 cttcctctgc tccccctttt ccctcggagt tcttcttgaa tggcaatgtt ttgcttttgc 3541 tcgatgcaga cagggggcca gaacaccaca catttcactg tctgtctggt ccatagctgt 3601 ggtgtagggg cttagaggca tgggcttgct gtgggttttt aattgatcag ttttcatgtg 3661 ggatcccatc tttttaacct ctgttcagga agtccttatc tagctgcata tcttcatcat 3721 attggtatat ccttttctgt gtttacagag atgtctctta tatctaaatc tgtccaactg 3781 agaagtacct tatcaaagta gcaaatgaga cagcagtctt atgcttccag aaacacccac 3841 aggcatgtcc catgtgagct gctgccatga actgtcaagt gtgtgttgtc ttgtgtattt 3901 cagttattgt ccctggcttc cttactatgg tgtaatcatg aaggagtgaa acatcataga 3961 aactgtctag cactccttg ccagtcttta gtgatcagga accatagttg acagttccaa 4021 tcagtagctt aagaaaaaac cgtgttgtc tctctggaa tggttagaag tgaggtt 4081 tgccccgttc tgtttgtaga gtctcatagt tggactttct agcatatatg tgtccattc 4141 cttatgctgt aaagcaagt cctgcaacca aactcccacc agcccaatcc ctgatccctg 4201 atcccttcca cctgctctgc tgatgacccc cccagctca cttctgactc ttccccagga 4261 agggagggg gtcagaga gaggtgagt cctccagaac tctcctcca aggacagaag 4321 gctcctgccc ccatagtgc ctcgaactcc tgcactacc aaaggacact ttchacgag 4381 agcgcagcat ccgaccaggt tgtcactgag aagatttta ttggtcag tggtttttt 4441 atgtattata cttagtcaa tgtaatgtgg cttctggaat cattgtccag agctgcttcc 4501 cgtcacctg gggtcatct gtcctgta aggagtgc gtgcccacc agggcccct 4561 gtcacccatg acagttcatt caggccgat gggcagtcg tggttgggaa cacagcattt 4621 caagcgtcac tttatttcat tcgggcccca cctgcagctc cctcaaagag gcagttgccc 4681 agcctctttc ccttccagtt tattccagag ctgccagtgg ggcctgaggc tccttagggt 4741 tttctctcta tttccccctt tcttcctcat tccctcgtct ttcccaaagg catcacgagt 4801 cagtcgcctt tcagcaggca gccttggcgg tttatcgccc tggcaggcag gggccctgca 4861 gctctcatgc tgcccctgcc ttggggtcag gttgacagga ggttggaggg aaagccttaa 4921 gctgcaggat tctcaccagc tgtgtccggc ccagttttgg ggtgtgacct caatttcaat 4981 tttgtctgta cttgaacatt atgaagatgg gggcctcttt cagtgaattt gtgaacagca 5041 gaattgaccg acagctttcc agtacccatg gggctaggtc attaaggcca catccacagt 5101 ctcccccacc cttgttccag ttgttagtta ctacctcctc tcctgacaat actgtatgtc 5161 gtcgagctcc ccccaggtct acccctcccg gccctgcctg ctggtgggct tgtcatagcc 5221 agtgggattg ccggtcttga cagctcagtg agctggagat acttggtcac agccaggcgc 5281 tagcacagct cccttctgtt gatgctgtat tcccatatca aaagacacag gggacaccca 5341 gaaacgccac atccccaat ccatcagtgc haaactagcc aacggcccca gcttctcagc 5401 tcgctggatg gcggaagctg ctactcgtga gcgccagtgc gggtgcagac aatcttctgt 5461 tgggtggcat cattccaggc ccgaagcatg aacagtgcac ctgggacagg gagcagcccc 5521 aaattgtcac ctgcttct gcccagcttt tcattgctt gagtgatg gcgaaagagg 5581 gtaatacca gacaacaact gccaagttgg gtggagaag gagttttctt agctgacaga 5641 atctctgaat ttaatcac ttagtaagcg gctcaagccc aggaggc agaggtac 5701 gagcggagtc ccctgcgcgg gaccatctgg aattggttta gcccagtgg agcctgacag 5761 ccagaactct gtgtccccg tctaccaca gctcctttc cagagcattc cagtcaggct 5821 ctctggctg actgggccag gggaggttac aggtaccagt tctttaagaa gatctttggg 5881 catatacatt tttagcctgt gtcattgccc caatggatt cctgtttcaa gttcacct 5941 gcagattcta ggactgtgt cctagacttc agggattcag ctgttctag agttcctacc 6001 atggagtggg tctggaggac ctgccggtg ggggggcaga gcctgctcc ctcggggtct 6061 tcctactctt tctctgctc tgacgggatt tgttgattct ctccattttg gtgtctttct 6121 cttttagata ttgtatcaat cttagaaaa ggcatagtct acttgttata aatcgttagg 6181 atactgcctc ccccagggtc taaattaca tattagagggg gaaaagctga acactgaagt 6241 cagttctcaa caatttagaa ggaaaacta gaaaacattt ggcagaaaat tacatttcga 6301 tgtttttgaa tgaatacgag caagctttta caacagtgct gatctaaaaa tacttagcac 6361 ttggcctgag atgcctggtg agcattacag gcaaggggaa tctggaggta gccgacctga 6421 ggacatggct tctgaacctg tctttggga gtggtatgga aggtggagcg ttcaccagtg 6481 acctggaagg cccagcacca ccctccttcc cactcttctc atcttgacag agcctgcccc 6541 agcgctgacg tgtcaggaaa acacccaggg aactaggaag gcacttctgc ctgaggggca 6601 gcctgccttg cccactcctg ctctgctcgc ctcggatcag ctgagccttc tgagctggcc 6661 tctcactgcc tcccaaggc cccctgcctg ccctgtcagg aggcagaagg aagcaggtgt 6721 gagggcagtg caaggagggga gcacaacccc cagctcccgc tccgggctcc gacttgtgca 6781 caggcagagc caggcaccctg gaggaaatcc taccttga ttcagaaca ttgggaat 6841 ttggaatct ctttgccc aaaccccat tctgtcctac ctttaatcag gtcctgctca 6901 gcagtgagag cagatgaggt gaaaaggcca agaggttgg ctcctgccca ctgatagccc 6961 ctctccccgc agtgttgtg tgtcaagtgg caagctgtt cttcctggtg accctgatta 7021 tatccagtaa cacatagact gtgcgcatag gcctgctttg tctcctat cctgggcttt 7081 tgtttgctt tttagtttg cttttagtttt tctgtccct tttattaac gcaccgacta 7141 Gacacacaa gcagttgaat tttatat atatctgtat attgcacaat tataaactca 7201 tttgttgt ggctccacac acacaaaaa agacctgtta aaattatacc tgttgcttaa 7261 'ttacaatatt tctgatacc atagcatagg acaaggaa aaaaaaag aaaaaaaga 7321 aaaaaaaacg aaatctgt ctgctgtca cttctctgt ccaagcagat tcgtggtctt 7381 ttcctcgctt ctttcaaggg ctttcctgtg ccaggtgaag gaggctccag gcagcaccca 7441 gttttgcac tcttgtttct cccgtgcttg tgaagaggt cccaagttc tggtgcagg 7501 agcgctccct tgacctgctg aagtccggaa cgtagtcggc acagcctggt cgccttccac 7561 ctctgggagc tggagtccac tggggtggcc tgactccccc agtccccttc ccgtgacctg 7621 gtcagggtga gcccatgtgg agtcagcctc gcaggcctcc ctgccagtag ggtccgagtg 7681 tgtttcatcc ttcccactct gtcgagcctg ggggctggag cggagacggg aggcctggcc 7741 tgtctcggaa cctgtgagct gcaccaggta gaacgccagg gaccccagaa tcatgtgcgt 7801 cagtccaagg ggtcccctcc aggagtagtg aagactccag aaatgtccct ttcttctccc 7861 ccatcctacg agtaattgca tttgcttttg taattcttaa tgagcaatat ctgctagaga 7921 gtttagctgt aacagttctt tttgatcatc tttttttaat aattagaaac accaaaaaaa 7981 tccagaaact tgttcttcca aagcagagag cattataatc accagggcca aaagcttccc 8041 tccctgctgt cattgcttct tctgaggcct gaatccaaaa gaaaaacagc cataggccct 8101 ttcagtggcc gggctacccg tgagcccttc ggaggaccag ggctggggca gcctctgggc 8161 ccacatccgg ggccagctcc ggcgtgtgtt cagtgttagc agtgggtcat gatgctcttt 8221 cccacccagc ctgggatagg ggcagaggag gcgaggaggc cgttgccgct gatgtttggc 8281 cgtgaacagg tgggtgtctg cgtgcgtcca cgtgcgtgtt ttctgactga catgaaatcg 8341 acgcccgagt tagcctcacc cggtgacctc tagccctgcc cggatggagc ggggcccacc 8401 cggttcagtg tttctgggga gctggacagt ggagtgcaaa aggcttgcag aacttgaagc 8461 ctgctccttc ccttgctacc acggcctcct ttccgtttga tttgtcactg cttcaatcaa 8521 taacagccgc tccagagtca gtagtcaatg aatatatgac caaatatcac caggactgtt 8581 actcaatgtg tgccgagccc ttgcccatgc tgggctcccg tgtatctgga cactgtaacg 8641 tgtgctgtgt ttgctcccct tccccttcct tctttgccct ttacttgtct ttctggggtt 8701 tttctgtttg ggtttggttt ggtttttatt tctccttttg tgttccaaac atgaggttct 8761 ctctactggt cctcttaact gtggtgttga ggcttatatt tgtgtaattt ttggtgggtg 8821 aaaggaattt tgctaagtaa atctcttctg tgtttgaact gaagtctgta ttgtaactat 8881 gtttaaagta attgttccag agacaaatat ttctagacac tttttcttta caaacaaaag 8941 cattcggagg gaggggatg gtgactgaga tgagaggga gagctgaaca gatgacccct 9001 gcccagatca gccagaagcc acccaaagca gtggagccca ggagtcccac tccaagccag 9061 caagccgaat agctgatgtg ttgccacttt ccaagtcact gcaaaaccag gttttgttcc 9121 gcccagtgga ttcttgtttt gcttcccctc cccccgagat tattaccacc atccccgtgct 9181 tttaaggaaa ggcaagattg atgtttcctt gaggggagcc aggaggggat gtgtgtgtgc 9241 agagctgaag agctggggag aatggggctg ggcccaccca agcaggaggc tgggacgctc 9301 tgctgtgggc acaggtcagg ctaatgttgg cagatgcagc tcttcctgga caggccaggt 9361 ggtgggcatt ctctctccaa ggtgtgcccc gtgggcatta ctgtttaaga cacttccgtc 9421 acatcccacc ccatcctcca gggctcaaca ctgtgacatc tctattcccc accctcccct 9481 tcccagggca ataaaatgac catggagggg gcttgcactc tcttggctgt cacccgatcg 9541 ccagcaaaac ttagatgtga gaaacccct tcccattcca tggcgaaaac atctccttag 9601 aaaagccatt accctcatta ggcatggttt tgggctccca aaacacctga cagcccctcc 9661 ctcctctgag aggcggagag tgctgactgt agtgaccatt gcatgccggg tgcagcatct 9721 ggaagagcta ggcagggtgt ctgccccctc ctgagttgaa gtcatgctcc cctgtgccag 9781 cccagaggcc gagagctatg gacagcattg ccagtaacac aggccaccct gtgcagaagg 9841 gagctggctc cagcctggaa acctgtctga ggttgggaga ggtgcacttg gggcacaggg 9901 agaggccggg acacacttag ctggagatgt ctctaaaagc cctgtatcgt attcaccttc 9961 agtttttgtg ttttgggaca attactttag aaaataagta ggtcgtttta aaaacaaaaa 10021 ttattgattg cttttttgta gtgttcagaa aaaaggttct ttgtgtatag ccaaatgact 10081 gaaagcactg atatatttaa aaacaaaagg caatttatta aggaaatttg taccatttca 10141 gtaaacctgt ctgaatgtac ctgtatacgt ttcaaaaaca cccccccccc actgaatccc 10201 tgtaacctat ttattatata aagagtttgc cttataaatt t
[0043] "Base editor (BE)" or "nucleobase editor (NBE)" refers to an agent that binds to a polynucleotide and has nucleobase-modifying activity. In various embodiments, the base editor comprises a nucleobase-modifying polypeptide (e.g., a deaminase) linked to a guide polynucleotide (e.g., a guide RNA) and a polynucleotide-programmable nucleotide-binding domain. In various embodiments, the agent is a biomolecular complex that includes a protein domain with base-editing activity, i.e., a domain that can modify a base (e.g., A, T, C, G, or U) in a nucleic acid molecule (e.g., DNA). In some embodiments, the polynucleotide-programmable DNA-binding domain is fused or linked to a deaminase domain. In one embodiment, the agent is a fusion protein that includes a domain with base-editing activity. In another embodiment, the protein domain with base-editing activity is linked to a guide RNA (e.g., via an RNA-binding motif on the guide RNA and an RNA-binding domain fused to a deaminase). In some embodiments, the domain with base-editing activity is capable of deaminating a base in a nucleic acid molecule. In some embodiments, the base editor is capable of deaminating a base in a DNA molecule. In some embodiments, the base editor is capable of deaminating cytosine (C) or adenosine (A) in DNA. In some embodiments, the base editor is a cytidine base editor (CBE). In some embodiments, the base editor is an adenosine base editor (ABE). In some embodiments, the adenosine deaminase is evolved from TadA. In some embodiments, the polynucleotide-programmable DNA-binding domain is a CRISPR-associated (e.g., Cas or Cpfl) enzyme. In some embodiments, the base editor is a catalytically dead Cas9 (dCas9) fused to a deaminase domain. In some embodiments, the base editor is a Cas9 nickase (nCas9) fused to a deaminase domain. In some embodiments, the base editor is fused to an inhibitor (inhibitor) of base excision repair (BER).In some embodiments, the inhibitor of base excision repair is a uracil DNA glycosylase inhibitor (UGI). In some embodiments, the inhibitor of base excision repair is an inosine base excision repair inhibitor. Details of base editors are described in International PCT Applications PCT / 2017 / 045381 (WO2018 / 027078) and PCT / US2016 / 058344 (WO2017 / 070632), each of which is incorporated herein by reference in its entirety. Also, Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage," Nature 533, 420-424 (2016); Gaudelli, NM, et al., "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage," Nature 551, 464-471 (2017); Komor, AC, et al., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity," Science Advances 3:eaao4774 (2017), and Rees, HA, et al., "Base editing: precision chemistry on the genome and transcriptome of living cells." Nat Rev Genet. 2018, the entire contents of which are incorporated herein by reference. Dec;19(12):770-788. See doi: 10.1038 / s41576-018-0059-1. By way of example, a cytidine base-editing CBE used in the base editing compositions, systems, and methods described herein has the following nucleic acid sequence (8877 base pairs) provided below: Addgene, Watertown, MA.; Komor AC, et al., 2017, Sci Adv., 30;3(8):eaao4774. doi: 10.1126 / sciadv.aao4774. Polynucleotide sequences having at least 95% or greater identity to the BE4 nucleic acid sequence are also encompassed. 1 atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgcc tggcattatg 61 cccagtacat gaccttatgg gactttccta cttggcagta catctacgta ttagtcatcg 121 ctattaccat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag cggtttgact 181 cacggggatt tccaagtctc caccccattg acgtcaatgg gagtttgttt tggcaccaaa 241 atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa atgggcggta 301 ggcgtgtacg gtgggaggtc tatataagca gagctggttt agtgaaccgt cagatccgct 361 agagatccgc ggccgctaat acgactcact atagggagag ccgccaccat gagctcagag 421 actggcccag tggctgtgga ccccacattg agacggcgga tcgagcccca tgagtttgag 481 gtattcttcg atccgagaga gctccgcaag gagacctgcc tgctttacga aattaattgg 541 gggggccggc actccatttg gcgacataca tcacagaaca ctaacaagca cgtcgaagtc 601 aacttcatcg agaagttcac gacagaaaga tatttctgtc cgaacacaag gtgcagcatt 661 acctggtttc tcagctggag cccatgcggc gaatgtagta gggccatcac tgaattcctg 721 tcaaggtatc cccacgtcac tctgtttatt tacatcgcaa ggctgtacca ccacgctgac 781 ccccgcaatc gacaaggcct gcgggatttg atctcttcag gtgtgactat ccaaattatg 841 actgagcagg agtcaggata ctgctggaga aactttgtga attatagccc gagtaatgaa 901 gcccactggc ctaggtatcc ccatctgtgg gtacgactgt acgttcttga actgtactgc 961 atcatactgg gcctgcctcc ttgtctcaac attctgagaa ggaagcagcc acagctgaca 1021 ttctttacca tcgctcttca gtcttgtcat taccagcgac tgcccccaca cattctctgg 1081 gccaccgggt tgaaatctgg tggttcttct ggtggttcta gcggcagcga gactcccggg 1141 acctcagagt ccgccacacc cgaaagttct ggtggttctt ctggtggttc tgataaaaag 1201 tattctattg gtttagccat cggcactaat tccgttggat gggctgtcat aaccgatgaa 1261 tacaaagtac cttcaaagaa atttaaggtg ttggggaaca cagaccgtca ttcgattaaa 1321 aagaatctta tcggtgccct cctattcgat agtggcgaaa cggcagaggc gactcgcctg 1381 aaacgaaccg ctcggagaag gtatacacgt cgcaagaacc gaatatgtta cttacaagaa 1441 atttttagca atgagatggc caaagttgac gattctttct ttcaccgttt ggaagagtcc 1501 ttccttgtcg aagaggacaa gaaacatgaa cggcacccca tctttggaaa catagtagat 1561 gaggtggcat atcatgaaaa gtacccaacg atttatcacc tcagaaaaaa gctagttgac 1621 tcaactgata aagcggacct gaggttaatc tacttggctc ttgcccatat gataaagttc 1681 cgtgggcact ttctcattga gggtgatcta aatccggaca actcggatgt cgacaaactg 1741 1801 ggcgtggatg cgaaggctat tcttagcgcc cgcctctcta aatcccgacg gctagaaaac 1861 ctgatcgcac aattacccgg agagaagaaa aatgggttgt tcggtaacct tagatcgctc 1921 tcactaggcc tgacaccaaa ttttaagtcg aacttcgact tagctgaaga tgccaaattg 1981 cagcttagta aggacacgta cgatgacgat ctcgacaatc tactggcaca attggagat 2041 cagtagcgg acttatttt ggctgccaa aaccttagcg atgcaatcct cctactcgac 2101 atactgagag ttatactga gattaccaag gcgccgtta ccgctcaat gatcaaagg 2161 tacgatgaac atcaccaga cttgacactt ctcaagccc tagtccgtca gcaactgcct 2221 gagaaata aggaaatatt cttgatcag tcgaaaaacg ggtacgcagg ttatattgac 2281 ggcggagcga gtcagagga attctacaag tttatcaac ccatattaga gagatggat 2341 gggacggaag agttgcttgt aaaaccaat cgcgagatc tactgcgaaa gcagcggact 2401 ttcgacacg gtagcattcc acatcaatc cacttaggcg aattgcatgc tatacttaga 2461 aggcaggagg atttttacc gttcccaaa gatacgtg aaagattga gaaaatccta 2521 acctttcgca taccttacta tgtgggaccc ctggcccgag ggaactcg gttcgcatgg 2581 atgacagaa agtccgaaga aacgattact ccatggaatt tgaggaagt tgtcgataaa 2641 gtgcgtcag ctcaatcgtt catcgagagg atgaccact ttgacagaa tttaccgac 2701 gaaaagtat tgcctaagca cagtttactt tacgagtatt tcacagtgta caatgaactc 2761 acgaaagtta agtatgtcac tgaggcatg cgtaaacccg cctttctaag cggagacag 2821 aagaaagcaa tagtagatct gttattcaag accaccgca aagtgacagt tagcattg 2881 aagaggact actttaagaa attgaatgc tcgattctg tcgagatc cggggtagaa 2941 gatcgattta atgcgtcact tgtacgtat catgacctcc taagataat taagataag 3001 gacttcctgg ataacgaaga gatgagat atcttagaag atagtgtt gactcttacc 3061 ctctttgaag atcgggaat gattgaggaa agactaaaa catacgctca cctgttcgac 3121 gataagtta tgaacagtt aaagaggcgt cgctatacgg gctgggacg attgtcgcgg 3181 aaacttatca acggataag agacaagcaa agtggtaaa ctattctcga ttttctaaag 3241 agcgacggct tcgccatag gaactttatg cagctgatcc atgatgactc tttaccttc 3301 aagaggata tacaaaggc acaggttcc ggacaagggg actcattgca cgaacatatt 3361 gcgaatcttg ctggttcgcc agccatcaa aagggcatac tccacagt caagtagtg 3421 gatgagctag ttaaggtcat gggacgtcac aaaccggaaa acattgtaat cgagatggca 3481 cgcgaaaatc aaacgactca gaagggcaa aaaaacagtc gagagcggat gaagagaata 3541 gaagggta ttaaagaact gggcagccag atcttaaagg agcatcctgt ggaaaatacc 3601 3661 3721 tccttttga aggacgattc aatcgacaat aaagtgctta cacgctcgga taagaaccga 3781 gggaaaagtg acaatgttcc aagcgaggaa gtcgtaaaga aaatgaagaa ctattggcgg 3841 3901 aggggtggct tgtctgaact tgacaaggcc ggatttatta aacgtcagct cgtggaaacc 3961 cgccaaatca caaagcatgt tgcacagata ctagattccc gaatgaatac gaatacgac 4021 gagaacgata agctgattcg ggaagtcaaa gtaatcactt taagtcaaa attggtgtcg 4081 4141 cacgacgctt atcttaatgc cgtcgtaggg accgcactca ttaagaata cccgaagcta 4201 gaagtgagt ttgtgtatgg tgattacaaa gtttatgacg tccgtagat gatcgcgaaa 4261 agcgacagg agataggcaa ggctacagcc aaatactct tttattctaa cattatgaat 4321 ttctttaga cggaatcac tctgcaac gagagagat gcaacgacc tttattgac 4381 accaatgggg agacaggtga aatcgtatgg gataagggcc gggactcgc gacggtgaga 4441 aaagttttgt ccatgcccca agtcacata gtaagaaaa ctgaggtgca gaccggaggg 4501 tttcaagg atcgattct tccaaaagg atagtgata agctcatcgc tcgtaaaag 4561 gactgggacc cgaaaagta cggtggctc gatagcccta cagttgccta ttctgtccta 4621 gtagtggcaa aagttgagaa gggaaaatcc aagaactga agtcagtcaa agaatttg 4681 gggataacga ttatggagcg ctcgtctttt gaaaagaacc ccatcgactt ccttgaggcg 4741 aaggttaca aggaagtaa aaaggatctc ataatttaac taccaagta tagtctgttt 4801 gagttagaaa atggccgaaa acggatgttg gctagcgccg gagagcttca aaagggaac 4861 gaactcgcac taccgtctaa atacgtgaat ttcctgtatt tagcgtccca ttacgagaag 4921 ttgaaaggtt cacctgaaga taacgaacag aagcaacttt ttgttgagca gcacaaacat 4981 tatctcgacg aaatcataga gcaaatttcg gaattcagta agagagtcat cctagctgat 5041 gccaatctgg acaaagtatt aagcgcatac aacaagcaca gggataaacc catacgtgag 5101 caggcggaaa atattatcca tttgtttact cttaccaacc tcggcgctcc agccgcattc 5161 aagtattttg acacaacgat agatcgcaaa cgatacactt ctaccaagga ggtgctagac 5221 gcgacactga ttcaccaatc catcacggga ttatatgaaa ctcggataga tttgtcacag 5281 cttgggggtg actctggtgg ttctggagga tctggtggtt ctactaatct gtcagatatt 5341 attgaaaagg agaccggtaa gcaactggtt atccaggaat ccatcctcat gctcccagag 5401 gaggtggaag aagtcattgg gaacaagccg gaaagcgata tactcgtgca caccgcctac 5461 gacgagagca ccgacgagaa tgtcatgctt ctgactagcg acgcccctga atacaagcct 5521 tgggctctgg tcatacagga tagcaacggt gagaacaaga ttaagatgct ctctggtggt 5581 tctggaggat ctggtggttc tactaatctg tcagatatta ttgaaaagga gaccggtaag 5641 caactggtta tccaggaatc catcctcatg ctcccagagg aggtggaaga agtcattggg 5701 aacaagccgg aaagcgatat actcgtgcac accgcctacg acgagagcac cgacgagaat 5761 gtcatgcttc tgactagcga cgcccctgaa tacaagcctt gggctctggt catacaggat 5821 agcaacggtg agaacaagat taagatgctc tctggtggtt ctcccaagaa gaagaggaaa 5881 gtctaaccgg tcatcatcac catcaccatt gagtttaaac ccgctgatca gcctcgactg 5941 tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg 6001 aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga 6061 gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg 6121 aagacaatag caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa 6181 ccagctgggg ctcgataccg tcgacctcta gctagagctt ggcgtaatca tggtcatagc 6241 tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca 6301 taaagtgtaa agcctagggt gcctaatgag tgagctaact cacattaatt gcgttgcgct 6361 cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac 6421 gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc 6481 tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt 6541 tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 6601 ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg 6661 agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 6721 accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 6781 ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct 6841 gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc 6901 ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa 6961 gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 7021 taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag 7081 tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagt ggtagctctt 7141 gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 7201 cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 7261 agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa agatcttca 7321 cctagatcct ttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 7381 cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgctat 7441 ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 7501 taccatctgg ccccagtgct gcaatgac cgcgagaccc acgctcaccg gctccagatt 7561 tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 7621 ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 7681 atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 7741 gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 7801 tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 7861 cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 7921 taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 7981 ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 8041 ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 8101 cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 8161 ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaagg 8221 gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa 8281 gcattatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaata 8341 aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc gacggatcgg 8401 gagatcgatc tcccgatccc ctagggtcga ctctcagtac aatctgctct gatgccgcat 8461 agttaagcca gtatctgctc cctgcttgtg tgttggaggt cgctgagtag tgcgcgagca 8521 aaatttaagc tacaacaagg caaggcttga ccgacaattg catgaagaat ctgcttaggg 8581 ttaggcgttt tgcgctgctt cgcgatgtac gggccagata tacgcgttga cattgattat 8641 tgactagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca tatatggagt 8701 tccgcgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac gacccccgcc 8761 cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact ttccattgac 8821 gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa gtgtatc BE4 amino acid sequence:
[0044] By way of example, the adenine base-editing ABE used in the base-editing compositions, systems, and methods described herein has the following nucleic acid sequence (8877 base pairs) provided below (Addgene, Watertown, MA; Gaudelli NM, et al., Nature. 2017 Nov 23;551(7681):464-471. doi: 10.1038 / nature24644; Koblan LW, et al., Nat Biotechnol. 2018 Oct;36(9):843-846. doi: 10.1038 / nbt.4172.). Polynucleotide sequences having at least 95% or greater identity to the ABE nucleic acid sequence are also encompassed. ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACAT GACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGG TTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGATTTCCAAGTCTCCACCCCATTG ACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCC ATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGT CAGATCCGCTAGAGATCCGCGGCCGCTAATACGACTCACTATAGGGAGAGCCGCCACCATGAAACGGACA GCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAAGTCTCTGAAGTCGAGTTTAGCCACGAGT ATTGGATGAGGCACGCACTGACCCTGGCAAAGCGAGCATGGGATGAAAGAGAAGTCCCCGTGGGCGCCGT GCTGGTGCACAACAATAGAGTGATCGGAGAGGGATGGAACAGGCCAATCGGCCGCCACGACCCTACCGCA CACGCAGAGATCATGGCACTGAGGCAGGGAGGCCTGGTCATGCAGAATTACCGCCTGATCGATGCCACCC TGTATGTGACACTGGAGCCATGCGTGATGTGCGCAGGAGCAATGATCCACAGCAGGATCGGAAGAGTGGT GTTCGGAGCACGGGACGCCAAGACCGGCGCAGCAGGCTCCCTGATGGATGTGCTGCACCACCCCGGCATG AACCACCGGGTGGAGATCACAGAGGGAATCCTGGCAGACGAGTGCGCCGCCCTGCTGAGCGATTTCTTTA GAATGCGGAGACAGGAGATCAAGGCCCAGAAGAAGGCACAGAGCTCCACCGACTCTGGAGGATCTAGCGG AGGATCCTCTGGAAGCGAGACACCAGGCACAAGCGAGTCCGCCACACCAGAGAGCTCCGGCGGCTCCTCC GGAGGATCCTCTGAGGTGGAGTTTTCCCACGAGTACTGGATGAGACATGCCCTGACCCTGGCCAAGAGGG CACGCGATGAGAGGGAGGTGCCTGTGGGAGCCGTGCTGGTGCTGAACAATAGAGTGATCGGCGAGGGCTG GAACAGAGCCATCGGCCTGCACGACCCAACAGCCCATGCCGAAATTATGGCCCTGAGACAGGGCGGCCTG GTCATGCAGAACTACAGACTGATTGACGCCACCCTGTACGTGACATTCGAGCCTTGCGTGATGTGCGCCG GCGCCATGATCCACTCTAGGATCGGCCGCGTGGTGTTTGGCGTGAGGAACGCAAAAACCGGCGCCGCAGG CTCCCTGATGGACGTGCTGCACTACCCCGGCATGAATCACCGCGTCGAAATTACCGAGGGAATCCTGGCA GATGAATGTGCCGCCCTGCTGTGCTATTTCTTTCGGATGCCTAGACAGGTGTTCAATGCTCAGAAGAAGG CCCAGAGCTCCACCGACTCCGGAGGATCTAGCGGAGGCTCCTCTGGCTCTGAGACACCTGGCACAAGCGA GAGCGCAACACCTGAAAGCAGCGGGGGCAGCAGCGGGGGGTCAGACAAGAAGTACAGCATCGGCCTGGCC ATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGG TGCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGA AACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGC TATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGT CCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGC CTACCACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGAC CTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACC TGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGA GGAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGA CGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGGAGAAAGAATGGCCTGTTCGGAAACCTGATTGCCC TGAGCCTGGGCCTGACCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAG CAAGGACACCTACGACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGGCCGACCTGTTTT CTGGCCGCCAAGAACCTGCTCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCA AGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGC TCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCC GGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGG ACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAA CGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTAC CCATTCCTGAAGGACAACCGGGAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCC CTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAA CTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAG AACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGC TGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGC CATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAG AAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACAT ACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGA AGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCC CACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCC GGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGG CTTCGCCAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAA GCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTA AGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGA GAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGA ATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACA CCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGA ACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGAC TCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAG AGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTT CGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAG CTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACG ACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGATTTCCG GAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAAC GCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACA AGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTT CTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGG CCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGC GGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAA AGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAG TACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGT CCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAA TCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAG TACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAA ACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATC GAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCT ACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAA TCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAA GAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTC AGCTGGGAGGTGACTCTGGCGGCTCAAAAAGAACCGCCGACGGCAGCGAATTCGAGCCCAAGAAGAAGAG GAAAGTCTAACCGGTCATCATCACCATCACCATTGAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTT CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCAC TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGT GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGATACCGTCGACCTCTAGCTAGAGCTTGGCGTA ATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGA AGCATAAAGTGTAAAGCCTAGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGC CCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGG TTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGA GCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACA TGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCT CCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAA AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGAT ACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTC GGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTA TCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTA ACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTA CACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGC TCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCA GAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACACTCAGTGGAACGAAAACTC ACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGG CACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTAC GATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCA GATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCT CCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGT TGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCC CAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGA TCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTAC TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGT ATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAA AAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGA GCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATAC TCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATG TATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGA TCGGGAGATCGATCTCCCGATCCCCTAGGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAA GCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC AAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGAT GTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCAT TAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCAT TGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
[0045] "Base editing activity" means acting to chemically modify a base in a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is a cytidine deaminase activity, e.g., converting a target C·G to T·A. In another embodiment, the base editing activity is an adenosine or adenine deaminase activity, e.g., converting A·T to G·C.
[0046] The term "base editor system" refers to a system for editing nucleobases of a target nucleotide sequence. In various embodiments, the base editor (BE) system comprises (1) a polynucleotide-programmable nucleotide-binding domain and a deaminase domain for deaminating the nucleobase, and (2) a guide polynucleotide (e.g., a guide RNA) linked to the polynucleotide-programmable nucleotide-binding domain. In some embodiments, the base editor system comprises (1) a polynucleotide-programmable DNA-binding domain and a deaminase domain for deaminating the nucleobase, and (2) a guide RNA linked to the polynucleotide-programmable DNA-binding domain. In some embodiments, the polynucleotide-programmable nucleotide-binding domain is a polynucleotide-programmable DNA-binding domain. In some embodiments, the base editor is a cytidine base editor (CBE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE).
[0047] In some embodiments, a nucleobase editor system may comprise two or more base editing components. For example, a nucleobase editor system may comprise two or more deaminases. In some embodiments, a nuclease base editor system may comprise one or more cytidine deaminases and / or one or more adenosine deaminases. In some embodiments, a single guide polynucleotide may be used to target different deaminases to a target nucleic acid sequence. In some embodiments, a pair of guide polynucleotides may be used to target different deaminases to a target nucleic acid sequence.
[0048] The nucleobase component and the polynucleotide-programmable nucleotide-binding component of the base editor system may be covalently or non-covalently linked to each other. For example, in some embodiments, the deaminase domain can be targeted to a target nucleotide sequence by a polynucleotide-programmable nucleotide-binding domain. In some embodiments, the polynucleotide-programmable nucleotide-binding domain can be fused or linked to the deaminase domain. In some embodiments, the polynucleotide-programmable nucleotide-binding domain can target the deaminase domain to a target nucleotide sequence by non-covalently interacting with or binding to the deaminase domain. For example, in some embodiments, the nucleobase editing component, e.g., the deaminase component, can include an additional heterologous moiety or domain that can interact with, associate with, or form a complex with an additional heterologous moiety or domain that is part of the polynucleotide-programmable nucleotide-binding domain. In some embodiments, the additional heterologous moiety can bind, interact, associate, or form a complex with a polypeptide. In some embodiments, the additional heterologous moiety can bind, interact, associate, or form a complex with a polynucleotide. In some embodiments, the additional heterologous moiety can bind to a guide polynucleotide. In some embodiments, the additional heterologous moiety can be attached to a polypeptide linker. In some embodiments, the additional heterologous moiety can be attached to a polynucleotide linker. The additional heterologous moiety can be a protein domain. In some embodiments, the additional heterologous moiety can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a steryl alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.
[0049] The base editor system may further comprise a guide polynucleotide component. It should be recognized that the components of the base editor system can associate with each other via covalent bonds, non-covalent interactions, or any combination of these associations and interactions. In some embodiments, the deaminase domain can be targeted to a target nucleotide sequence by the guide polynucleotide. For example, in some embodiments, the nucleic acid base editing component of the base editor system, e.g., the deaminase component, can include an additional heterologous moiety or domain (e.g., a polynucleotide binding domain such as an RNA or DNA binding protein) that can interact, associate, or form a complex with a portion or segment (e.g., a polynucleotide motif) of the guide polynucleotide. In some embodiments, the additional heterologous moiety or domain (e.g., a polynucleotide binding domain such as an RNA or DNA binding protein) can be fused or linked to the deaminase domain. In some embodiments, the additional heterologous moiety can bind, interact, associate, or form a complex with a polypeptide. In some embodiments, the additional heterologous moiety can bind, interact, associate, or form a complex with a polynucleotide. In some embodiments, the additional heterologous moiety can bind to a guide polynucleotide. In some embodiments, the additional heterologous moiety can be attached to a polypeptide linker. In some embodiments, the additional heterologous moiety can be attached to a polynucleotide linker. The additional heterologous moiety can be a protein domain. In some embodiments, the additional heterologous moiety can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a steryl alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.
[0050] In some embodiments, the base editor system may further comprise an inhibitor of a base excision repair (BER) component. It should be appreciated that the components of the base editor system may associate with each other via covalent bonds, non-covalent interactions, or any combination thereof. The inhibitor of a BER component may comprise a base excision repair inhibitor. In some embodiments, the inhibitor of base excision repair may be a uracil DNA glycosylase inhibitor (UGI). In some embodiments, the inhibitor of base excision repair may be an inosine base excision repair inhibitor. In some embodiments, the inhibitor of base excision repair can be targeted to a target nucleotide sequence by a polynucleotide programmable nucleotide binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain can be fused or linked to the inhibitor of base excision repair. In some embodiments, the polynucleotide programmable nucleotide binding domain can be fused or linked to a deaminase domain and an inhibitor of base excision repair. In some embodiments, the polynucleotide programmable nucleotide binding domain can target the inhibitor of base excision repair to a target nucleotide sequence by non-covalently interacting with or associating with the inhibitor of base excision repair. For example, in some embodiments, the inhibitor of a base excision repair component may comprise an additional heterologous moiety or domain that can interact with, associate with, or form a complex with an additional heterologous moiety or domain that is part of the polynucleotide programmable nucleotide binding domain. In some embodiments, the inhibitor of base excision repair can be targeted to a target nucleotide sequence by a guide polynucleotide. For example, in some embodiments, the inhibitor of base excision repair may comprise an additional heterologous moiety or domain (e.g., a polynucleotide binding domain such as an RNA or DNA binding protein) that can interact with, associate with, or form a complex with a portion or segment (e.g., a polynucleotide motif) of the guide polynucleotide.In some embodiments, an additional heterologous moiety or domain of the guide polynucleotide (e.g., a polynucleotide binding domain such as an RNA or DNA binding protein) can be fused or linked to an inhibitor of base excision repair. In some embodiments, the additional heterologous moiety can bind, interact, associate, or form a complex with the polynucleotide. In some embodiments, the additional heterologous moiety can be linked to the guide polynucleotide. In some embodiments, the additional heterologous moiety can be linked to a polypeptide linker. In some embodiments, the additional heterologous moiety can be linked to a polynucleotide linker. The additional heterologous moiety can be a protein domain. In some embodiments, the additional heterologous moiety can be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a steryl alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif.
[0051] The term "Cas9" or "Cas9 domain" refers to an RNA-guided nuclease comprising the Cas9 protein, or a fragment thereof (e.g., an active, inactive, or partially active DNA cleavage domain of Cas9, and / or a gRNA-binding domain of Cas9). Cas9 nucleases are also sometimes referred to as casn1 nucleases or CRISPR (clustered regularly interspaced short palindromic repeat)-associated nucleases. An exemplary Cas9 is Streptococcus pyogenes Cas9, the amino acid sequence of which is provided below. TIFF0007596259000001.tif162167 (Single underline: HNH domain, double underline: RuvC domain)
[0052] The term "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid with another amino acid that shares common properties. A functional method for defining common properties between individual amino acids is to analyze the normalized frequency of amino acid changes between corresponding proteins of the same organism (Schulz, GE and Schirmer, RH, Principles of Protein Structure, Springer-Verlag, New York (1979)). Such analysis allows the definition of groups of amino acids when the amino acids within a group are preferentially exchanged with each other and are therefore most similar to each other in their effect on the overall protein structure (Schulz, GE and Schirmer, RH, supra). Non-limiting examples of conservative mutations include, for example, amino acid substitutions from lysine to arginine, which maintain a positive charge; glutamic acid to aspartic acid, which maintain a negative charge; serine to threonine, which maintain a free -OH group; and glutamine to asparagine, which maintain a free -NH group.
[0053] The terms "coding sequence" or "protein-coding sequence," as used interchangeably herein, refer to a segment of a polynucleotide that encodes a protein. This region or sequence is bounded proximal to the 5' end by an initiation codon and proximal to the 3' end by a termination codon. A coding sequence may also be referred to as an open reading frame.
[0054] As used herein, the term "deaminase" or "deaminase domain" refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase, which catalyzes the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. In some embodiments, the deaminase or deaminase domain is a cytosine deaminase, which catalyzes the hydrolytic deamination of cytosine to uracil. In some embodiments, the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenine to hypoxanthine. In some embodiments, the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenosine or adenine (A) to inosine (I). In some embodiments, the deaminase or deaminase domain is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA). The adenosine deaminases provided herein (e.g., engineered adenosine deaminases, evolved adenosine deaminases) can be from any organism, such as bacteria. In some embodiments, the adenosine deaminase is from bacteria, such as E. coli, S. aureus, S. typhi, S. putrefaciens, H. influenzae, or C. crescentus. In some embodiments, the adenosine deaminase is TadA deaminase. In some embodiments, the deaminase or deaminase domain is a variant of a naturally occurring deaminase from an organism such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is not naturally occurring.For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a naturally occurring deaminase. For example, deaminase domains are described in International PCT Applications PCT / 2017 / 045381 (WO2018 / 027078) and PCT / US2016 / 058344 (WO2017 / 070632), each of which is incorporated herein by reference in its entirety.Also, Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage," Nature 533, 420-424 (2016); Gaudelli, NM, et al., "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage," Nature 551, 464-471 (2017); Komor, AC, et al., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity," Science Advances 3:eaao4774 (2017)), and Rees, HA, et al., "Base editing: precision chemistry on the genome and transcriptome of living cells," Nat Rev Genet. 2018, the entire contents of which are incorporated herein by reference. Dec;19(12):770-788. See doi: 10.1038 / s41576-018-0059-1.
[0055] "Detectable label" means a composition that, when attached to a molecule of interest, renders the molecule detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in ELISA), biotin, digoxigenin, or haptens.
[0056] "Disease" means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include Rett Syndrome.
[0057] An "effective amount" refers to the amount required to improve the symptoms of a disease in an untreated patient. The effective amount of an active compound used to practice the present invention for the therapeutic treatment of a disease will vary depending on the mode of administration, the age, weight, and general health of the subject. Ultimately, the attending physician or veterinarian will determine the appropriate amount and dosing regimen. Such an amount is referred to as an "effective" amount. In one embodiment, an effective amount is the amount of a base editor of the present invention sufficient to introduce a modification into a gene of interest (e.g., Mecp2) in a cell (e.g., in vitro or in vivo). In one embodiment, an effective amount is the amount of a base editor required to achieve a therapeutic effect (e.g., reduction or control of Rett syndrome or a symptom or pathology thereof). Such a therapeutic effect need not be sufficient to modify Mecp2 in all cells of a subject, tissue, or organ, but may be sufficient to modify Mecp2 in about 1%, 5%, 10%, 25%, 50%, 75%, or more of the cells present in the subject, tissue, or organ. In one embodiment, an effective amount is sufficient to improve one or more symptoms of Rett syndrome.
[0058] "Fragment" refers to a portion of a polypeptide or nucleic acid molecule. This portion preferably comprises at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. Fragments can comprise 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
[0059] "Hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen, or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. For example, adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds.
[0060] The term "inhibitor of base repair" or "IBR" refers to a protein capable of inhibiting the activity of a nucleic acid repair enzyme, such as a base excision repair enzyme. In some embodiments, the IBR is an inhibitor of inosine base excision repair. Exemplary base repair inhibitors include inhibitors of APE1, Endo III, Endo IV, Endo V, Endo VIII, Fpg, hOGGl, hNEILl, T7 Endol, T4PDG, UDG, hSMUGl, and hAAG. In some embodiments, the IBR is an inhibitor of Endo V or hAAG. In some embodiments, the IBR is catalytically inactive Endo V or catalytically inactive hAAG. In some embodiments, the base repair inhibitor is an inhibitor of Endo V or hAAG. In some embodiments, the base repair inhibitor is catalytically inactive Endo V or catalytically inactive hAAG. In some embodiments, the base repair inhibitor is a uracil glycosylase inhibitor (UGI). UGI refers to a protein capable of inhibiting a uracil DNA glycosylase base excision repair enzyme. In some embodiments, the UGI domain comprises wild-type UGI or a fragment of wild-type UGI. In some embodiments, the UGI proteins provided herein comprise fragments of UGI and proteins homologous to UGI or UGI fragments. In some embodiments, the base repair inhibitor is an inhibitor of inosine base excision repair. In some embodiments, the base repair inhibitor is a "catalytically inactive inosine-specific nuclease" or "dead inosine-specific nuclease." Without wishing to be bound by any particular theory, catalytically inactive inosine glycosylases (e.g., alkyladenine glycosylases (AAG)) can bind to inosine but cannot create an abasic site or remove the inosine, thereby sterically blocking the newly formed inosine moiety from DNA damage / repair mechanisms. In some embodiments, catalytically inactive inosine-specific nucleases can bind to inosine in nucleic acids but do not cleave the nucleic acids.Non-limiting examples of catalytically inactive inosine-specific nucleases include catalytically inactive alkyladenosine glycosylase (AAG nuclease), e.g., from humans, and catalytically inactive endonuclease V (Endo V nuclease), e.g., from E. coli. In some embodiments, the catalytically inactive AAG nuclease comprises an E125Q mutation or a corresponding mutation in another AAG nuclease.
[0061] The terms "isolated," "purified," or "biologically pure" refer to material that has been removed, to varying degrees, from components that normally accompany it when found in its native state. "Isolated" refers to a degree of separation from the original source or environment. "Purified" refers to a degree of separation greater than isolation. A "purified" or "biologically pure" protein has been sufficiently free of other materials so that any impurities do not substantially affect the biological properties of the protein or cause other adverse effects. That is, a nucleic acid or peptide of the invention is purified if it is substantially free of cellular material, viral material, or culture medium if produced by recombinant DNA techniques, or chemical precursors or other chemicals if chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high-performance liquid chromatography. The term "purified" can mean that the nucleic acid or protein yields essentially one band in an electrophoretic gel. For proteins that can be subject to modification, such as phosphorylation or glycosylation, various modifications can yield different isolated proteins, which can be individually purified.
[0062] An "isolated polynucleotide" refers to a nucleic acid (e.g., DNA) that is free of the genes that flank it in the naturally occurring genome of the organism from which the nucleic acid molecule of the invention is derived. Thus, the term includes recombinant DNA that is, for example, incorporated into a vector, an autonomously replicating plasmid or virus, or incorporated into the genomic DNA of a prokaryote or eukaryote, or that exists as a separate molecule independent of other sequences (e.g., cDNA or genomic or cDNA fragments generated by PCR or restriction endonuclease digestion). Furthermore, the term includes RNA molecules transcribed from DNA molecules, as well as recombinant DNA that is part of a hybrid gene that encodes additional polypeptide sequences.
[0063] "Isolated polypeptide" refers to a polypeptide of the invention that has been separated from components that naturally accompany it. Typically, a polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a polypeptide of the invention. Isolated polypeptides of the invention can be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
[0064] The term "linker," as used herein, can refer to a covalent linker (e.g., a covalent bond), a non-covalent linker, a chemical group, or a molecule that connects two molecules or moieties, e.g., two components of a protein complex or a ribonucleic acid complex, or two domains of a fusion protein, such as a polynucleotide-programmable DNA-binding domain (e.g., dCas9) and a deaminase domain (e.g., adenosine deaminase or cytidine deaminase). A linker can join different components, or different parts of components, of a base editor system. For example, in some embodiments, a linker can join the guide polynucleotide-binding domain of a polynucleotide-programmable nucleotide-binding domain and the catalytic domain of a deaminase. In some embodiments, a linker can join a CRISPR polypeptide and a deaminase. In some embodiments, a linker can join a Cas9 and a deaminase. In some embodiments, a linker can join a dCas9 and a deaminase. In some embodiments, a linker can join an nCas9 and a deaminase. In some embodiments, a linker can join a guide polynucleotide and a deaminase. In some embodiments, a linker can join a deaminating component and a polynucleotide-programmable nucleotide-binding component of a base editor system. In some embodiments, a linker can join an RNA-binding portion of a deaminating component and a polynucleotide-programmable nucleotide-binding component of a base editor system. In some embodiments, a linker can join an RNA-binding portion of a deaminating component and an RNA-binding portion of a polynucleotide-programmable nucleotide-binding component of a base editor system. A linker can be located between or near two groups, molecules, or other moieties and connect them to each other via a covalent bond or a non-covalent interaction, thereby linking the two. In some embodiments, the linker can be an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker can be a polynucleotide.In some embodiments, the linker can be a DNA linker. In some embodiments, the linker can be an RNA linker. In some embodiments, the linker can include an aptamer capable of binding to a ligand. In some embodiments, the ligand can be a carbohydrate, peptide, protein, or nucleic acid. In some embodiments, the linker can include an aptamer derived from a riboswitch. The riboswitch from which the aptamer is derived can be selected from a theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch, an S-adenosylmethionine (SAM) riboswitch, an SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, or a prekeosin 1 (PreQ1) riboswitch. In some embodiments, the linker can include an aptamer bound to a domain of a polypeptide or protein, such as a polypeptide ligand. In some embodiments, the polypeptide ligand may be a K homology (KH) domain, an MS2 coat protein domain, a PP7 coat protein domain, an SfMu Com coat protein domain, a steryl alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or an RNA recognition motif. In some embodiments, the polypeptide ligand may be part of a base editor system component. For example, a nucleic acid base editing component may comprise a deaminase domain and an RNA recognition motif.
[0065] In some embodiments, the linker can be an amino acid or multiple amino acids (e.g., a peptide or protein). In some embodiments, the linker can be about 5-100 amino acids in length, e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100 amino acids in length. In some embodiments, the linker can be about 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, or 450-500 amino acids in length. Longer or shorter linkers are also contemplated.
[0066] In some embodiments, a linker joins the gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, to the catalytic domain of a nucleic acid-editing protein (e.g., cytidine or adenosine deaminase). In some embodiments, the linker joins dCas9 to a nucleic acid-editing protein. For example, the linker is located between or adjacent to two groups, molecules, or other moieties, covalently linking them, thereby linking the two. In some embodiments, the linker is an amino acid or multiple amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-200 amino acids in length, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 45, 50, 55, 60, 60, 65, 70, 70, 75, 80, 85, 90, 90, 95, 100, 101, 102, 103, 104, 105, 110, 120, 130, 140, 150, 160, 175, 180, 190, or 200 amino acids in length. Longer or shorter linkers are also contemplated. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES, also referred to as an XTEN linker. In some embodiments, the linker comprises the amino acid sequence SGGS. In some embodiments, the linker is (SGGS) n , (GGGS) n , (GGGGS) n , (G) n , (EAAAK) n , (GGS) n , SGSETPGTSESATPES, or (XP) nmotif, or any combination thereof, where n is independently an integer between 1 and 30, and X is any amino acid. In some embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, the linker comprises multiple proline residues and is 5 to 21, 5 to 14, 5 to 9, or 5 to 7 amino acids in length, e.g., PAPAP, PAPAPA, PAPAPAP, PAPAPAPA, P(AP)4, P(AP)7, P(AP) 10 Such proline-rich linkers are also called "rigid" linkers.
[0067] In some embodiments, the base editor domain is fused via a linker comprising the amino acid sequence of SGGSSGSETPGTSESATPESSGGS, SGGSSGGSSGSETPGTSESATPESSGGSSGGS, or GGSGGSPGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTE PSEGSAPGTSTEPSEGSAPGTSESATPESGPGSEPATSGGSGGS. In some embodiments, the base editor domain is fused via a linker comprising the amino acid sequence SGSETPGTSESATPES, which is also referred to as an XTEN linker. In some embodiments, the linker is 24 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPES. In some embodiments, the linker is 40 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSSGGSSGGS. In some embodiments, the linker is 64 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGSSGGSSGGSSGSETPGTSESATPESSGGS SGGS. In some embodiments, the linker is 92 amino acids in length. In some embodiments, the linker comprises the amino acid sequence PGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAP GTSTEPSEGSAPGTSESATPESGPGSEPATS.
[0068] The term "mutation," as used herein, refers to the substitution of a residue in a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or the deletion or insertion of one or more residues in a sequence. Mutations are typically described herein by identifying the original residue, followed by the position of the residue in the sequence, and the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are known in the art and are provided, for example, by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)). In some embodiments, the base editors disclosed herein can efficiently generate "intended mutations," such as point mutations, in nucleic acids (e.g., nucleic acids in a genome of a subject) without generating a significant number of unintended mutations (e.g., unintended point mutations). In some embodiments, the intended mutations are mutations generated by a specific base editor (e.g., a cytidine base editor or an adenosine base editor) bound to a guide polynucleotide (e.g., a gRNA) specifically designed to generate the intended mutation. Generally, mutations made or identified in a sequence (e.g., an amino acid sequence described herein) are numbered relative to a reference (or wild-type) sequence, i.e., a sequence that does not contain the mutation. Those skilled in the art can readily understand how to determine the location of mutations in amino acid and nucleic acid sequences relative to a reference sequence.
[0069] The terms "nucleic acid" and "nucleic acid molecule," as used herein, refer to a compound comprising a nucleobase and an acid moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides, are linear molecules in which adjacent nucleotides are linked to each other via phosphodiester linkages. In some embodiments, "nucleic acid" refers to individual nucleic acid residues (e.g., nucleotides and / or nucleosides). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms "oligonucleotide" and "polynucleotide" are used interchangeably and refer to a polymer of nucleotides (e.g., a chain of at least three nucleotides). In some embodiments, "nucleic acid" encompasses RNA and single- and / or double-stranded DNA. Nucleic acids can occur naturally, e.g., in association with a genome, transcript, mRNA, tRNA, rRNA, siRNA, snRNA, plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. Alternatively, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., recombinant DNA or RNA, an artificial chromosome, an engineered genome or fragment thereof, or synthetic DNA, RNA, DNA / RNA hybrid, or non-naturally occurring nucleotide or nucleoside. Furthermore, the terms "nucleic acid," "DNA," "RNA," and / or similar terms include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems, optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can include nucleoside analogs, such as analogs having chemically modified bases or sugar and backbone modifications. Nucleic acid sequences are presented in the 5' to 3' direction unless otherwise indicated.In some embodiments, nucleic acids are selected from the group consisting of naturally occurring nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyluridine, C5-propynylcytidine, C ... The base may be or contain: 7-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine; chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioates and 5'-N-phosphoramidite linkages).
[0070] The term "nuclear localization sequence," "nuclear localization signal," or "NLS" refers to an amino acid sequence that facilitates the import of a protein into a cell nucleus. Nuclear localization sequences are known in the art and are described, for example, in International PCT Application PCT / EP2000 / 011690, filed November 23, 2000, by Plank et al., published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated by reference herein for disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, for example, as described by Koblan et al., Nature Biotech. 2018 doi:10.1038 / nbt.4172. In some embodiments, the NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV, KRPAATKKAGQAKKKK, KKTELQTTNAENKTKKL, KRGINDRNFWRGENGRKTR, RKSGKIAAIVVKRPRK, PKKKRKV, or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC.
[0071] The terms "nucleobase," "nitrogenous base," or "base," as used interchangeably herein, refer to nitrogen-containing biological compounds that form nucleosides, which are the building blocks of nucleotides. The ability of nucleobases to base pair and stack one on top of the other directly leads to long-chain helical structures such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The five nucleobases, adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U), are referred to as primary or canonical. Adenine and guanine are derived from purines, while cytosine, uracil, and thymine are derived from pyrimidines. DNA and RNA can also contain other (non-primary) bases that are modified. Non-limiting exemplary modified nucleobases may include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine (m5C), and 5-hydromethylcytosine. Hypoxanthine and xanthine can both be created by deamination (replacement of an amine group with a carbonyl group) in the presence of a mutagen. Hypoxanthine can be modified from adenine. Xanthine can be modified from guanine. Uracil can be derived from the deamination of cytosine. A "nucleoside" consists of a nucleobase and a five-carbon sugar (ribose or deoxyribose). Examples of nucleosides include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U), deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. Examples of nucleosides containing modified nucleobases include inosine (I), xanthosine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), and pseudouridine (Φ). A "nucleotide" consists of a nucleobase, a five-carbon sugar (ribose or deoxyribose), and at least one phosphate group.
[0072] The term "nucleic acid programmable DNA-binding protein" or "napDNAbp" is used interchangeably with "polynucleotide programmable nucleotide-binding protein" and refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid that guides the napDNAbp to a specific nucleic acid sequence. For example, a Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, such as nuclease-active Cas9, Cas9 nickase (nCas9), or nuclease-inactive Cas9 (dCas9). Examples of nucleic acid programmable DNA-binding proteins include, without limitation, Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i. Other nucleic acid programmable DNA binding proteins are also within the scope of the present disclosure, although not specifically listed herein. See, for example, Makarova et al. "Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?" CRISPR J. 2018 Oct;1:325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., "Functionally diverse type V CRISPR-Cas systems" Science. 2019 Jan 4;363(6422):88-91. doi: 10.1126 / science.aav7271, the entire contents of each of which are incorporated herein by reference.
[0073] The term "nucleobase editing domain" or "nucleobase editing protein," as used herein, refers to a protein or enzyme that can catalyze the modification of nucleobases in RNA or DNA, for example, the deamination of cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine), and adenine (or adenosine) to hypoxanthine (or inosine), as well as the addition and insertion of untemplated nucleotides. In some embodiments, the nucleobase editing domain is a deaminase domain (e.g., cytidine deaminase, cytosine deaminase, adenine deaminase, or adenosine deaminase). In some embodiments, the nucleobase editing domain can be a naturally occurring nucleobase editing domain. In some embodiments, the nucleobase editing domain can be a nucleobase editing domain engineered or evolved from a naturally occurring nucleobase editing domain. The nucleobase editing domain can be from any organism, such as a bacterium, human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. For example, nucleobase-editing proteins are described in International PCT Application Nos. PCT / 2017 / 045381 (WO2018 / 027078) and PCT / US2016 / 058344 (WO2017 / 070632), each of which is incorporated herein by reference in its entirety.See also Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" Nature 533, 420-424 (2016); Gaudelli, NM, et al., "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage" Nature 551, 464-471 (2017); and Komor, AC, et al., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity" Science Advances 3:eaao4774 (2017), the entire contents of which are incorporated herein by reference.
[0074] As used herein, "obtaining," as in "obtaining an agent," includes synthesizing, purchasing, or otherwise acquiring an agent.
[0075] As used herein, "patient" or "subject" refers to a mammalian subject who has been diagnosed with or is suspected of having or developing a disease or disorder. In some embodiments, the term "patient" refers to a mammalian subject who has a higher than average likelihood of developing a disease or disorder. Exemplary patients can be humans, non-human primates, cats, dogs, pigs, cows, felines, horses, goats, sheep, rodents (e.g., mice, rabbits, rats, or guinea pigs), and other mammals that may benefit from the therapies disclosed herein. Exemplary human patients can be male and / or female.
[0076] A "patient in need thereof" or "subject in need thereof," as used herein, means a patient diagnosed with or suspected of having a disease or disorder, for example, but not limited to, Rett Syndrome (RTT).
[0077] The terms "pathogenic mutation," "pathogenic variant," "disease-causing mutation," "disease-causing variant," "deleterious mutation," or "predisposing mutation" refer to an alteration or mutation in a gene that increases an individual's susceptibility or predisposition to a disease or disorder. In some embodiments, a pathogenic mutation comprises the substitution of at least one wild-type amino acid with at least one pathogenic amino acid in a protein encoded by the gene.
[0078] The term "non-conservative mutation" includes amino acid substitutions between different groups, such as lysine with tryptophan or phenylalanine with serine. In this case, the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution can enhance the biological activity of the functional variant, thereby increasing the biological activity of the functional variant compared to the wild-type protein.
[0079] The terms "protein," "peptide," "polypeptide," and their grammatical equivalents are used interchangeably herein to refer to a polymer of amino acid residues linked together by peptide (amide) bonds. This term refers to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids in length. A protein, peptide, or polypeptide can refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide can be modified, for example, by the addition of a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, or other chemical entity. A protein, peptide, or polypeptide can be a single molecule or a multi-molecular complex. A protein, peptide, or polypeptide can be simply a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide can be naturally occurring, recombinant, synthetic, or any combination thereof. As used herein, the term "fusion protein" refers to a hybrid polypeptide containing protein domains from at least two different proteins. One protein can be located at the amino-terminal (N-terminal) or carboxy-terminal (C-terminal) portion of the fusion protein, thereby forming an amino-terminal fusion protein or a carboxy-terminal fusion protein, respectively. The protein can contain different domains, such as a nucleic acid-binding domain (e.g., the gRNA-binding domain of Cas9, which directs binding of the protein to a target site) and a nucleic acid cleavage domain, or the catalytic domain of a nucleic acid-editing protein. In some embodiments, the protein comprises a protein portion, e.g., an amino acid sequence constituting the nucleic acid-binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent. In some embodiments, the protein is in a complex with or associated with a nucleic acid, e.g., RNA or DNA.Any of the proteins provided herein can be produced by any method known in the art. For example, the proteins provided herein can be produced through recombinant protein expression and purification, which is particularly suitable for fusion proteins containing peptide linkers. Methods for recombinant protein expression and purification are known and include those described in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), the entire contents of which are incorporated herein by reference.
[0080] The polypeptides and proteins disclosed herein (including functional portions and functional variants thereof) may contain synthetic amino acids in place of one or more naturally occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexanecarboxylic acid, norleucine, α-amino-n-decanoic acid, homoserine, S-acetylaminomethylcysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine, β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, isopropylaminopropanol ... Examples of amino acids include lysine-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyllysine, N',N'-dibenzyllysine, 6-hydroxylysine, ornithine, α-aminocyclopentanecarboxylic acid, α-aminocyclohexanecarboxylic acid, α-aminocycloheptanecarboxylic acid, α-(2-amino-2-norbornane)carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine. Polypeptides and proteins can be combined with post-translational modifications of one or more amino acids in the polypeptide construct. Non-limiting examples of post-transcriptional modifications include phosphorylation, acylation, including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation, including methylation and ethylation, ubiquitylation, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypiation, lipoylation, and iodination.
[0081] The term "polynucleotide programmable nucleotide binding domain" refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., guide RNA), that guides the polynucleotide programmable DNA binding domain to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. The Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence complementary to the guide RNA. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 domain, such as a nuclease-active Cas9, Cas9 nickase (nCas9), or a nuclease-inactive Cas9 (dCas9). Non-limiting examples of nucleic acid programmable DNA binding proteins include Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i.Non-limiting examples of Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, Csy1, Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csn3, Csn4, Csn5, Csn6, Csn7, Csn8, Csn9, Csn10, Csn11, Csn12, Csn13, Csn14, Csn15, Csn16, Csn17, Csn18, Csn19, Csn20, Csn21, Csn22, Csn23, Csn24, Csn25, Csn26, Csn27, Csn28, Csn29, Csn211, Csn212, Csn213, Csn22, Csn23, Csn24, Csn25, Csn26, Csn27, Csn28, Csn29, Csn214, Csn215, Csn216, Csn22, Csn23, Csn24, Csn25, Csn26, Csn27, Csn28, Csn29, Csn29 These include sm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, type II Cas effector proteins, type V Cas effector proteins, type VI Cas effector proteins, CARF, DinG, homologs thereof, or modified or engineered versions thereof. Other nucleic acid programmable DNA binding proteins not specifically listed herein are also within the scope of this disclosure.
[0082] The term "recombinant," as used herein with respect to a protein or nucleic acid, means a protein or nucleic acid that is not naturally occurring but is the product of human manipulation. For example, in some embodiments, a recombinant protein or nucleic acid comprises an amino acid or nucleotide sequence that contains at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations compared to any naturally occurring sequence.
[0083] By "reduction" is meant a negative alteration of at least 10%, 25%, 50%, 75%, or 100%.
[0084] "Reference" refers to a standard or control condition. In one embodiment, the reference is a wild-type or healthy cell.
[0085] A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence, for example, a fragment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence. For polypeptides, the length of a reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of a reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, even more preferably about 100 nucleotides, or about 300 nucleotides, or any integer therebetween.
[0086] The terms "RNA-programmable nuclease" and "RNA-guided nuclease" are used in conjunction with (e.g., bound to or associated with) one or more RNAs that are not targets for cleavage. In some embodiments, an RNA-programmable nuclease, when in a complex with an RNA, may be referred to as a nuclease:RNA complex. Typically, the bound RNA is referred to as a guide RNA (gRNA). A gRNA can exist as a complex of two or more RNAs or as a single RNA molecule. A gRNA that exists as a single RNA molecule may be referred to as a single guide RNA (sgRNA), although "gRNA" is used interchangeably to refer to a guide RNA that exists as a single molecule or as a complex of two or more molecules. Typically, a gRNA that exists as a single RNA species contains two domains: (1) a domain that shares homology with the target nucleic acid (e.g., also directs binding of the Cas9 complex to the target) and (2) a domain that binds to the Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as tracrRNA and contains a stem-loop structure. For example, in some embodiments, domain (2) is identical to or homologous to tracrRNA, as provided in Jinek et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Other examples of gRNAs (e.g., those containing domain 2) can be found in U.S. Provisional Patent Application No. 61 / 874,682, entitled "Switchable Cas9 Nucleases and Uses Thereof," filed September 6, 2013, and U.S. Provisional Patent Application No. 61 / 874,746, entitled "Delivery System For Functional Nucleases," filed September 6, 2013, the entire contents of each of which are incorporated herein by reference in their entirety. In some embodiments, a gRNA comprises two or more of domains (1) and (2), and is referred to as an "extended gRNA." For example, an extended gRNA will bind to two or more Cas9 proteins and bind to a target nucleic acid at two or more distinct regions, as described herein.The gRNA contains a nucleotide sequence complementary to a target site, which mediates binding of the nuclease / RNA complex to said target site and provides sequence specificity for the nuclease:RNA complex. In some embodiments, the RNA-programmable nuclease is a (CRISPR-associated system) Cas9 endonuclease, e.g., Cas9 (Csnl) of Streptococcus pyogenes (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes." Ferretti JJ, McShan WM, Ajdic DJ, Savic DJ, Savic G., Lyon K., Primeaux C, Sezate S., Suvorov AN, Kenton S., Lai HS, Lin SP, Qian Y., Jia HG, Najar FZ, Ren Q., Zhu H., Song L., White J., Yuan X., Clifton SW, Roe BA, McLaughlin RE, Proc. Natl. Acad. Sci. USA 98:4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.”, Deltcheva E., Chylinski K., Sharma CM., Gonzales K., Chao Y., Pirzada ZA, Eckert MR, Vogel J., Charpentier E., Nature 471:602-607(2011)).
[0087] The term "single nucleotide polymorphism (SNP)" refers to a single nucleotide variation occurring at a specific position in the genome, with each variation occurring to some appreciable extent (e.g., greater than 1%) in a population. For example, at a specific base position in the human genome, a C nucleotide may occur in most individuals, while in a minority of individuals, the position is occupied by an A. This means that a SNP exists at this specific position, with two possible nucleotide variations, C or A, being alleles for this position. SNPs underlie differences in susceptibility to disease and a wide range of human diseases. The severity of disease and our body's response to treatment are also manifestations of genetic variation. SNPs can be found in the coding region of a gene, the non-coding region of a gene, or an intergenic region (the region between genes). In some embodiments, SNPs in coding sequences do not necessarily change the amino acid sequence of the protein produced due to the degeneracy of the genetic code. SNPs in coding regions are of two types: synonymous SNPs and non-synonymous SNPs. Synonymous SNPs do not affect the sequence of a protein, while nonsynonymous SNPs change the amino acid sequence of a protein. There are two types of nonsynonymous SNPs: missense and nonsense. SNPs that are not in protein-coding regions can still affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of non-coding RNA. Gene expression affected by this type of SNP is called an eSNP (expressed SNP) and can be located upstream or downstream of the gene. Single nucleotide variants (SNVs) are variations in a single nucleotide with unlimited frequency and can occur somatically. Somatic single nucleotide variations (e.g., caused by cancer) can also be referred to as single nucleotide alterations.
[0088] "Specifically binds" refers to a nucleic acid molecule, polypeptide, or complex thereof (e.g., a nucleic acid programmable DNA binding domain and a guide nucleic acid), compound, or molecule that recognizes and binds to a polypeptide and / or nucleic acid molecule of the invention, but does not substantially recognize or bind to other molecules in a sample, e.g., a biological sample.
[0089] Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical to an endogenous nucleic acid sequence, but will typically exhibit substantial identity. A polynucleotide having "substantial identity" to an endogenous sequence is typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical to an endogenous nucleic acid sequence, but will typically exhibit substantial identity. A polynucleotide having "substantial identity" to an endogenous sequence is typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. "Hybridize" refers to the pairing of complementary polynucleotide sequences (e.g., genes described herein) or portions thereof to form double-stranded molecules under various conditions of stringency (see, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152:399; Kimmel, AR (1987) Methods Enzymol. 152:507).
[0090] For example, stringent salt concentrations typically result in less than about 750 mM NaCl and less than 75 mM trisodium citrate, preferably less than about 500 mM NaCl and less than 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and less than 25 mM trisodium citrate. Low stringency hybridization is achieved in the absence of organic solvents, such as formamide, while high stringency hybridization is achieved in the presence of at least about 35% formamide, more preferably at least about 50% formamide. Stringent temperature conditions typically include temperatures of at least about 30°C, more preferably at least about 37°C, and most preferably at least about 42°C. Further parameters, such as hybridization time, concentration of detergents, such as sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are known to those skilled in the art. Various levels of stringency can be achieved by combining these various conditions as needed. In a preferred embodiment, hybridization occurs in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS at 30° C. In a more preferred embodiment, hybridization occurs in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In a most preferred embodiment, hybridization occurs in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA at 42° C. Useful variations on these conditions will be readily apparent to those of skill in the art.
[0091] For most applications, the wash steps following hybridization will also be of varying stringency. Wash stringency conditions can be defined by salt concentration and temperature. As noted above, wash stringency can be increased by decreasing salt concentration or increasing temperature. For example, stringent salt concentrations for wash steps are preferably less than about 30 mM NaCl and less than 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and less than 1.5 mM trisodium citrate. Stringent temperature conditions for wash steps typically include temperatures of at least about 25°C, more preferably at least about 42°C, and even more preferably at least about 68°C. In a preferred embodiment, wash steps will be performed at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will be performed at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the wash steps will be performed in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS at 68° C. Further variations of these conditions will be readily apparent to one of skill in the art.Hybridization techniques are known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0092] "Subject" means a mammal, including, but not limited to, a human or a non-human mammal such as a cow, horse, dog, sheep, or cat.
[0093] "Substantially identical" refers to a polypeptide or nucleic acid molecule that exhibits at least 50% identity with a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). Preferably, such a sequence has at least 60%, more preferably 80% or 85%, more preferably 90%, 95%, or even 99% identity at the amino acid or nucleic acid level with the sequence used for comparison.
[0094] Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, COBALT, EMBOSS Needle, GAP, or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following group: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. An exemplary approach to determining the degree of identity uses the BLAST program, e -3 and e -100 COBALT is used, for example, with the following parameters: a) Alignment parameters: gap penalty -11, -1 and end gap penalty -5, -1 b) CDD parameters: Use RPS BLAST on; BLAST E-value 0.003; Find and recalculate conserved columns; and c) Query clustering parameters: use query cluster on; word size 4, max cluster distance 0.8; alphabet regular. An EMBOSS needle is used, for example, with the following parameters: a) Matrix: BLOSUM62 b) GAP OPEN: 10; c)GAP EXTEND: 0.5; d)OUTPUT FORMAT: Pair; e)END GAP PENALTY: FALSE; f)END GAP OPEN: 10, and g)END GAP EXTEND: 0.5.
[0095] The term "target site" refers to a sequence within a nucleic acid molecule that is modified by a nucleobase editor. In one embodiment, the target site is determined by a deaminase or a fusion protein comprising a deaminase (e.g., cytidine deaminase or adenine deaminase).
[0096] Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, these proteins can in principle target any sequence specified by a guide RNA. Methods for using RNA-programmable nucleases such as Cas9 for site-specific cleavage (e.g., to modify a genome) are known in the art (e.g., Cong, L. et al., Multiplex genome engineering using CRISPR / Cas systems. Science 339, 819-823 (2013); Mali, P. et al., RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, WY et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al., RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, JE et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas, the entire contents of each of which are incorporated herein by reference). systems. Nucleic acids research (2013); Jiang, W. et al. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013).
[0097] As used herein, the terms "treat," "treating," "treatment," and the like refer to reducing or ameliorating a disorder and / or its associated symptoms, or achieving a desired pharmacological and / or physiological effect. It is recognized that treating a disorder or condition does not require, but does not exclude, complete elimination of the disorder, condition, or its associated symptoms. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, alleviates, neutralizes, attenuates, alleviates, diminishes, or cures the disease and / or the deleterious symptoms resulting from the disease. In some embodiments, the effect is prophylactic, i.e., the effect protects against or prevents the occurrence or recurrence of the disease or condition. To this end, the methods disclosed herein comprise administering a therapeutically effective amount of a composition described herein.
[0098] "Uracil glycosylase inhibitor" refers to an agent that inhibits the uracil excision repair system. In one embodiment, the agent is a protein or fragment thereof that binds to the host's uracil DNA glycosylase and prevents the removal of uracil residues from DNA.
[0099] Reference to a list of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. Reference to an embodiment of a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0100] Any composition or method provided herein can be combined with any one or more of the other compositions or methods provided herein.
[0101] DNA editing has emerged as a viable means to modify disease states by correcting pathogenic mutations at the gene level. Until recently, all DNA editing platforms functioned by inducing DNA double-strand breaks (DSBs) at defined genomic sites and relying on endogenous DNA repair pathways to determine the resulting product in a semi-stochastic manner, resulting in a complex population of gene products. While the homology-directed repair (HDR) pathway can achieve precise, user-defined repair outcomes, numerous challenges have hindered highly efficient repair using HDR in therapeutically relevant cell types. In fact, this pathway is less efficient than the competing, error-prone non-homologous end-joining pathway. Furthermore, HDR is strictly restricted to the G1 and S phases of the cell cycle, preventing it from accurately repairing DSBs in post-mitotic cells. As a result, it has proven difficult or impossible to modify genomic sequences in these populations with high efficiency in a user-defined, programmable manner.
[0102] Nucleic acid base editor Disclosed herein are base editors or nucleobase editors for editing, modifying, or altering a target nucleotide sequence of a polynucleotide. Described herein are nucleobase editors or base editors comprising a polynucleotide-programmable nucleotide-binding domain and a nucleobase-editing domain. The polynucleotide-programmable nucleotide-binding domain, when combined with a bound guide polynucleotide (e.g., gRNA), specifically binds to a target polynucleotide sequence (i.e., via complementary base pairing between the bases of the bound guide nucleic acid and the bases of the target polynucleotide sequence), thereby localizing the base editor to the target nucleic acid sequence where editing is desired. In some embodiments, the target polynucleotide sequence comprises single-stranded DNA or double-stranded DNA. In some embodiments, the target polynucleotide sequence comprises RNA. In some embodiments, the target polynucleotide sequence comprises a DNA-RNA hybrid.
[0103] Polynucleotide-programmable nucleotide-binding domains The term "polynucleotide programmable nucleotide binding domain" or "nucleic acid programmable DNA binding protein (napDNAbp)" refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., guide RNA), that guides the polynucleotide programmable nucleotide binding domain to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cpf1 protein.
[0104] CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). CRISPR clusters contain a spacer, a sequence complementary to the preceding mobile element, and a target aggressive nucleic acid. The CRISPR cluster is transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, proper processing of the pre-crRNA requires a transcoding small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and the Cas9 protein. The tracrRNA acts as a guide for ribonuclease 3-assisted processing of the pre-crRNA. Cas9 / crRNA / tracrRNA then endonucleolytically cleaves linear or circular dsDNA targets complementary to the spacer. Target strands not complementary to the crRNA are first endonucleolytically cleaved and then 3'-5' exonucleolytically trimmed. In nature, DNA binding and cleavage typically require both protein and RNA. However, single guide RNA ("sgRNA", or simply "gRNA") can be engineered to incorporate both crRNA and tracrRNA aspects into a single RNA species. See, for example, Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna JA, Charpentier E. Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes a short motif (PAM or protospacer adjacent motif) in the CRISPR repeat sequence, helping to distinguish self from non-self.
[0105] Nucleobase editor Cas9 domain The nuclease sequence and structure of Cas9 are known to those skilled in the art (e.g., "Complete genome sequence of an M1 strain of Streptococcus pyogenes," Ferretti et al., Natl. Acad. Sci. USA 98:4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III," Deltcheva E., Chylinski K., Sharma CM., Gonzales K., Chao Y., Pirzada ZA, Eckert MR, Vogel J., Charpentier E., Nature 471:602-607 (2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity," Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna JA, the entire contents of each of which are incorporated herein by reference). Charpentier E. Science 337:816-821 (2012). Orthologs of Cas9 have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, including Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference.
[0106] In some aspects, the nucleic acid programmable DNA binding protein (napDNAbp) is a Cas9 domain. Non-limiting exemplary Cas9 domains are provided herein. The Cas9 domain can be a nuclease-active Cas9 domain, a nuclease-inactive Cas9 domain, or a Cas9 nickase. In some embodiments, the Cas9 domain is a nuclease-active domain. For example, the Cas9 domain can be a Cas9 domain that cleaves both strands of a double-stranded nucleic acid (e.g., both strands of a double-stranded DNA molecule). In some embodiments, the Cas9 domain comprises any one of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to any one of the amino acid sequences described herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues compared to any one of the amino acid sequences described herein.
[0107] In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain. That is, Cas9 is a nickase, referred to as an "nCas9" protein (for "nickase" Cas9). Nuclease-inactivated Cas9 proteins may be interchangeably referred to as "dCas9" proteins (for nuclease-dead Cas9). Methods for producing Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains are known (see, e.g., Jinek et al., Science. 337:816-821 (2012); Qi et al., "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) Cell. 28; 152(5): 1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to contain two subdomains: the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, and the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of Cas9 in S. pyogenes (Jinek et al., Science. 337:816-821 (2012); Qi et al., Cell. 28;152(5): 1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided. For example, in some embodiments, the protein comprises one of two Cas9 domains: (1) the gRNA-binding domain of Cas9 or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or a fragment thereof are referred to as "Cas9 variants." Cas9 variants share homology with Cas9 or a fragment thereof.For example, the Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild-type Cas9. In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild-type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., the gRNA binding domain or the DNA cleavage domain), wherein the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild-type Cas9. In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of the corresponding wild-type Cas9.
[0108] In some embodiments, the fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length. In some embodiments, the wild-type Cas9 corresponds to Cas9 of Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, nucleotide and amino acid sequences are as follows: TIFF0007596259000002.tif164170 (single underline: HNH domain, double underline: RuvC domain).
[0109] In some embodiments, the wild-type Cas9 corresponds to or comprises the following nucleotide and / or amino acid sequence: TIFF0007596259000003.tif161168 (Single underline: HNH domain, double underline: RuvC domain)
[0110] In some embodiments, the wild-type Cas9 corresponds to Streptococcus pyogenes Cas9 (NCBI Reference Sequence: NC_002737.2 (nucleotide sequence as follows) and Uniprot Reference Sequence: Q99ZW2 (amino acid sequence as follows)). TIFF0007596259000004.tif164169 (Single underline: HNH domain, double underline: RuvC domain)
[0111] In some embodiments, Cas9 is Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1) or Neisseria meningitidis (NCBI Ref: YP_002342100.1), or Cas9 from other organisms.
[0112] In some embodiments, the dCas9 corresponds to or comprises, in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the activity of the Cas9 nuclease. For example, in some embodiments, the dCas9 domain comprises the D10A and H840A mutations or corresponding mutations in another Cas9. In some embodiments, the dCas9 comprises the amino acid sequence of dCas9 (D10A and H840A): Contains TIFF0007596259000005.tif163170 (single underline: HNH domain, double underline: RuvC domain).
[0113] In some embodiments, the Cas9 domain comprises a D10A mutation, while residue 840 remains a histidine at the corresponding position in any of the amino acid sequences provided above or provided herein.
[0114] In other embodiments, dCas9 variants are provided that have mutations other than D10A and H840A, resulting in, for example, a nuclease-inactivated Cas9 (dCas9). Such mutations include, for example, other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or the RuvC1 subdomain). In some embodiments, variants or homologs of dCas9 are provided that are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical. In some embodiments, variants of dCas9 are provided having amino acid sequences that are shorter or longer than about 5 amino acids, about 10 amino acids, about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 40 amino acids, about 50 amino acids, about 75 amino acids, about 100 amino acids, or more.
[0115] In some embodiments, the Cas9 fusion proteins provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. However, in other embodiments, the fusion proteins provided herein do not comprise the full-length Cas9 sequence, but rather only one or more fragments thereof. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein. Additional suitable sequences for Cas9 domains and fragments will be apparent to those skilled in the art.
[0116] The Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence complementary to the guide RNA. In some embodiments, the polynucleotide-programmable nucleotide-binding domain is a Cas9 domain, such as a nuclease-active Cas9, a Cas9 nickase (nCas9), or a nuclease-inactive Cas9 (dCas9). Examples of nucleic acid-programmable DNA-binding proteins include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), CasX, CasY, Cpfl, Cas12b / C2cl, and Cas12c / C2c3.
[0117] Nuclease-inactivated Cas9 proteins may be interchangeably referred to as "dCas9" proteins (meaning nuclease-dead Cas9) or catalytically inactive Cas9. Methods for producing Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains are known (see, e.g., Jinek et al., Science. 337:816-821 (2012); Qi et al., "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) Cell. 28;152(5):1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to contain two subdomains: the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, and the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of Cas9 in S. pyogenes (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28;152(5):1173-83 (2013)).
[0118] In some embodiments, the Cas9 domain is a Cas9 nickase. The Cas9 nickase can be a Cas9 protein that can cleave only one strand of a double-stranded nucleic acid molecule (e.g., a double-stranded DNA molecule). In some embodiments, the Cas9 nickase cleaves the targeted strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base-paired (complementary) to a gRNA (e.g., an sgRNA) bound to the Cas9. In some embodiments, the Cas9 nickase comprises a D10A mutation and a histidine at position 840. In some embodiments, the Cas9 nickase cleaves the non-targeted, non-base-edited strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base-paired to a gRNA (e.g., an sgRNA) bound to the Cas9. In some embodiments, the Cas9 nickase comprises a H840A mutation and an aspartic acid residue at position 10, or a corresponding mutation. In some embodiments, the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those of skill in the art based on this disclosure and knowledge in the art, and are within the scope of this disclosure.
[0119] In some embodiments, the Cas9 domain is a nuclease-inactive Cas9 domain (dCas9). For example, the dCas9 domain can bind to a duplexed nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the duplexed nucleic acid molecule. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10X mutation and a H840X mutation in the amino acid sequence described herein, or a corresponding mutation in any of the amino acid sequences provided herein, where X is any amino acid alteration. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10A mutation and a H840A mutation in the amino acid sequence described herein, or a corresponding mutation in any of the amino acid sequences provided herein. As an example, a nuclease-inactive Cas9 domain comprises the amino acid sequence provided in the cloning vector pPlatTET-gRNA2 (Accession No. BAV54124): (See, e.g., Qi et al., "Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression." Cell. 2013; 152(5):1173-83), the entire contents of which are incorporated herein by reference.)
[0120] It should be appreciated that additional Cas9 proteins (e.g., nuclease-dead Cas9 (dCas9), Cas9 nickase (nCas9), or nuclease-active Cas9), including variants and homologs thereof, are within the scope of this disclosure. Exemplary Cas9 proteins include, without limitation, those provided below. In some embodiments, the Cas9 protein is nuclease-dead Cas9 (dCas9). In some embodiments, the Cas9 protein is Cas9 nickase (nCas9). In some embodiments, the Cas9 protein is nuclease-active Cas9.
[0121] Exemplary catalytically inactive Cas9 (dCas9):
[0122] Exemplary catalytic Cas9 nickases (nCas9):
[0123] Exemplary catalytically active Cas9:
[0124] In some embodiments, Cas9 refers to Cas9 from Archaea (e.g., Nanoarchaea), which constitute the domain and kingdom of unicellular prokaryotic microorganisms. In some embodiments, nucleic acid-programmable DNA-binding protein refers to CasX or CasY, e.g., as described in Burstein et al., "New CRISPR-Cas systems from uncultivated microbes." Cell Res. 2017 Feb 21. doi: 10.1038 / cr.2017.21, the entire contents of which are incorporated herein by reference. Using genome-driven metagenomics, several CRISPR-Cas systems, including the first reported Cas9, have been identified in the Archaea domain of the living kingdom. This diverse Cas9 protein was found as part of an active CRISPR-Cas system in the less-studied Nanoarchaea. In bacteria, two previously unknown systems, CRISPR-CasX and CRISPR-CasY, have been discovered, which are among the most compact systems discovered to date. In some embodiments, in the base editing systems described herein, Cas9 is replaced with CasX or a variant of CasX. In some embodiments, in the base editing systems described herein, Cas9 is replaced with CasY or a variant of CasY. It should be recognized that other RNA-guided DNA-binding proteins can also be used as nucleic acid programmable DNA-binding proteins (napDNAbp) and are within the scope of the present disclosure.
[0125] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) of any of the fusion proteins provided herein can be a CasX or CasY protein. In some embodiments, the napDNAbp is a CasX protein. In some embodiments, the napDNAbp is a CasY protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally occurring CasX or CasY protein. In some embodiments, the napDNAbp is a naturally occurring CasX or CasY protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any CasX or CasY protein described herein. It should be recognized that CasX and CasY from other bacterial species may also be used in accordance with the present disclosure.
[0126] CasX (uniprot.org / uniprot / F0NN87; uniprot.org / uniprot / F0NH53) tr|F0NN87|F0NN87_SULIH CRISPR-associated Casx protein OS = Sulfolobus islandicus (strain HVE10 / 4) GN = SiH_0402 PE=4 SV=1 MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKKGEEGETTSNIILPLSGNDKNPWTETLKCYNFPTTTVALSEVFKNFSQVKECEEVSAPSFVKPEFYEFGRSPGMVERTRRVKLEVEPHYLIIAAGWVLTRLGKAKVSEGDYVGVNVFTPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVVSSVTNPNVSVVRIYTISDAVGQNPTTINGGFSIDLTKLLEKRYLLSERLEAIARNALSISSNMRERYIVLANYIYEYLTG SKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAYVNGELIRGEG
[0127] >tr|F0NH53|F0NH53_SULIR CRISPR associated protein, Casx OS = Sulfolobus islandicus(strain REY15A) GN=SiRe_0771 PE=4 SV=1 MEVPLYNIFGDNYIIQVATEAENSTIYNNKVEIDDEELRNVLNLAYKIAKNNEDAAAERRGKAKKKKGEEGETTSNIILPLSGNDKNPWTETLKCYNFPTTTVALSEVFKNFSQVKECEEVSAPSFVKPFEYKFGRSPGMVERTRRVKLEVEPHYLIMAAAGWVLTRLGKAKVSEGDYVGVNVFTPTRGILYSLIQNVNGIVPGIKPETAFGLWIARKVVSSVTNPNVSVVSIYTISDAVGQNPTTINGGFSIDLTKLLEKRDLLSERLEAIARNALSISSNMRERYIVLANYIYEYLTGSKRLEDLLYFANRDLIMNLNSDDGKVRDLKLISAYVNGELIRGEG Deltaproteobacteria CasX MEKRINKIRKKLSADNATKPVSRSGPMKTLLVRVMTDDLKKRLEKRRKKPEVMPQVISNNAANNLRMLLDDYTKMKEAILQVYWQEFKDDHVGLMCKFAQPASKKIDQNKLKPEMDEKGNLTTAGFACSQCGQPLFVYKLEQVSEKGKAYTNYFGRCNVAEHEKLILLAQLKPVKDSDEAVTYSLGKFGQRALDFYSIHVTKESTHPVKPLAQIAGNRYASGPVGKALSDACMGTIASFLSKYQDIIIEHQKVVKGNQKRLESLRELAGKENLEYPSVTLPPQPHTKEGVDfAYNEVIARVRMWVNLLWQKLKLSRDDAKPLLRLKGFPSFPVVERRENEVDWWNTINEVKKLIDAKRDMGRVFWSGVTAEKRNTILEGYNYLPNENDHKKREGSLENPKKPAKRQFGDLLLYLEKKYAGDWGKVFDEAWERIDKKIAGLTSHIEREEARNAEDAQSKAVLTDWLRAKASFVLERLKEMDEKEFYACEIQLQ KWYGDLRGNPFAVEAENRVVDISGFSIGSDGHSIQYRNLLAWKYLENGKREFYLLMNYGKKGRIRFTDGTDIKKSGKWQGLLYGGGGKAKVIDLTFDPDDEQLIILPLAFGTRQGREFIWNDLLSLETGLIKLANGRVIEKTIYNKKIGRDEPALFVALTFERREVVDPSNIKPVNLIGVARGENIPAVIALTDPEGCPLPEFKDSSGGPTDILRIGEGYKEKQRAIQAAKEVEQRRAGGYSRKFASKSRNLADDMVRNSARDLFYHAVTHDAVLVFANLSRGFGRQGKRTFMTERQYTKMEDWLTAKLAYEGLTSKTYLSKTLAQYTSKTCSNCGFTITYADMDVMLVRLKKTSDGWATTLNNKELKAEYQITYYNRYKRQTVEKELSAELDRLSEESGNNDISKWTKGRRDEALFLLKKRFSHRPVQEQFVCLDCGHEVHAAEQAALNIARSWLFLNSNSTEFKSYKSGKQPFVGAWQAFYKRRLKEVWKPNA
[0128] CasY (ncbi.nlm.nih.gov / protein / APG80656.1) >APG80656.1 CRISPR-associated protein CasY [uncultured Parcubacteria group bacterium]
[0129] It should be appreciated that polynucleotide programmable nucleotide binding domain also includes nucleic acid programmable protein that binds to RNA.For example, polynucleotide programmable nucleotide binding domain can associate with nucleic acid, which guides polynucleotide programmable nucleotide binding domain to RNA.Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, although not specifically listed in this disclosure. Cas proteins that can be used herein include class 1 and class 2. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, and Cas9. (also known as Csn1 or Csx12), Cas10, Csy1, Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx CRISPR enzymes include Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i, CARF, DinG, homologs thereof, or modified versions thereof. Unmodified CRISPR enzymes can have DNA cleavage activity, such as Cas9, which has two functional endonuclease domains, RuvC and HNH. CRISPR enzymes can direct cleavage of one or both strands of a target sequence, such as within the target sequence and / or within the complement of the target sequence. For example, the CRISPR enzyme can direct cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs of the first or last nucleotide of the target sequence.
[0130] Vectors can be used that encode CRISPR enzymes that are mutated relative to the corresponding wild-type enzyme, such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide that contains the target sequence. Cas9 can refer to a polypeptide having at least (about) 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology to a wild-type exemplary Cas9 polypeptide (e.g., S. pyogenes Cas9). Cas9 can refer to a polypeptide having at most (about) 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology to a wild-type exemplary Cas9 polypeptide (e.g., S. pyogenes Cas9). Cas9 can refer to wild-type or modified forms of the Cas9 protein, which may include amino acid changes such as deletions, insertions, substitutions, variants, mutations, fusions, chimeras, or any combination thereof.
[0131] In some embodiments, the methods described herein can utilize engineered Cas proteins. Guide RNAs (gRNAs) are short synthetic RNAs that contain a scaffold sequence required for Cas binding and a user-defined spacer of approximately 20 nucleotides that defines the genomic target to be modified. Thus, one skilled in the art can alter the genomic target of a Cas protein. Specificity is determined, in part, by how specific the gRNA target sequence is for that genomic target relative to other parts of the genome.
[0132] The Cas9 nuclease has two functional endonuclease domains, RuvC and HNH. Upon target binding, Cas9 undergoes a second conformational change that positions the nuclease domains to cleave opposite strands of the target DNA. The end result of Cas9-mediated DNA cleavage is a double-strand break (DSB) in the target DNA (approximately 3–4 nucleotides upstream of the PAM sequence). The resulting DSB is then repaired by one of two general repair pathways: (1) the efficient but error-prone non-homologous end joining (NHEJ) pathway, or (2) the less efficient but highly fidelity homology-directed repair (HDR) pathway.
[0133] The "efficiency" of non-homologous end joining (NHEJ) and / or homology-guided repair (HDR) can be calculated by any convenient method. For example, in some cases, efficiency can be expressed as the percentage of successful HDR. For example, a surveyor nuclease assay can be used to generate cleavage products, and the product-to-substrate ratio can be used to calculate the percentage. For example, a surveyor nuclease enzyme can be used to directly cleave DNA containing the newly incorporated restriction sequence as a result of successful HDR. A larger number of cleaved substrates indicates a larger percentage of HDR (larger HDR efficiency). As an illustrative example, the fraction (percentage) of HDR can be calculated using the following formula: [(cleavage product) / (substrate + cleavage product)] (e.g., (b + c) / (a + b + c), where "a" is the band intensity of the DNA substrate, and "b" and "c" are the band intensities of the cleavage products).
[0134] In some cases, efficiency can be expressed as the percentage of successful NHEJ. For example, a T7 endonuclease I assay can be used to generate cleavage products, and the product-to-substrate ratio can be used to calculate the percentage of NHEJ. T7 endonuclease I cleaves mismatched heteroduplex DNA resulting from hybridization of wild-type and mutant DNA strands (NHEJ produces small random insertions or deletions (indels) at the original break site). More cleavages indicate a higher percentage of NHEJ (higher efficiency of NHEJ). As an illustrative example, the percentage of NHEJ can be calculated using the following formula: (1-(1-(b+c) / (a+b+c)) 1 / 2 ) × 100, where "a" is the band intensity of the DNA substrate, and "b" and "c" are the band intensities of the cleavage products (Ran et al., Cell. 2013 Sep. 12; 154(6):1380-9; and Ran et al., Nat Protoc. 2013 Nov.; 8(11): 2281-2308).
[0135] The NHEJ repair pathway is the most active repair mechanism, which often results in small nucleotide insertions or deletions (indels) at DSB sites. The random nature of NHEJ-mediated DSB repair has important practical implications, as a population of cells expressing Cas9 and a gRNA or guide polynucleotide can result in diverse mutations. In most cases, NHEJ generates small indels that result in amino acid deletions, insertions, or frameshift mutations in the target DNA, which leads to premature stop codons in the open reading frame (ORF) of the target gene. The ideal end result is a loss-of-function mutation in the target gene.
[0136] While NHEJ-mediated DSB repair often disrupts the open reading frame of a gene, homology-directed repair (HDR) can be used to generate specific nucleotide changes ranging from single nucleotide changes to large insertions such as the addition of fluorophores or tags.
[0137] To utilize HDR for gene editing, a DNA repair template containing the desired sequence can be delivered to the cell type of interest along with a gRNA and Cas9 or Cas9 nickase. The repair template can contain the desired edit and additional homologous sequences directly upstream or downstream of the target (termed left and right homology arms). The length of each homology arm can depend on the magnitude of the modification to be introduced; larger insertions require larger homology arms. The repair template can be a single-stranded oligonucleotide, a double-stranded oligonucleotide, or a double-stranded DNA plasmid. HDR efficiency is generally low (less than 10% modified alleles) even in cells expressing Cas9, gRNA, and an exogenous repair template. Because HDR occurs during the S and G2 phases of the cell cycle, HDR efficiency can be improved by synchronizing cells. Chemical or genetic inhibition of genes involved in NHEJ can also increase the frequency of HDR.
[0138] In some embodiments, the Cas9 is a modified Cas9. A given gRNA target sequence may have additional sites throughout the genome where partial homology exists. These sites are called off-targets and must be considered when designing the gRNA. In addition to optimizing the gRNA design, Cas9 can also be modified to increase CRISPR specificity. Cas9 generates double-strand breaks (DSBs) by combining the activities of two nuclease domains, RuvC and HNH. Cas9 nickase is a D10A mutant of SpCas9 that retains one nuclease domain and generates DNA nicks rather than DSBs. For specific gene editing, the nickase system can also be combined with HDR-mediated gene editing.
[0139] In some cases, the Cas9 is a variant Cas9 protein. A variant Cas9 polypeptide has an amino acid sequence that differs by a single amino acid compared to the amino acid sequence of a wild-type Cas9 protein (e.g., has a deletion, insertion, substitution, or fusion). In some cases, the variant Cas9 polypeptide has an amino acid change (e.g., a deletion, insertion, or substitution) that reduces the nuclease activity of the Cas9 polypeptide. For example, in some cases, the variant Cas9 polypeptide has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nuclease activity of the corresponding wild-type Cas9 protein. In some cases, the variant Cas9 protein does not have substantial nuclease activity. When the subject Cas9 protein is a variant Cas9 protein that does not have substantial nuclease activity, it may be referred to as "dCas9."
[0140] In some cases, the variant Cas9 protein has reduced nuclease activity, e.g., the variant Cas9 protein exhibits less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or less than about 0.1% of the nuclease activity of a wild-type Cas9 protein, e.g., a wild-type Cas9 protein.
[0141] In some cases, a variant Cas9 protein can cleave the complementary strand of a guide target sequence but has reduced ability to cleave the non-complementary strand of a double-stranded guide target sequence. For example, a variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the RuvC domain. As a non-limiting example, in some embodiments, the variant Cas9 protein has D10A (aspartic acid to alanine at amino acid position 10), and thus is able to cleave the complementary strand of a double-stranded guide target sequence but has reduced ability to cleave the non-complementary strand of a double-stranded guide target sequence (thus resulting in a single-strand break (SSB) instead of a double-strand break (DSB) when the variant Cas9 protein cleaves a double-stranded target nucleic acid (see, e.g., Jinek et al., Science. 2012 Aug. 17; 337(6096):816-21).
[0142] In some cases, a variant Cas9 protein can cleave the non-complementary strand of a double-stranded guide target sequence but has reduced ability to cleave the complementary strand of the guide target sequence. For example, a variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the HNH domain (RuvC / HNH / RuvC domain motif). As a non-limiting example, in some embodiments, a variant Cas9 protein has an H840A (histidine to alanine at amino acid position 840) mutation, and thus is able to cleave the non-complementary strand of a guide target sequence but has reduced ability to cleave the complementary strand of a guide target sequence (thus resulting in an SSB instead of a DSB when the variant Cas9 protein cleaves a double-stranded guide target sequence). Such a Cas9 protein has reduced ability to cleave a guide target sequence (e.g., a single-stranded guide target sequence) but retains the ability to bind to the guide target sequence (e.g., a single-stranded guide target sequence).
[0143] In some cases, the variant Cas9 protein has a reduced ability to cleave both the complementary and non-complementary strands of a double-stranded target DNA. As a non-limiting example, in some cases, the variant Cas9 protein has both the D10A and H840A mutations, such that the polypeptide has a reduced ability to cleave both the complementary and non-complementary strands of a double-stranded target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retain the ability to bind to target DNA (e.g., single-stranded target DNA).
[0144] As another non-limiting example, in some cases, a variant Cas9 protein has the W476A and W1126A mutations, such that the polypeptide has a reduced ability to cleave target DNA. Such a Cas9 protein has a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retains the ability to bind to target DNA (e.g., single-stranded target DNA).
[0145] As another non-limiting example, in some cases, a variant Cas9 protein has the following mutations: P475A, W476A, N477A, D1125A, W1126A, and D1127A, such that the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA), but retain the ability to bind to target DNA (e.g., single-stranded target DNA).
[0146] As another non-limiting example, in some cases, a variant Cas9 protein has the mutations H840A, W476A, and W1126A, such that the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). As another non-limiting example, in some cases, a variant Cas9 protein has the mutations H840A, D10A, W476A, and W1126A, such that the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). In some embodiments, a variant Cas9 has a catalytic His residue restored to position 840 of the Cas9 HNH domain (A840H).
[0147] As another non-limiting example, in some cases, a variant Cas9 protein has the following mutations: H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A, and thus the polypeptide has a reduced ability to cleave target DNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). As another non-limiting example, in some cases, a variant Cas9 protein has the following mutations: D10A, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A, and thus the polypeptide has a reduced ability to cleave target DNA (e.g., single-stranded target DNA). Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). In some cases, when a variant Cas9 protein has the W476A and W1126A mutations, or when a variant Cas9 protein has the P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, the variant Cas9 protein does not efficiently bind to the PAM sequence. Thus, in some such cases, when such a variant Cas9 protein is used in a binding method, the method does not require a PAM sequence. In other words, in some cases, when such a variant Cas9 protein is used in a binding method, the method can include a guide RNA, but can be performed in the absence of a PAM sequence (thus, binding specificity is provided by the target segment of the guide RNA). Other residues (i.e., inactive residues or other nuclease moieties) can be mutated to achieve the above-mentioned effects. By way of non-limiting example, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987 can be altered (i.e., substituted). Also, mutations other than alanine substitutions are suitable.
[0148] In some embodiments, a variant Cas9 protein with reduced catalytic activity (e.g., if the Cas9 protein has mutations at D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987, e.g., D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and / or D986A) can still bind to target DNA in a site-specific manner (as it is guided to the target DNA sequence by the guide RNA), so long as it retains the ability to interact with the guide RNA.
[0149] Alternatives to S. pyogenes Cas9 include RNA-guided endonucleases of the Cpf1 family that exhibit cleavage activity in mammalian cells. CRISPR from Prevotella and Francisella 1 (CRISPR / Cpf1) is a DNA editing technology similar to the CRISPR / Cas9 system. Cpf1 is an RNA-guided endonuclease of a class II CRISPR / Cas system. This adaptive immune mechanism is found in Prevotella and Francisella bacteria. The Cpf1 gene is associated with the CRISPR locus and encodes an endonuclease that uses guide RNA to find and cleave viral DNA. Cpf1 is a smaller and simpler endonuclease than Cas9, overcoming some of the limitations of the CRISPR / Cas9 system. Unlike Cas9 nuclease, Cpf1-mediated DNA cleavage results in a double-strand break with a short 3' overhang. The zigzag cleavage pattern of Cpf1 allows for directional gene transfer, similar to conventional restriction enzyme cloning, thereby increasing the efficiency of gene editing. Like the Cas9 variants and orthologs described above, Cpf1 can expand the number of sites that can be targeted by CRISPR in AT-rich regions or AT-rich genomes that lack the NGG PAM site favored by SpCas9. The Cpf1 locus contains a mixed α / β domain, a helical region followed by RuvC-I, RuvC-II, and a zinc finger-like domain. The Cpf1 protein possesses a RuvC-like endonuclease domain similar to the RuvC domain of Cas9. Furthermore, Cpf1 lacks the HNH endonuclease domain, and the N-terminus of Cpf1 lacks the α-helical recognition lobe of Cas9. The organization of the Cpf1 CRISPR-Cas domain indicates that Cpf1 is functionally unique and classifies it as a class 2, type V CRISPR system. The Cpf1 locus encodes Cas1, Cas2, and Cas4 proteins that are closer to type I and type III than to type II systems.Functional Cpf1 does not require trans-activating CRISPR RNA (tracrRNA) and therefore only requires CRISPR (crRNA). Cpf1 is not only smaller than Cas9, but also possesses a smaller sgRNA molecule (almost half the number of nucleotides as Cas9), which is advantageous for genome editing. The Cpf1-crRNA complex cleaves the target DNA or RNA by identifying the protospacer-adjacent motif 5'-YTN-3', as opposed to the G-rich PAM targeted by Cas9. After PAM identification, Cpf1 introduces a sticky-end-like DNA double-strand break with a 4- to 5-nucleotide overhang.
[0150] Some aspects of the present disclosure provide fusion proteins containing a domain acting as a nucleic acid-programmable DNA-binding protein, which can be used to guide proteins such as base editors to specific nucleic acid (e.g., DNA or RNA) sequences. In certain embodiments, the fusion protein comprises a nucleic acid-programmable DNA-binding protein domain and a deaminase domain. DNA-binding proteins include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, and Cas12i. One example of a programmable polynucleotide-binding protein with PAM specificity different from Cas9 is Clustered Regularly Interspaced Short Palindromic Repeats (Cpfl) from Provotella and Francisella 1. Like Cas9, Cpfl is also a class 2 CRISPR effector. Cpf1 has been shown to mediate robust DNA interference with characteristics distinct from Cas9. Cpf1 is a single RNA-guided endonuclease lacking tracrRNA, which utilizes a T-rich protospacer adjacent motif (TTN, TTTN, or YTN). Furthermore, Cpf1 cleaves DNA through zigzag DNA double-strand breaks. Among the 16 Cpf1 family proteins, two enzymes from Acidaminococcus and Lachnospiraceae have been shown to have efficient genome editing activity in human cells. Cpf1 proteins are known in the art and have been previously described, for example, in Yamano et al., "Crystal structure of Cpf1 in complex with guide RNA and target DNA," Cell (165) 2016, pp. 949-962, the entire contents of which are incorporated herein by reference.
[0151] Nuclease-inactive Cpf1 (dCpf1) variants are also useful in the compositions and methods of the present invention and can be used as guide nucleotide sequence-programmable polynucleotide-binding protein domains. The Cpf1 protein has a RuvC-like endonuclease domain similar to the RuvC domain of Cas9, but does not have the HNH endonuclease domain, and the N-terminus of Cpf1 lacks the α-helical recognition lobe of Cas9. Zetsche et al., Cell, 163, 759-771, 2015 (incorporated herein by reference) showed that the RuvC-like domain of Cpf1 is involved in cleaving both DNA strands, and inactivating the RuvC-like domain inactivates the nuclease activity of Cpf1. For example, mutations corresponding to D917A, E1006A, or D1255A in Francisella novicida Cpf1 inactivate the nuclease activity of Cpf1. In some embodiments, dCpfl of the present disclosure comprises mutations corresponding to D917A, E1006A, D1255A, D917A / E1006A, D917A / D1255A, E1006A / D1255A, or D917A / E1006A / D1255A. It is understood that any mutation, e.g., a substitution mutation, deletion, or insertion that inactivates the RuvC domain of Cpfl, can be used in accordance with the present disclosure.
[0152] In some embodiments, the nucleic acid-programmable nucleotide-binding protein of any of the fusion proteins provided herein can be a Cpfl protein. In some embodiments, the Cpfl protein is a Cpfl nickase (nCpfl). In some embodiments, the Cpfl protein is a nuclease-inactive Cpfl (dCpfl). In some embodiments, the Cpfl, nCpfl, or dCpfl comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cpfl sequence disclosed herein. In some embodiments, the dCpfl comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cpfl sequence disclosed herein, and includes mutations corresponding to D917A, E1006A, D1255A, D917A / E1006A, D917A / D1255A, E1006A / D1255A, or D917A / E1006A / D1255A. It will be appreciated that Cpfl from other bacterial species may also be used in accordance with the present disclosure.
[0153] Wild-type Francisella novicida Cpf1 (D917, E1006, and D1255 are bold and underlined). MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI DRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF E DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA D ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0154] Cpf1 D917A from Francisella novicida (A917, E1006, and D1255 are bold and underlined). MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI ARGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF E DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA D ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0155] Cpf1 E1006A from Francisella novicida (D917, A1006, and D1255 are bold and underlined). MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI DRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF A DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA D ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0156] Cpf1 D1255A from Francisella novicida (D917, E1006, and A1255 are bold and underlined). MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI DRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF E DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA A ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0157] Francisella novicida Cpf1 D917A / E1006A (A917, A1006, and D1255 are bold and underlined) MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI ARGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF A DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA D ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0158] Francisella novicida Cpf1 D917A / D1255A (A917, E1006, and A1255 are bold and underlined) MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI ARGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF E DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA A ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0159] Cpf1 E1006A / D1255A from Francisella novicida (D917, A1006, and A1255 are bold and underlined). MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI DRGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF A DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA A ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0160] Francisella novicida Cpf1 D917A / E1006A / D1255A (A917, A1006, and A1255 are bold and underlined) MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDLQKDFKSAKDTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELFKANSDITDIDEALEIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQRVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYEQIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKL ALEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQGKKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHFYLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKNKEPDNTAILFIKDDKYYLGVMNKKNNKIFDKAIKENKGEGYKKIVYKKLLPGANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLTFENISEYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERNLQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDLIKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSI ARGERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVF A DLNFGFKRGRFKVEKQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKGYFEFSFDY KNFGDKAAKGKWTIASFFGSRLINFRNSDKNHNWDTREVYPTKELEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTELDYLISPVADVNGNFFDSRQAPKNMPQDA A ANGAYHIGLKGLMLLGRIKNNQEGKKLNLVIKNEEYFEFVQNRNN
[0161] In some embodiments, one of the Cas9 domains present in the fusion protein may be replaced with a guide nucleotide sequence-programmable DNA binding protein domain that has no requirement for a PAM sequence.
[0162] In some embodiments, the nucleic acid programmable DNA-binding protein (napDNAbp) is a single effector of a microbial CRISPR / Cas system. Single effectors of microbial CRISPR / Cas systems include, but are not limited to, Cas9, Cpf1, Cas12b / C2c1, and Cas12c / C2c3. Typically, microbial CRISPR / Cas systems are divided into class 1 and class 2 systems. Class 1 systems contain multi-subunit effector complexes, while class 2 systems contain single protein effectors. For example, Cas9 and Cpf1 are class 2 effectors. In addition to Cas9 and Cpf1, three distinct Class 2 CRISPR / Cas systems (Cas12b / C2c1, and Cas12c / C2c3) have been described by Shmakov et al., "Discovery and Functional Characterization of Diverse Class 2 CRISPR Cas Systems," Mol. Cell, 2015 Nov. 5; 60(3): 385-397, the entire contents of which are incorporated herein by reference. Two effectors in systems Cas12b / C2c1 and Cas12c / C2c3 contain a RuvC-like endonuclease domain related to Cpf1. The third system contains an effector with two described HEPN ribonuclease domains. Unlike CRISPR RNA production by Cas12b / C2c1, mature CRISPR RNA production is independent of tracrRNA. Cas12b / C2c1 depends on both CRISPR RNA and tracrRNA for DNA cleavage.
[0163] The crystal structure of Alicyclobacillus acidoterrastris Cas12b / C2c1 (AacC2c1) has been reported in complex with a chimeric single-molecule guide RNA (sgRNA). See, e.g., Liu et al., "C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism," Mol. Cell, 2017 Jan. 19; 65(2):310-322, the entire contents of which are incorporated herein by reference. The crystal structure of Alicyclobacillus acidoterrestris C2c1 bound to target DNA as a ternary complex has also been reported. See, e.g., Yang et al., "PAM-dependent Target DNA Recognition and Cleavage by C2C1 CRISPR-Cas endonuclease," Cell, 2016 Dec. 15; 167(7):1814-1828, the entire contents of which are incorporated herein by reference. The catalytically competent AacC2c1 conformation is independently trapped within a single RuvC catalytic pocket along with both the target and non-target DNA strands, and Cas12b / C2c1-mediated cleavage results in a zigzag seven-nucleotide cut in the target DNA. Structural comparison of the Cas12b / C2c1 ternary complex with its previously identified Cas9 and Cpf1 counterparts demonstrates the mechanistic diversity employed by the CRISPR-Cas9 system.
[0164] In some embodiments, the nucleic acid programmable DNA-binding protein (napDNAbp) of any of the fusion proteins provided herein can be a Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, the napDNAbp is a Cas12b / C2c1 protein. In some embodiments, the napDNAbp is a Cas12c / C2c3 protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally occurring Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, the napDNAbp is a naturally occurring Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the napDNAbp sequences provided herein. It should be recognized that Cas12b / C2c1 or Cas12c / C2c3 from other bacterial species may also be used in accordance with the present disclosure. Cas12b / C2c1 (uniprot.org / uniprot / T0D7A2#2) sp|T0D7A2| / C2C1_ALIAG CRISPR-associated endo-nuclease C2c1 OS = =Alicyclobacillus acido-terrestris ((strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) GN=c2c1 PE=1 SV=1 BhCas12b (Bacillus hisashii) NCBI Reference Sequence: WP_095142515
[0165] In some embodiments, the Cas12b is BvCas12B, which is a variant of BhCas12b and contains the following changes relative to BhCas12B: S893R, K846R, and E837G. BvCas12b (Bacillus sp. V3-13) NCBI Reference Sequence: WP_101661451.1
[0166] In some embodiments, the Cas9 domain is a Staphylococcus aureus Cas9 domain (SaCas9). In some embodiments, the SaCas9 domain is a nuclease-active SaCas9, a nuclease-inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 comprises an N579A mutation or a corresponding mutation in any of the amino acid sequences provided herein.
[0167] In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence with a non-canonical PAM. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence with an NNGRRT or NNNRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of the following mutations: E781X, N967X, and R1014X, or a corresponding mutation in any of the amino acid sequences provided herein, where X is any amino acid. In some embodiments, the SaCas9 domain comprises one or more of the following mutations: E781K, N967K, and R1014H, or a corresponding mutation in any of the amino acid sequences provided herein. In some embodiments, the SaCas9 domain comprises the following mutations: E781K, N967K, or R1014H, or a corresponding mutation in any of the amino acid sequences provided herein.
[0168] In some embodiments, the variant Cas protein can be SpCas9, SpCas9-VRQR, SpCas9-VRER, xCas9 (sp), SaCas9, SaCas9-KKH, SpCas9-MQKSER, SpCas9-LRKIQK, or SpCas9-LRVSQL.
[0169] Exemplary SaCas9 Sequences KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQ KKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLPKKVDLSQQK EIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEE NSKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNLDVKVKSINGGFTSFLRRKWKFKKERNKGY KHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKL KKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVI KKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG Residue N579, shown above in bold and underlined, may be mutated (e.g., to A579) to obtain a SaCas9 nickase.
[0170] Exemplary SaCas9n Sequences KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQ KKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLPKKVDLSQQK EIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEE ASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNLDVKVKSINGGFTSFLRRKWKFKKERNKGY KHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKL KKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVI KKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG
[0171] Residue A579, shown above, which can be mutated from N579 to yield SaCas9 nickase, is underlined and in bold.
[0172] Exemplary SaKKH Cas9 KRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQ KKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLPKKVDLSQQK EIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEE A SKKGNRTPFQYLSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEITEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNR K LINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFY KNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPP H IIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG. Residue A579, which can be mutated from N579 to yield SaCas9 nickase, is underlined and in bold above. Residues K781, K967, and H1014, which can be mutated from E781, N967, and R1014 to yield SaKKH Cas9, are underlined and in italics above.
[0173] The polynucleotide-programmable nucleotide-binding domain of a base editor itself comprises one or more domains. For example, a polynucleotide-programmable nucleotide-binding domain can comprise one or more nuclease domains. In some embodiments, the nuclease domain of a polynucleotide-programmable nucleotide-binding domain can comprise an endonuclease or exonuclease. As used herein, the term "exonuclease" refers to a protein or polypeptide capable of digesting nucleic acids (e.g., RNA or DNA) from their free ends, and the term "endonuclease" refers to a protein or polypeptide capable of catalyzing (e.g., cleaving) an internal region of a nucleic acid (e.g., DNA or RNA). In some embodiments, an endonuclease can cleave one strand of a double-stranded nucleic acid. In some embodiments, an endonuclease can cleave both strands of a double-stranded nucleic acid molecule. In some embodiments, a polynucleotide-programmable nucleotide-binding domain can be a deoxyribonuclease. In some embodiments, a polynucleotide-programmable nucleotide-binding domain can be a ribonuclease.
[0174] In some embodiments, the nuclease domain of a polynucleotide-programmable nucleotide-binding domain can cleave zero, one, or two strands of a target polynucleotide. In some cases, the polynucleotide-programmable nucleotide-binding domain can include a nickase domain. As used herein, the term "nickase" refers to a polynucleotide-programmable nucleotide-binding domain that includes a nuclease domain that can cleave only one of the two strands of a double-stranded nucleic acid molecule (e.g., DNA). In some embodiments, a nickase can be derived from a fully catalytically active (e.g., native) form of the polynucleotide-programmable nucleotide-binding domain by introducing one or more mutations into the active polynucleotide-programmable nucleotide-binding domain. For example, if the polynucleotide-programmable nucleotide-binding domain includes a nickase domain derived from Cas9, the Cas9-derived nickase domain can include a D10A mutation and a histidine at position 840. In such a case, residue H840 retains catalytic activity and is therefore capable of cleaving one strand of a nucleic acid duplex. In another example, a Cas9-derived nickase domain can contain an H840A mutation, but the amino acid residue at position 10 remains D. In some embodiments, a nickase can be derived from a fully catalytically active (e.g., native) form of a polynucleotide-programmable nucleotide-binding domain by removing all or part of a nuclease domain that is not required for nickase activity. For example, if a polynucleotide-programmable nucleotide-binding domain comprises a Cas9-derived nickase domain, the Cas9-derived nickase domain can include a deletion of all or part of the RuvC domain or the HNH domain.
[0175] Thus, a base editor comprising a polynucleotide-programmable nucleotide-binding domain comprising a nickase domain can generate a single-stranded DNA break (nick) at a specific polynucleotide target sequence (e.g., as determined by the complementary sequence of a bound guide nucleic acid). In some embodiments, the strand of a nucleic acid double-stranded target polynucleotide sequence cleaved by a base editor comprising a nickase domain (e.g., a nickase domain derived from Cas9) is the strand that is not edited by the base editor (i.e., the strand cleaved by the base editor is the strand opposite the strand containing the base to be edited). In other embodiments, a base editor comprising a nickase domain (e.g., a nickase domain derived from Cas9) can cleave the strand of a DNA molecule that is targeted for editing. In such cases, the non-targeted strand is not cleaved.
[0176] Also provided herein are base editors comprising catalytically dead (i.e., incapable of cleaving a target polynucleotide sequence) polynucleotide-programmable nucleotide binding domains. The terms "catalytically dead" and "nuclease-dead" are used interchangeably herein to refer to polynucleotide-programmable nucleotide binding domains with one or more mutations and / or deletions that result in the loss of their ability to cleave a strand of nucleic acid. In some embodiments, a catalytically dead polynucleotide-programmable nucleotide binding domain base editor can lack nuclease activity as a result of specific point mutations in one or more nuclease domains. For example, in the case of a base editor comprising a Cas9 domain, Cas9 can contain both the D10A and H840A mutations. Such mutations inactivate both nuclease domains, thereby resulting in the loss of nuclease activity. In other embodiments, a catalytically dead polynucleotide-programmable nucleotide binding domain can contain one or more deletions of all or part of a catalytic domain (e.g., the RuvC1 and / or HNH domain). In further embodiments, the catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g., D10A or H840A) as well as a deletion of all or part of the nuclease domain.
[0177] Mutations that can produce catalytically dead polynucleotide-programmable nucleotide-binding domains from previously functional versions of the polynucleotide-programmable nucleotide-binding domain are also contemplated herein. For example, in the case of catalytically dead Cas9 ("dCas9"), variants with mutations other than D10A and H840A are provided, resulting in nuclease-inactivated Cas9. Such mutations include, for example, other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or the RuvC1 subdomain).
[0178] Additional suitable nuclease-inactive dCas9 domains will be apparent to those skilled in the art based on this disclosure and knowledge in the art and are within the scope of the present disclosure. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, the D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference). In some embodiments, the dCas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the dCas9 domains provided herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences described herein.In some embodiments, the Cas9 domain comprises an amino acid sequence having at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues compared to any one of the amino acid sequences described herein.
[0179] Non-limiting examples of polynucleotide-programmable nucleotide-binding domains that can be incorporated into base editors include CRISPR protein-derived domains, restriction nucleases, meganucleases, TAL nucleases (TALENs), and zinc finger nucleases (ZFNs). In some cases, the base editor comprises a polynucleotide-programmable nucleotide-binding domain comprising a natural or modified protein or portion thereof that can bind to a nucleic acid sequence via a bound guide nucleic acid during CRISPR (i.e., Clustered Regularly Interspaced Short Palindromic Repeats)-mediated modification of the nucleic acid. Such proteins are referred to herein as "CRISPR proteins." Thus, disclosed herein are base editors that comprise a polynucleotide-programmable nucleotide-binding domain comprising all or a portion of a CRISPR protein (i.e., a base editor that comprises all or a portion of a CRISPR protein as a domain, also referred to as the "CRISPR protein-derived domain" of the base editor). The CRISPR protein-derived domain incorporated into the base editor can be modified compared to a wild-type or natural version of the CRISPR protein. For example, as described below, a domain derived from a CRISPR protein can include one or more mutations, insertions, deletions, rearrangements, and / or modifications relative to a wild-type or naturally occurring version of the CRISPR protein.
[0180] In some embodiments, the domain derived from a CRISPR protein incorporated into the base editor is an endonuclease (e.g., a deoxyribonuclease or ribonuclease) capable of binding to a target polynucleotide when linked to a bound guide nucleic acid. In some embodiments, the domain derived from a CRISPR protein incorporated into the base editor is a nickase capable of binding to a target polynucleotide together with a bound guide nucleic acid. In some embodiments, the domain derived from a CRISPR protein incorporated into the base editor is a catalytically dead domain capable of binding to a target polynucleotide together with a bound guide nucleic acid. In some embodiments, the target polynucleotide bound by the CRISPR protein-derived domain of the base editor is DNA. In some embodiments, the target polynucleotide bound by the CRISPR protein-derived domain of the base editor is RNA.
[0181] In some embodiments, the base editor CRISPR protein-derived domains are derived from Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquis (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1); Listeria innocua (NCBI Ref: NP_472073.1); Campylobacter jejuni (NCBI Ref: YP_002344900.1); Neisseria meningitidis (NCBI Ref: YP_002342100.1), Streptococcus pyogenes, or Staphylococcus aureus.
[0182] In some embodiments, the Cas9-guided domain of the base editor is a Staphylococcus aureus Cas9 domain (SaCas9). In some embodiments, the SaCas9 domain is a nuclease-active SaCas9, a nuclease-inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 domain comprises an N579X mutation. In some embodiments, the SaCas9 domain comprises an N579A mutation. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain is capable of binding to a nucleic acid sequence with a non-canonical PAM. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain is capable of binding to a nucleic acid sequence with an NNGRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of the following mutations: E781X, N967X, and R1014X.
[0183] A base editor can comprise a domain derived from all or a portion of a high-fidelity Cas9, Cas9. In some embodiments, the high-fidelity Cas9 domain of a base editor is an engineered Cas9 domain that comprises one or more mutations that reduce the electrostatic interaction between the Cas9 domain and the sugar-phosphate backbone of DNA relative to the corresponding wild-type Cas9 domain. A high-fidelity Cas9 domain with reduced electrostatic interactions with the sugar-phosphate backbone of DNA can have fewer off-target effects. In some embodiments, the Cas9 domain (e.g., a wild-type Cas9 domain) comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of DNA. In some embodiments, the Cas9 domain comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of the DNA by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70% or more.
[0184] In some embodiments, the modified Cas9 is a high-fidelity Cas9 enzyme. In some embodiments, the high-fidelity Cas9 enzyme is SpCas9(K855A), eSpCas9(1.1), SpCas9-HF1, or a hyper-precise Cas9 variant (HypaCas9). The modified Cas9 eSpCas9(1.1) contains an alanine substitution that weakens the interaction between the HNH / RuvC groove and the non-target DNA strand, preventing strand separation and cleavage at off-target sites. Similarly, SpCas9-HF1 reduces off-target editing through an alanine substitution that disrupts the interaction of Cas9 with the DNA phosphate backbone. HypaCas9 contains mutations in the REC3 domain (SpCas9 N692A / M694A / Q695A / H698A) that enhance Cas9 proofreading and target discrimination. All three high-fidelity enzymes produce fewer off-target edits than wild-type Cas9. Exemplary high-fidelity Cas9s are provided below. High-fidelity Cas9 domain mutations to Cas9 are shown in bold and underlined. MDKKYSIGL A IGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEK YPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFK SNFDLAEDAKLQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTA FDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWG A LSRKLINGIRDKQSGKTILDFLKSDGFANRNFM A LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEK LYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETR A ITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKY FFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVA KVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQL FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0185] Guide polynucleotide
[0186] As used herein, the term "guide polynucleotide" refers to a polynucleotide that can be specific to a target sequence and can form a complex with a polynucleotide-programmable nucleotide-binding domain protein (e.g., Cas9 or Cpfl). In one embodiment, the guide polynucleotide is a guide RNA. As used herein, the term "guide RNA (gRNA)" and its grammatical equivalents can refer to an RNA that can be specific to a target DNA and can form a complex with a Cas protein. The RNA / Cas complex can assist in "guiding" the Cas protein to the target DNA. Cas9 / crRNA / tracrRNA cleaves linear or circular dsDNA targets complementary to the spacer by endonucleolytic degradation. The target strand that is not complementary to the crRNA is first cleaved by endonucleolytic degradation and then trimmed by 3'-5' exonucleolytic degradation. In nature, DNA binding and cleavage typically require both proteins and RNAs. However, single guide RNAs ("sgRNAs" or simply "gRNAs") can be engineered to incorporate aspects of both crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes a short motif (the PAM or protospacer adjacent motif) in the CRISPR repeat sequence, which helps distinguish self from non-self.The nuclease sequence and structure of Cas9 are known to those skilled in the art (see, for example, "Complete genome sequence of an M1 strain of Streptococcus pyogenes," Ferretti, JJ et al., Natl. Acad. Sci. USA 98:4658-4663(2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III," Deltcheva E. et al., Nature 471:602-607(2011); and "Programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity," Jinek M.et al., Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Orthologs of Cas9 include, but are not limited to, S. pyogenes and S. Cas9 nucleases have been described in various species, including B. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, including Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference. In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain, i.e., Cas9 is a nickase.
[0187] In some embodiments, the guide polynucleotide is at least one single guide RNA ("sgRNA" or "gRNA"). In some embodiments, the guide polynucleotide is at least one tracrRNA. In some embodiments, the guide polynucleotide does not require a PAM sequence to guide the polynucleotide-programmable DNA-binding domain (e.g., Cas9 or Cpfl) to the target nucleotide sequence.
[0188] The polynucleotide-programmable nucleotide-binding domain (e.g., a CRISPR guidance domain) of the base editor disclosed herein can recognize a target polynucleotide sequence by associating with a guide polynucleotide. The guide polynucleotide (e.g., a guide RNA) is typically single-stranded and can be programmed to site-specifically bind to a polynucleotide target sequence (e.g., via complementary base pairing), thereby guiding a base editor associated with the guide nucleic acid to the target sequence. The guide polynucleotide can be DNA. The guide polynucleotide can be RNA. In some cases, the guide polynucleotide includes natural nucleotides (e.g., adenosine). In some cases, the guide polynucleotide includes unnatural (or non-natural) nucleotides (e.g., peptide nucleic acids or nucleotide analogs). In some cases, the target region of the guide nucleic acid sequence can be at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The target region of the guide nucleic acid can be 10-30 nucleotides in length, or 15-25 nucleotides in length, or 15-20 nucleotides in length.
[0189] In some embodiments, a guide polynucleotide comprises two or more individual polynucleotides, which can interact with each other, e.g., through complementary base pairing (e.g., a dual guide polynucleotide). For example, a guide polynucleotide can comprise a CRISPR RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). For example, a guide polynucleotide can comprise one or more trans-activating CRISPR RNAs (tracrRNAs).
[0190] In Type II CRISPR systems, targeting of nucleic acids by CRISPR proteins (e.g., Cas9) typically requires complementary base pairing between a first RNA molecule (crRNA) that contains a sequence that recognizes the target sequence and a second RNA molecule (trRNA) that contains a repeat sequence that forms a scaffold region that stabilizes the guide RNA-CRISPR protein complex. Such dual-guide RNA systems can be employed as guide polynucleotides to direct the base editors disclosed herein to target polynucleotide sequences.
[0191] In some embodiments, the base editors provided herein utilize a single guide polynucleotide (e.g., a gRNA). In some embodiments, the base editors provided herein utilize a dual guide polynucleotide (e.g., a dual gRNA). In some embodiments, the base editors provided herein utilize one or more guide polynucleotides (e.g., multiple gRNAs). In some embodiments, a single guide polynucleotide is utilized for the various base editors described herein. For example, a single guide polynucleotide can be utilized for a cytidine base editor and an adenosine base editor.
[0192] In other embodiments, a guide polynucleotide can include both a polynucleotide target portion of a nucleic acid and a scaffold portion of a nucleic acid within a single molecule (i.e., a single-molecule guide nucleic acid). For example, a single-molecule guide polynucleotide can be a single guide RNA (sgRNA or gRNA). As used herein, the term guide polynucleotide sequence contemplates any single, double, or multiple molecule nucleic acid that can interact with and guide a base editor to a target polynucleotide sequence.
[0193] Typically, a guide polynucleotide (e.g., a crRNA / trRNA complex or a gRNA) comprises a "polynucleotide targeting segment" that includes a sequence capable of recognizing and binding to a target polynucleotide sequence, and a "protein-binding segment" that stabilizes the guide polynucleotide within the polynucleotide-programmable nucleotide-binding domain component of a base editor. In some embodiments, the polynucleotide targeting segment of a guide polynucleotide recognizes and binds to a DNA polynucleotide, thereby facilitating base editing in the DNA. In other cases, the polynucleotide targeting segment of a guide polynucleotide recognizes and binds to an RNA polynucleotide, thereby facilitating base editing in the RNA. As used herein, a "segment" refers to a segment or region of a molecule, e.g., a contiguous stretch of nucleotides in a guide polynucleotide. A segment can also refer to a region / segment of a complex, such that a segment can comprise regions of more than one molecule. For example, in cases where a guide polynucleotide comprises multiple nucleic acid molecules, the protein-binding segment can comprise all or part of multiple individual molecules, e.g., hybridizing along regions of complementarity. In some embodiments, the protein-binding segment of a DNA-targeting RNA comprising two separate molecules may comprise (i) base pairs 40-75 of a first RNA molecule that is 100 base pairs in length, and (ii) base pairs 10-25 of a second RNA molecule that is 50 base pairs in length. The definition of "segment," unless otherwise specifically defined in a particular context, is not limited to a particular number of total base pairs, is not limited to any particular number of base pairs in a given RNA molecule, is not limited to a particular number of separate molecules in a complex, and may include regions of RNA molecules of any overall length and may include regions having complementarity with other molecules.
[0194] The guide RNA or guide polynucleotide may comprise two or more RNAs, such as a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA). The guide RNA or guide polynucleotide may comprise a single-stranded RNA or a single guide RNA (sgRNA) formed by the fusion of a portion (e.g., a functional portion) of the crRNA and the tracrRNA. The guide RNA or guide polynucleotide may also be a duplex RNA comprising a crRNA and a tracrRNA. Furthermore, the crRNA can hybridize with the target DNA.
[0195] As discussed above, guide RNA or guide polynucleotide can be an expression product.For example, DNA encoding guide RNA can be a vector containing a sequence encoding guide RNA.Guide RNA or guide polynucleotide can be transferred into cells by transfecting cells with isolated guide RNA or plasmid DNA containing a sequence encoding guide RNA and a promoter.Guide RNA or guide polynucleotide can also be transferred into cells by other methods, such as using virus-mediated gene delivery.
[0196] Guide RNA or guide polynucleotide can be isolated.For example, guide RNA can be transfected into cells or organisms in the form of isolated RNA.Guide RNA can be prepared by in vitro transcription using any in vitro transcription system known in the art.Guide RNA can be transferred into cells in the form of isolated RNA, not in the form of a plasmid containing a sequence encoding guide RNA.
[0197] A guide RNA or guide polynucleotide may comprise three regions: a first region at the 5' end that may be complementary to a target site in a chromosomal sequence, a second internal region that may form a stem-loop structure, and a third 3' region that may be single-stranded. The first region of each guide RNA may be different, thereby allowing each guide RNA to guide the fusion protein to a specific target site. Furthermore, the second and third regions of each guide RNA may be identical among all guide RNAs.
[0198] The first region of the guide RNA or guide polynucleotide can be complementary to a sequence at a target site in a chromosomal sequence, thereby allowing the first region of the guide RNA to base-pair with the target site. In some cases, the first region of the guide RNA can comprise approximately 10 to 25 nucleotides (i.e., 10 nucleotides to nucleotides, or about 10 nucleotides to about 25 nucleotides, or 10 nucleotides to about 25 nucleotides, or about 10 nucleotides to 25 nucleotides) or more. For example, the region of base-pairing between the first region of the guide RNA and the target site in a chromosomal sequence can be approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, or more nucleotides in length. Sometimes, the first region of the guide RNA can be approximately 19, 20, or 21 nucleotides in length.
[0199] The guide RNA or guide polynucleotide may also include a second region that forms a secondary structure. For example, the secondary structure formed by the guide RNA may include a stem (or hairpin) and a loop. The lengths of the loop and stem may vary. For example, the loop may be approximately 3-10 nucleotides in length, and the stem may be approximately 6-20 base pairs in length. The stem may include one or more bulges of 1-10 or about 10 nucleotides in length. The total length of the second region may be approximately 16-60 nucleotides in length. For example, the loop may be approximately 4 nucleotides in length, and the stem may be approximately 12 base pairs in length.
[0200] The guide RNA or guide polynucleotide may include a third region at its 3' end, which may be essentially single-stranded. For example, the third region may sometimes not be complementary to any chromosomal sequence in the target cell, and sometimes not complementary to the remainder of the guide RNA. Furthermore, the length of the third region may vary. The third region may be greater than approximately 4 nucleotides in length. For example, the length of the third region may range from approximately 5 to 60 nucleotides in length.
[0201] The guide RNA or guide polynucleotide can target any exon or intron of the gene target. In some cases, the guide can target exon 1 or 2 of the gene. In other cases, the guide can target exon 3 or 4 of the gene. The composition can contain multiple guide RNAs that all target the same exon, and in some cases, multiple guide RNAs that can target different exons. The exons and introns of the gene can be targeted.
[0202] The guide RNA or guide polynucleotide can target a nucleic acid sequence of approximately 20 nucleotides. The target nucleic acid can be less than approximately 20 nucleotides. The target nucleic acid can be at least approximately 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or any length between 1 and 100 nucleotides. The target nucleic acid can be at most approximately 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, or any length between 1 and 100 nucleotides. The target nucleic acid sequence can be approximately 20 bases 5' to the first nucleotide of the PAM. The guide RNA can target a nucleic acid sequence. The target nucleic acid can be at least approximately 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, 1-90, or 1-100 nucleotides.
[0203] A guide polynucleotide, e.g., a guide RNA, can refer to a nucleic acid that can hybridize to another nucleic acid, e.g., a target nucleic acid or a protospacer in the genome of a cell. A guide polynucleotide can be RNA. A guide polynucleotide can be DNA. A guide polynucleotide can be programmed or designed to bind to a nucleic acid sequence in a site-specific manner. A guide polynucleotide can include one polynucleotide strand and be referred to as a single guide polynucleotide. A guide polynucleotide can include two polynucleotide strands and be referred to as a double guide polynucleotide. A guide RNA can be introduced into a cell or embryo as an RNA molecule. For example, the RNA molecule can be transcribed in vitro and / or chemically synthesized. The RNA can be transcribed from a synthetic DNA molecule, e.g., a gBlocks® gene fragment. The guide RNA can then be introduced into a cell or embryo as an RNA molecule. A guide RNA can also be introduced into a cell or embryo in the form of a non-RNA nucleic acid molecule, e.g., a DNA molecule. For example, DNA encoding the guide RNA can be operably linked to a promoter regulatory sequence for expression of the guide RNA in the cell or embryo of interest. The RNA coding sequence can be operably linked to a promoter sequence recognized by RNA polymerase III (Pol III). Plasmid vectors that can be used to express guide RNA include, but are not limited to, px330 vector and px333 vector. In some cases, a plasmid vector (such as a px333 vector) can contain at least two guide RNA coding DNA sequences.
[0204] Methods for selecting, designing, and validating guide polynucleotides, e.g., guide RNAs, and target sequences are described herein and are known to those skilled in the art. For example, to minimize the impact of potential substrate hybridization of the deaminase domain (e.g., the AID domain) in a nucleobase editor system, the number of residues that may be unintentionally targeted for deamination (e.g., off-target C residues that may be present on ssDNA in the target nucleic acid locus) may be minimized. Furthermore, software tools can be used to optimize gRNAs corresponding to target nucleic acid sequences, e.g., to minimize overall off-target activity across the genome. For example, for each possible target domain using S. pyogenes Cas9, all off-target sequences (preceding a selected PAM, e.g., NAG or NGG) containing up to a certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base pairs may be identified across the genome. The first region of the gRNA complementary to the target site can be identified, and all first regions (e.g., crRNAs) can be ranked according to their overall predicted off-target scores. The top ranked targeting domains represent those likely to have the greatest on-target and least off-target activity. Candidate targeting gRNAs can be functionally evaluated using methods known in the art and / or described herein.
[0205] As a non-limiting example, target DNA hybridizing sequences in the crRNA of guide RNAs for use with Cas9 may be identified using a DNA sequence search algorithm. gRNA design may be performed using custom gRNA design software based on the public tool cas-offinder, described in Bae S., Park J., & Kim J.-S. Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473-1475 (2014). This software scores guides by calculating their genome-wide off-target propensity. Typically, matches ranging from perfect matches to seven mismatches are considered for guides ranging in length from 17 to 24. Once off-target sites are determined computationally, a combined score is calculated for each guide and summarized in a tabular output using a web interface. In addition to identifying potential target sites adjacent to the PAM sequence, the software also identifies all PAM-flanking sequences that differ from the selected target site by 1, 2, 3, or more than 3 nucleotides. A target nucleic acid sequence, such as a genomic DNA sequence for a target gene, is obtained, and repeat elements are screened using publicly available tools, such as the RepeatMasker program. RepeatMasker searches the input DNA sequence for repeated elements and low-complexity regions. A detailed annotation of the repeats present in a given query sequence is output.
[0206] Following identification, the first region of the guide RNA, e.g., crRNA, may be ranked in stages based on its distance to the target site, its orthogonality, and the presence of a 5' nucleotide for a close match to the relevant PAM sequence (e.g., a 5' G based on the identification of a close match in the human genome with a relevant PAM, e.g., an NGG PAM for S. pyogenes, or an NNGRRT or NNGRRV PAM for S. aureus). As used herein, orthogonality refers to the number of sequences in the human genome that contain the fewest mismatches to the target sequence. "High level of orthogonality" or "good orthogonality" may refer, for example, to a 20-mer target domain that has no identical sequences in the human genome other than the intended target and has no sequences that contain one or two mismatches in the target sequence. To minimize off-target DNA cleavage, target domains with good orthogonality may be selected.
[0207] In some embodiments, a reporter system may be used to test base editing activity and candidate guide polynucleotides. In some embodiments, the reporter system may include a reporter gene-based assay in which base editing activity results in expression of the reporter gene. For example, the reporter system may include a reporter gene containing an inactivated start codon, e.g., a mutation in the template strand from 3'-TAC-5' to 3'-CAC-5'. If the target C is successfully deaminated, the corresponding mRNA is transcribed as 5'-AUG-3' instead of 5'-GUG-3', allowing translation of the reporter gene. Suitable reporter genes will be apparent to those of skill in the art. Non-limiting examples of reporter genes include genes encoding green fluorescent protein (GFP), red fluorescent protein (RFP), luciferase, secreted alkaline phosphatase (SEAP), and any other gene whose expression is detectable and apparent to those of skill in the art. For example, many different gRNAs can be tested using the reporter system to determine which residues in the target DNA sequence each deaminase targets. To assess the off-target effects of a particular base-editing protein, such as a Cas9 deaminase fusion protein, sgRNAs targeting the non-template strand can also be tested. In some embodiments, such gRNAs can be designed so that a mutated start codon does not base-pair with the gRNA. The guide polynucleotide can contain standard ribonucleotides, modified ribonucleotides (e.g., pseudouridine), ribonucleotide isomers, and / or ribonucleotide analogs. In some embodiments, the guide polynucleotide can contain at least one detectable label. The detectable label can be a fluorophore (e.g., FAM, TMR, Cy3, Cy5, Texas Red, Oregon Green, Alexa Fluors, Halo Tags, or a suitable fluorescent dye), a detection tag (e.g., biotin, digoxigenin, etc.), a quantum dot, or a gold particle.
[0208] The guide polynucleotide can be chemically synthesized, enzymatically synthesized, or a combination thereof. For example, the guide RNA can be synthesized using standard phosphoramidite-based solid-phase synthesis methods. Alternatively, the guide RNA can be synthesized in vitro by operably linking the guide RNA-encoding DNA to a promoter regulatory sequence recognized by a phage RNA polymerase. Examples of suitable phage promoter sequences include T7, T3, and SP6 promoter sequences, or variations thereof. In embodiments where the guide RNA comprises two separate molecules (e.g., crRNA and tracrRNA), the crRNA can be chemically synthesized and the tracrRNA can be enzymatically synthesized.
[0209] In some embodiments, a base editor system may comprise multiple guide polynucleotides, e.g., gRNAs. For example, the gRNAs may target one or more target loci included in the base editor system (e.g., at least one gRNA, at least two gRNAs, at least five gRNAs, at least 10 gRNAs, at least 20 gRNAs, at least 30 gRNAs, at least 50 gRNAs). The multiple gRNA sequences may be arranged in tandem, preferably separated by direct repeats.
[0210] The DNA sequence encoding the guide RNA or guide polynucleotide may be part of a vector. Furthermore, the vector may contain additional expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcription termination sequences, etc.), selectable marker sequences (e.g., GFP or antibiotic resistance genes such as puromycin), origins of replication, etc. The DNA molecule encoding the guide RNA may be linear. The DNA molecule encoding the guide RNA or guide polynucleotide may be circular.
[0211] In some embodiments, one or more components of the base editor system may be encoded by DNA sequences. Such DNA sequences may be introduced together or separately into an expression system, e.g., a cell. For example, DNA sequences encoding a polynucleotide programmable nucleotide binding domain and a guide RNA are introduced into a cell, and each DNA sequence may be part of a separate molecule (e.g., one vector containing sequences encoding the polynucleotide programmable nucleotide binding domain and a second vector containing sequences encoding the guide RNA), or both may be part of the same molecule (e.g., one vector containing coding (and regulatory) sequences for both the polynucleotide programmable nucleotide binding domain and the guide RNA).
[0212] The guide polynucleotide may contain one or more modifications to provide new or improved characteristics to the nucleic acid. The guide polynucleotide may contain a nucleic acid affinity tag. The guide polynucleotide may contain synthetic nucleotides, synthetic nucleotide analogs, nucleotide derivatives, and / or modified nucleotides.
[0213] In some cases, the gRNA or guide polynucleotide may contain modifications. The modifications can be made at any position in the gRNA or guide polynucleotide. Two or more modifications can be made in a single gRNA or guide polynucleotide. The gRNA or guide polynucleotide can be subjected to quality control after modification. In some examples, quality control can include PAGE, HPLC, MS, or any combination thereof.
[0214] Modifications of the gRNA or guide polynucleotide can be substitutions, insertions, deletions, chemical modifications, physical modifications, stabilization, purification, or any combination thereof.
[0215] The gRNA or guide polynucleotide may be 5' adenylate, 5' guanosine triphosphate cap, 5' N7 methyl guanosine triphosphate cap, 5' triphosphate cap, 3' phosphate, 3' thiophosphate, 5' phosphate, 5' thiophosphate, Cis-Syn thymidine dimer, trimer, C12 spacer, C3 spacer, C6 spacer, d spacer, PC spacer, r spacer, spacer 18, spacer 9, 3'-3' modified, 5'-5' modified, abasic, acridine, azobenzene, biotin, biotin BB, biotin TEG, cholesteryl TEG, desthiobiotin TEG, DNP TEG, DNP-X, DOTA, dT-biotin, dual biotin, PC-biotin, psoralen C2, psoralen C6, TINA, 3'DABCYL, black hole quencher 1, black hole quencher 2, DABCYL SE, dT-DABCYL, IRDye The nucleic acid may also be modified with QC-1, QSY-21, QSY-35, QSY-7, QSY-9, a carboxyl linker, a thiol linker, a 2'-deoxyribonucleoside analog purine, a 2'-deoxyribonucleoside analog pyrimidine, a ribonucleoside analog, a 2'-O-methylribonucleoside analog, a sugar-modified analog, a wobble / universal base, a fluorescent dye label, a 2'-fluoroRNA, a 2'-O-methylRNA, a methylphosphonate, a phosphodiester DNA, a phosphodiester RNA, a phosphothioate DNA, a phosphorothioate RNA, a UNA, a pseudouridine-5'-triphosphate, a 5'-methylcytidine-5'-triphosphate, or any combination thereof.
[0216] In some cases, the modification is permanent. In other cases, the modification is transient. In some cases, multiple modifications are made to the gRNA or guide polynucleotide. The modification of the gRNA or guide polynucleotide can alter the physicochemical properties of the nucleotide, such as conformation, polarity, hydrophobicity, chemical reactivity, base pairing interaction, or any combination thereof.
[0217] The modification may be a phosphorothioate substitution. In some cases, native phosphodiester bonds may be susceptible to rapid degradation by cellular nucleases, and modification of the internucleotide linkage with a phosphorothioate (PS) bond substitution may be more stable to hydrolysis by cellular degradation. Modifications may increase the stability of the gRNA or guide polynucleotide. Modifications may also enhance biological activity. In some cases, phosphorothioate-enhanced RNA gRNAs can inhibit RNase A, RNase T1, bovine serum nuclease, or any combination thereof. These properties enable the use of PS-RNA gRNAs in applications where exposure to nucleases is likely in vivo or in vitro. For example, phosphorothioate (PS) bonds can be introduced between the last 3–5 nucleotides at the 5′ or 10′ end of the gRNA, which can inhibit exonucleolytic degradation. In some cases, phosphorothioate bonds can be added throughout the gRNA to reduce attack by endonucleases.
[0218] Protospacer adjacent motif The term "protospacer adjacent motif (PAM)" or PAM-like motif refers to a 2-6 base pair DNA sequence that directly follows the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system. In some embodiments, the PAM can be a 5' PAM (i.e., located upstream of the 5' end of the protospacer). In other embodiments, the PAM can be a 3' PAM (i.e., located downstream of the 5' end of the protospacer).
[0219] A protospacer adjacent motif (PAM) or PAM-like motif refers to a 2-6 base pair DNA sequence that directly follows the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system. In some embodiments, the PAM can be a 5' PAM (i.e., located upstream of the 5' end of the protospacer). In other embodiments, the PAM can be a 3' PAM (i.e., located downstream of the 5' end of the protospacer). The PAM sequence is important for target binding, but its exact sequence depends on the type of Cas protein.
[0220] Base editors provided herein can include a domain derived from a CRISPR protein that can bind to a nucleotide sequence containing a canonical or non-canonical protospacer adjacent motif (PAM) sequence. A PAM site is a nucleotide sequence adjacent to a target polynucleotide sequence. Some embodiments of the present disclosure provide base editors that include all or part of a CRISPR protein with various PAM specificities. For example, Cas9 proteins, such as S. pyogenes Cas9 (SpCas9), typically require a canonical NGG PAM sequence to bind to a specific nucleic acid region. Here, "N" in "NGG" is adenine (A), thymine (T), guanine (G), or cytosine (C), and G is guanine. The PAM can be CRISPR protein-specific and can vary among different base editors containing domains derived from different CRISPR proteins. The PAM can be 5' or 3' of the target sequence. The PAM can be upstream or downstream of the target sequence. A PAM can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides in length. PAMs are often 2-6 nucleotides in length.
[0221] In some embodiments, the Cas9 domain is a Streptococcus pyogenes Cas9 domain (SpCas9). In some embodiments, the SpCas9 domain is a nuclease-active SpCas9, a nuclease-inactive SpCas9 (SpCas9d), or a Cas9 nickase (SpCas9n). In some embodiments, the SpCas9 comprises a D9X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, where X is any amino acid except D. In some embodiments, the SpCas9 comprises a D9A mutation, or a corresponding mutation in any of the amino acid sequences provided herein. In some embodiments, the SpCas9 domain, SpCas9d domain, or SpCas9n domain is capable of binding to nucleic acid sequences with non-canonical PAMs. In some embodiments, the SpCas9 domain, SpCas9d domain, or SpCas9n domain is capable of binding to nucleic acid sequences with NGG, NGA, or NGCG PAM sequences. In some embodiments, the SpCas9 domain comprises one or more of D1135X, R1335X, and T1137X mutations, or corresponding mutations in any of the amino acid sequences provided herein, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of D1135E, R1335Q, and T1137R mutations, or corresponding mutations in any of the amino acid sequences provided herein. In some embodiments, the SpCas9 domain comprises D1135E, R1335Q, and T1137R mutations, or corresponding mutations in any of the amino acid sequences provided herein. In some embodiments, the SpCas9 domain comprises one or more of D1135X, R1335X, and T1137X mutations, or corresponding mutations in any of the amino acid sequences provided herein, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of the D1135V, R1335Q, and T1337R mutations, or the corresponding mutations in any of the amino acid sequences provided herein.In some embodiments, the SpCas9 domain comprises D1135V, R1335Q, and T1337R mutations, or corresponding mutations in any of the amino acid sequences provided herein. In some embodiments, the SpCas9 domain comprises one or more of D1135X, G1218X, R1335X, and T1337X mutations, or corresponding mutations in any of the amino acid sequences provided herein, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of D1135V, G1218R, R1335Q, and T1337R mutations, or corresponding mutations in any of the amino acid sequences provided herein. In some embodiments, the SpCas9. In some embodiments, the SpCas9 domain comprises D1135V, G1218R, R1335Q, and T1337R mutations, or corresponding mutations in any of the amino acid sequences provided herein.
[0222] In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cas9 polypeptide described herein. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any Cas9 polypeptide described herein. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any Cas9 polypeptide described herein.
[0223] The sequence of an exemplary SpCas9 protein that can bind to a PAM sequence is as follows:
[0224] Exemplary SpCas9
[0225] Exemplary SpCas9n
[0226] Exemplary SpEQR Cas9 E SPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK Q Y R STKEVLDATLIHQSITGLYETRIDLSQLGGD Residues E1135, Q1335, and R1337, which can be mutated from D1135, R1335, and T1337 to yield SpEQR Cas9, are underlined and in bold.
[0227] Exemplary SpVQR Cas9 V SPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK Q Y R STKEVLDATLIHQSITGLYETRIDLSQLGGD Residues V1135, Q1335, and R1337, which can be mutated from D1135, R1335, and T1337 to yield SpVQR Cas9, are underlined and in bold.
[0228] Exemplary SpVRER Cas9 V SPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELEGNRKRMLASA R ELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK E Y R STKEVLDATLIHQSITGLYETRIDLSQLGGD. Exemplary SpVRQR Cas9 V SPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASA R ELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRK Q Y R STKEVLDATLIHQSITGLYETRIDLSQLGGD. Residues V1135, R1218, Q1335, and R1337, which can be mutated from D1135, G1218, R1335, and T1337 to yield SpVRQR Cas9, are underlined and in bold.
[0229] In some embodiments, the Cas9 domain is a recombinant Cas9 domain. In some embodiments, the recombinant Cas9 domain is a SpyMacCas9 domain. In some embodiments, the SpyMacCas9 domain is a nuclease-active SpyMacCas9, a nuclease-inactive SpyMacCas9 (SpyMacCas9d), or a SpyMacCas9 nickase (SpyMacCas9n). In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain is capable of binding to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SpyMacCas9 domain, SpCas9d domain, or SpCas9n domain is capable of binding to a nucleic acid sequence having a NAA PAM sequence. Exemplary SpyMacCas9
[0230] High-fidelity Cas9 domain Some aspects of the present disclosure provide high-fidelity Cas9 domains. In some embodiments, the high-fidelity Cas9 domain is an engineered Cas9 domain that includes one or more mutations that reduce the electrostatic interaction between the Cas9 domain and the sugar-phosphate backbone of DNA compared to the corresponding wild-type Cas9 domain. Without wishing to be bound by any particular theory, a high-fidelity Cas9 domain with reduced electrostatic interactions with the sugar-phosphate backbone of DNA may have fewer off-target effects. In some embodiments, the Cas9 domain (e.g., a wild-type Cas9 domain) includes one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of DNA. In some embodiments, the Cas9 domain comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of the DNA by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70%.
[0231] In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of N497X, R661X, Q695X, and / or Q926X mutations, or corresponding mutations in any of the amino acid sequences provided herein, where X is any amino acid. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more of N497A, R661A, Q695A, and / or Q926A mutations, or corresponding mutations in any of the amino acid sequences provided herein. In some embodiments, the Cas9 domain comprises a D10A mutation, or corresponding mutations in any of the amino acid sequences provided herein. High-fidelity Cas9 domains are known in the art and will be apparent to those of skill in the art. For example, high-fidelity Cas9 domains are described in Kleinstiver, BP, et al. "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects." Nature 529, 490-495 (2016); and Slaymaker, IM, et al. "Rationally engineered Cas9 nucleases with improved specificity." Science 351, 84-88 (2015), the entire contents of each of which are incorporated herein by reference. High-fidelity Cas9 domain mutations to Cas9 are shown in bold and underlined. MDKKYSIGL AIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLNLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKIKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMT A FDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRIEMIEERLKTYAHLFDDKVMKQLKRRRYTGWG A LSRKLINGIRDKQSGKTILDFLKSDGFANRNFM A LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETR AITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRLKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD.
[0232] In some cases, the variant Cas9 protein has the following mutations: H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A, and thus the polypeptide has a reduced ability to cleave target DNA and RNA. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). As another non-limiting example, in some cases, the variant Cas9 protein has the following mutations: D10A, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A, and thus the polypeptide has a reduced ability to cleave target DNA (e.g., single-stranded target DNA). Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA). In some cases, when a variant Cas9 protein has the W476A and W1126A mutations, or when a variant Cas9 protein has the P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, the variant Cas9 protein does not efficiently bind to the PAM sequence. Thus, in some such cases, when such a variant Cas9 protein is used in a binding method, the method does not require a PAM sequence. In other words, in some cases, when such a variant Cas9 protein is used in a binding method, the method can include a guide RNA, but can be performed in the absence of a PAM sequence (thus, binding specificity is provided by the target segment of the guide RNA). Other residues (i.e., inactive residues or other nuclease moieties) can be mutated to achieve the above-mentioned effect. By way of non-limiting example, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and / or A987 can be altered (i.e., substituted). Also, mutations other than alanine substitutions are suitable.
[0233] In some embodiments, the CRISPR protein-derived domain of the base editor can include all or a portion of a Cas9 protein with a canonical PAM sequence (NGG). In other embodiments, the Cas9-derived domain of the base editor can employ a non-canonical PAM sequence. Such sequences are known in the art and will be apparent to those skilled in the art. For example, Cas9 domains that bind to non-canonical PAM sequences are described in Kleinstiver, BP, et al., "Engineered CRISPR-Cas9 nucleases with altered PAM specificities" Nature 523, 481-485 (2015); and Kleinstiver, BP, et al., "Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition" Nature Biotechnology 33, 1293-1298 (2015), the entire contents of each of which are incorporated herein by reference.
[0234] In some examples, the PAM recognized by the CRISPR protein-derived domain of a base editor disclosed herein can be provided to a cell on a separate oligonucleotide from the insert (e.g., AAV insert) encoding the base editor. In such cases, providing the PAM on a separate oligonucleotide allows for cleavage of a target sequence that would otherwise not be cleaved due to the absence of an adjacent PAM on the same polynucleotide as the target sequence.
[0235] In one embodiment, S. pyogenes Cas9 (SpCas9) can be used as a CRISPR endonuclease for genome manipulation. However, others may also be used. In some cases, different endonucleases can be used to target certain genomic targets. In some cases, synthetic SpCas9-derived variants with non-NGG PAM sequences can be used. Additionally, other Cas9 orthologs from various species have been identified, and these "non-SpCas9" can bind to various PAM sequences that may be useful in the present disclosure. For example, the relatively large size of SpCas9 (approximately 4 kb coding sequence) may result in a plasmid carrying the SpCas9 cDNA that cannot be efficiently expressed in cells. Conversely, the coding sequence of Staphylococcus aureus Cas9 (SaCas9) is approximately 1 kilobase shorter than SpCas9, potentially allowing it to be efficiently expressed in cells. Like SpCas9, the SaCas9 endonuclease can modify target genes in vitro in mammalian cells or in vivo in mice. In some cases, Cas proteins can target different PAM sequences. In some cases, target genes can be adjacent to a Cas9 PAM, such as 5'-NGG. In other cases, other Cas9 orthologs can have different PAM requirements. Other PAMs, such as those in S. thermophilus (5'-NNAGAA for CRISPR1 and 5'-NGGNG for CRISPR3) and Neisseria meningiditis (5'-NNNNGATT), can also be found adjacent to target genes.
[0236] In some embodiments, for S. pyogenes systems, the target gene sequence can precede (i.e., be 5' to) a 5'-NGG PAM, and a 20-nt guide RNA sequence can base-pair with the opposing strand to mediate Cas9 cleavage adjacent to the PAM. In some cases, the adjacent cleavage can be approximately 3 base pairs upstream of the PAM. In some cases, the adjacent cleavage can be approximately 10 base pairs upstream of the PAM. In some examples, the adjacent cleavage can be approximately 0-20 base pairs upstream of the PAM. For example, the adjacent cleavage can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 base pairs upstream of the PAM. The adjacent cleavage can also be 1-30 base pairs downstream of the PAM. Fusion proteins containing nuclear localization sequences (NLS) In some embodiments, the fusion proteins provided herein further comprise one or more (e.g., 2, 3, 4, 5) nuclear targeting sequences, e.g., nuclear localization sequences (NLSs). In one embodiment, a bicomponent NLS is used. In some embodiments, the NLS comprises an amino acid sequence that facilitates import of the protein comprising the NLS into a cell nucleus (e.g., by nuclear transport). In some embodiments, any of the fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 domain. In some embodiments, the NLS is fused to the C-terminus of the nCas9 domain or dCas9 domain. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker. In some embodiments, the NLS comprises the amino acid sequence of any one of the NLS sequences provided or referenced herein. Additional nuclear localization sequences are known in the art and will be apparent to those skilled in the art. For example, NLS sequences are described in PCT / EP2000 / 011690 to Plank et al., the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, the NLS comprises the amino acid sequence PKKKRKVEGADKRTADGSEFESPKKKRKV, KRTADGSEFESPKKKRKV, KRPAATKKAGQAKKKK, KKTELQTTNAENKTKKL, KRGINDRNFWRGENGRKTR, RKSGKIAAIVVKRPRKPKKKRKV, or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC. In some embodiments, the NLS is present within a linker, or the NLS is located adjacent to a linker, such as a linker described herein. In some embodiments, the N-terminal or C-terminal NLS is a two-component NLS.Two-component NLSs contain two clusters of basic amino acids separated by a relatively short spacer sequence (hence the two-component—two parts; one-component NLSs are not). The nucleoplasmic NLS, KR[PAATKKAGQA]KKKK, is a prototype of a ubiquitous two-component signal, consisting of two clusters of basic amino acids separated by a spacer of approximately 10 amino acids. The sequence of an exemplary two-component NLS is: PKKKRKVEGADKRTADGSEFES PKKKRKV.
[0237] In some embodiments, the fusion proteins of the invention do not comprise a linker sequence. In some embodiments, there is a linker sequence between one or more of the domains or proteins.
[0238] It should be appreciated that the fusion proteins of the present disclosure may include one or more additional features. For example, in some embodiments, the fusion protein may include an inhibitor, an export sequence such as a cytoplasmic localization sequence, a nuclear export sequence, or other localization sequence, as well as a sequence tag useful for solubilizing, purifying, or detecting the fusion protein. Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc tags, calmodulin tags, FLAG tags, hemagglutinin (HA) tags, polyhistidine tags, also known as histidine tags or His tags, maltose-binding protein (MBP) tags, nus tags, glutathione-S-transferase (GST) tags, green fluorescent protein (GFP) tags, thioredoxin tags, S tags, Softags (e.g., Softag1, Softag3), Strep tags, biotin ligase tags, F1AsH tags, V5 tags, and SBP tags. Additional suitable sequences will be apparent to those skilled in the art. In some embodiments, the fusion protein comprises one or more His tags.
[0239] A vector encoding a CRISPR enzyme containing one or more nuclear localization sequences (NLS) can be used. For example, approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 NLSs can be used. The CRISPR enzyme can contain an NLS at or near the amino terminus, approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLSs at or near the carboxy terminus, or any combination thereof (for example, one or more NLSs at the amino terminus and one or more NLSs at the carboxy terminus). When two or more NLSs are present, each can be selected independently from the others, and thus a single NLS can be present in two or more copies and / or in combination with one or more other NLSs present in one or more copies.
[0240] The CRISPR enzyme used in the method may contain about six NLSs. An NLS is considered to be proximal to the N- or C-terminus if the amino acid closest to the NLS is within about 50 amino acids, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, or 50 amino acids, along the polypeptide chain from the N- or C-terminus.
[0241] The PAM sequence can be any PAM sequence known in the art. Suitable PAM sequences include, but are not limited to, NGG, NGA, NGC, NGN, NGT, NGCG, NGAG, NGAN, NGNG, NGCN, NGCG, NGTN, NNGRRT, NNNRRT, NNGRR(N), TTTV, TYCV, TYCV, TATV, NNNNGATT, NNAGAAW, or NAAAAC. Y is a pyrimidine, N is any nucleotide base, and W is A or T.
[0242] Reduced exclusivity Cas9 domains Typically, Cas9 proteins, such as S. pyogenes Cas9 (spCas9), require a canonical NGG PAM sequence to bind to specific nucleic acid regions. Here, the "N" in "NGG" is adenosine (A), thymidine (T), or cytosine (C), and the G is guanosine. This can limit their ability to edit desired bases in the genome. In some embodiments, the base to be edited by the fusion proteins provided herein must be placed at a precise location, e.g., upstream of the PAM, in a region containing the target base. See, e.g., Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage," Nature 533, 420-424 (2016), the entire contents of which are incorporated herein by reference. Thus, in some embodiments, any of the fusion proteins provided herein may contain a Cas9 domain capable of binding to nucleotide sequences that do not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and will be apparent to those of skill in the art.For example, Cas9 domains that bind to non-canonical PAM sequences are described in Kleinstiver, B.P., et al., "Engineered CRISPR-Cas9 nucleases with altered PAM specificities" Nature 523, 481-485 (2015); and Kleinstiver, B.P., et al., "Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition" Nature Biotechnology 33, 1293-1298 (2015); Nishimasu, H., et al., "Engineered CRISPR-Cas9 nuclease with expanded targeting space" Science. 2018 Sep 21;361(6408):1259-1262, Chatterjee, P., et al., "Minimal PAM specificity of a highly similar SpCas9," the entire contents of each of which are incorporated herein by reference. ortholog” Sci Adv. 2018 Oct 24;4(10):eaau0766. doi: 10.1126 / sciadv.aau0766. Some PAM variants are listed in Table 1 below. Table 1. Cas9 proteins and corresponding PAM sequences [Table 1]
[0243] Nucleobase editing domain Described herein are base editors comprising fusion proteins comprising a polynucleotide-programmable nucleotide-binding domain and a nucleobase-editing domain (e.g., a deaminase domain). The base editor can be programmed to edit one or more bases in a target polynucleotide sequence by interacting with a guide polynucleotide capable of recognizing the target sequence. Once the target sequence is recognized, the base editor is anchored to the polynucleotide where editing is to occur, and the deaminase domain component of the base editor can then edit the target base.
[0244] In some embodiments, the nucleobase editing domain is a deaminase domain. In some cases, the deaminase domain can be a cytosine deaminase or a cytidine deaminase. In some embodiments, the terms "cytosine deaminase" and "cytidine deaminase" can be used interchangeably. In some cases, the deaminase domain can be an adenine deaminase or an adenosine deaminase. In some embodiments, the terms "adenine deaminase" and "adenosine deaminase" can be used interchangeably. Details of nucleobase editing proteins are described in International PCT Applications PCT / 2017 / 045381 (WO 2018 / 027078) and PCT / US2016 / 058344 (WO 2017 / 070632), each of which is incorporated herein by reference in its entirety. See also Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" Nature 533, 420-424 (2016); Gaudelli, NM, et al., "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage" Nature 551, 464-471 (2017); and Komor, AC, et al., "Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity" Science Advances 3:eaao4774 (2017), the entire contents of which are incorporated herein by reference.
[0245] C to T Edit In some embodiments, a base editor disclosed herein comprises a fusion protein comprising a cytidine deaminase that can deaminate a targeted cytidine (C) base in a polynucleotide to produce a uridine (U), which has the property of base-pairing with thymine. In some embodiments, for example, if the polynucleotide is double-stranded (e.g., DNA), the uridine base can then be replaced by a thymidine base (e.g., by the cellular repair machinery) to produce a C:G to T:A transition. In other embodiments, deamination of C to U in a nucleic acid by a base editor cannot be accompanied by a U to T substitution.
[0246] Deamination of a targeted C in a polynucleotide to produce a U is a non-limiting example of the type of base editing that can be performed by the base editors described herein. In another example, a base editor comprising a cytidine deaminase domain can mediate the conversion of a cytosine (C) base to a guanine (G) base. For example, a U in a polynucleotide produced by deamination of a cytidine by the cytidine deaminase domain of a base editor can be excised from the polynucleotide by a base excision repair mechanism (e.g., by a uracil DNA glycosylase (UDG) domain), generating an abasic site. The nucleobase opposite the abasic site can then be replaced (e.g., by a base repair machine) with another base, such as C, by, for example, a transresection polymerase. Typically, the nucleobase opposite the abasic site is replaced with C, although other substitutions (e.g., A, G, or T) are also possible.
[0247] Thus, in some embodiments, base editors described herein comprise a deamination domain (e.g., a cytidine deaminase domain) that can deaminate a targeted C in a polynucleotide to U. Additionally, as described below, base editors may comprise additional domains that facilitate converting the deamination-resulting U to T or G in some embodiments. For example, a base editor comprising a cytidine deaminase domain may further comprise a uracil glycosylase inhibitor (UGI) domain that mediates the replacement of U with T, completing the C to T base editing event. In another example, a base editor can incorporate a transregion polymerase to improve the efficiency of C to G base editing, as a transregion polymerase can facilitate the incorporation of a C opposite an abasic site (i.e., resulting in the incorporation of a G at the abasic site, completing the C to G base editing event).
[0248] Base editors that include a cytidine deaminase domain can deaminate a targeted C in any polynucleotide, including DNA, RNA, and DNA-RNA hybrids. Typically, cytidine deaminase catalyzes a C nucleobase located relative to a single-stranded portion of a polynucleotide. In some embodiments, the entire polynucleotide containing the targeted C can be single-stranded. For example, a cytidine deaminase incorporated into a base editor can deaminate a targeted C in a single-stranded RNA polynucleotide. In other embodiments, a base editor that includes a cytidine deaminase domain can act on a double-stranded polynucleotide, but the targeted C can be located in a portion of the polynucleotide that is single-stranded during the deamination reaction. For example, in embodiments in which the NAGPB domain includes a Cas9 domain, some nucleotides can remain unbase-paired during formation of the Cas9-gRNA-target DNA complex, resulting in the formation of a Cas9 "R-loop complex." These non-base-pairing nucleotides form bubbles of single-stranded DNA that can serve as substrates for single-strand-specific nucleotide deaminase enzymes (e.g., cytidine deaminase).
[0249] In some embodiments, the base editor cytidine deaminase can comprise all or part of a deaminase from the apolipoprotein B mRNA editing complex (APOBEC) family. Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) is an evolutionarily conserved family of cytidine deaminases. Members of this family are C-to-U editing enzymes. The N-terminal domain of APOBEC-like proteins is the catalytic domain, while the C-terminal domain is the pseudo-catalytic domain. More specifically, the catalytic domain is a zinc-dependent cytidine deaminase domain, which is important for cytidine deamination. APOBEC family members include APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D (now referred to as "APOBEC3E"), APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, and activation-induced (cytidine) deaminase. Several modified cytidine deaminases are commercially available, including, but not limited to, SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, VRER-BE3, YE1-BE3, EE-BE3, YE2-BE3, and YEE-BE3, which are available from Addgene (plasmids 85169, 85170, 85171, 85172, 85173, 85174, 85175, 85176, 85177). In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC1 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC2 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3A deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3B deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3C deaminase.In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3D deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3E deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3F deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3G deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3H deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC4 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an activation-induced deaminase (AID).
[0250] In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of cytidine deaminase 1 (CDA1). It is recognized that the base editor can comprise a deaminase from any suitable organism (e.g., human or rat). In some embodiments, the deaminase domain of the base editor is from human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase domain of the base editor is derived from rat (e.g., rat APOBEC1). In some embodiments, the deaminase domain of the base editor is human APOBEC1. In some embodiments, the deaminase domain of the base editor is pmCDA1.
[0251] The nucleotide sequence and amino acid sequence of PmCDA1 and the nucleotide sequence and amino acid sequence of the CDS of human AID are shown below.
[0252] >tr|A5H718|A5H718_PETMA Cytosine deaminase OS=Petromyzon marinus OX=7757 PE=2 SV=1 MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNKPQSG TERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRGNGHTLK IWACKLYYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQLNENRWLEKT LKRAEKRRSELSIMIQVKILHTTKSPAV >EF094822.1 Petromyzon marinus isolate PmCDA.21 cytosine deaminase mRNA, complete cds TGACACGACACAGCCGTGTATATGAGGAAGGGTAGCTGGATGGGGGGGGGGGGAATACGTTCAGAGAGGA CATTAGCGAGCGTCTTGTTGGTGGCCTTGAGTCTAGACACCTGCAGACATGACCGACGCTGAGTACGTGA GAATCCATGAGAAGTTGGACATCTACACGTTTAAGAAACAGTTTTTCAACAACAAAAAATCCGTGTCGCA TAGATGCTACGTTCTCTTTGAATTAAAACGACGGGGTGAACGTAGAGCGTGTTTTTGGGGCTATGCTGTG AATAAACCACAGAGCGGGACAGAACGTGGAATTCACGCCGAAATCTTTAGCATTAGAAAAGTCGAAGAAT ACCTGCGCGACAACCCCGGACAATTCACGATAAATTGGTACTCATCCTGGAGTCCTTGTGCAGATTGCGC TGAAAAGATCTTAGAATGGTATAACCAGGAGCTGCGGGGGAACGGCCACACTTTGAAAATCTGGGCTTGC AAACTCTATTACGAGAAAAATGCGAGGAATCAAATTGGGCTGTGGAACCTCAGAGATAACGGGGTTGGGT TGAATGTAATGGTAAGTGAACACTACCAATGTTGCAGGAAAATATTCATCCAATCGTCGCACAATCAATT GAATGAGAATAGATGGCTTGAGAAGACTTTGAAGCGAGCTGAAAAACGACGGAGCGAGTTGTCCATTATG ATTCAGGTAAAAATACTCCACACCACTAAGAGTCCTGCTGTTTAAGAGGCTATGCGGATGGTTTTC >tr|Q6QJ80|Q6QJ80_HUMAN Activation-induced cytidine deaminase OS=Homo sapiens OX=9606 GN=AICDA PE=2 SV=1 MDSLLMNRRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFSLDFGYLRNKNGCHVELL FLRYISDWDLDPGRCYRVTWFTSWSPCYDCARHVADFLRGNPNLSLRIFTARLYFCEDRK AEPEGLRRLHRAGVQIAIMTFKAPV >NG_011588.1:5001-15681 Homo sapiens activation induced cytidine deaminase (AICDA), RefSeqGene (LRG_17) on chromosome 12 AGAGAACCATCATTAATTGAAGTGAGATTTTTCTGGCCTGAGACTTGCAGGGAGGCAAGAAGACACTCTG GACACCACTATGGACAGGTAAAGAGGCAGTCTTCTCGTGGGTGATTGCACTGGCCTTCCTCTCAGAGCAA ATCTGAGTAATGAGACTGGTAGCTATCCCTTTCTCTCATGTAACTGTCTGACTGATAAGATCAGCTTGAT CAATATGCATATATTTTTTGATCTGTCTCCTTTTCTTCTATTCAGATCTTATACGCTGTCAGCCCAAT TCTTTCTGTTTCAGACTTCTCTTGATTTCCCTCTTTTCATGTGGCAAAAGAAGTAGTGCGTACAATGTA CTGATTCGTCCTGAGATTTGTACCATGGTTGAAACTAATTTATGGTAATAATATTAACATAGCAAATCTT TAGAGACTCAAATCATGAAAAGGTAATAGCAGTACTGTACTAAAAACGGTAGTGCTAATTTTCGTAATAA TTTTGTAAATATTCAAACAGTAAAACACTTGAAGACACACTTTCCTAGGGAGGCGTTTACTGAAATAATTT AGCTATAGTAAGAAAATTTGTAATTTTAGAAATGCCAAGCATTCTAAATTAATTGCTTGAAAGTCACTAT GATTGTGTCCATTATAAGGAGACAAATTCATTCAAGCAAGTTATTTAATGTTAAAGGCCCAATTGTTAGG CAGTTAATGGCACTTTTACTATTAACTAATCTTTCCATTTGTTCAGACGTAGCTTAACTTACCTCTTAGG TGTGAATTTGGTTAAGGTCCTCATAATGTCTTTATGTGCAGTTTTTGATAGGTTATTGTCATAGAACTTA TTCTATTCCTACATTTTATGATTACTATGGATGTATGAGAATAACACCTAATCCTTTACTTTACCTCAAT TTAACTCCTTTATAAAGAACTTACATTACAGAATAAAGATTTTTTAAAAAATATTTTTTGTAGGACA GGGTCTTAGCCCAGCCGAGGCTGGTCTCTAAGTCCTGGCCCAAGCGATCCTCCTGCCTGGGCCTCCTAAA GTGCTGGAATTATAGACATGAGCCATCACATCCAATATACAGAATAAAGATTTTTAATGGAGGATTTAAT GTTCTTCAGAAAATTTTCTTGAGGTCAGACAATGTCAAATGTCTCCTCAGTTTACACTGAGATTTTGAAA ACAAGTCTGAGCTATAGGTCCTTGTGAAGGGTCCATTGGAAATACTTGTTCAAAGTAAAATGGAAAGCAA AGGTAAAATCAGCAGTTGAAATTCAGAGAAAGACAGAAAAGGAGAAAAGATGAAATTCAACAGGACAGAA GGGAAATATATTATCATTAAGGAGGACAGTATCTGTAGAGCTCATTAGTGATGGCAAAATGACTTGGTCA GGATTATTTTTAACCCGCTTGTTTCTGGTTTGCACGGCTGGGGATGCAGCTAGGGTTCTGCCTCAGGGAG CACAGCTGTCCAGAGCAGCTGTCAGCCTGCAAGCCTGAAACACTCCCTCGGTAAAGTCCTTCCTACTCAG GACAGAAATGACGAGAACAGGGAGCTGGAAACAGGCCCCTAACCAGAGAAGGGAAGTAATGGATCAACAA AGTTAACTAGCAGGTCAGGATCACGCAATTCATTTCACTCTGACTGGTAACATGTGACAGAAACAGTGTA GGCTTATTGTATTTTCATGTAGAGTAGGACCCAAAAATCCACCCAAAGTCCTTTATCTATGCCACATCCT TCTTATCTATACTTCCAGGACACTTTTTCTTCCTTATGATAAGGCTCTCTCTCTCTCCACACACACACAC ACACACACACACACACACACACACACACACACAAACACACACCCCGCCAACCAAGGTGCATGTAAAAAGA TGTAGATTCCTCTGCCTTTCTCATCTACACAGCCCAGGAGGGTAAGTTAATATAAGAGGGATTTATTGGT AAGAGATGATGCTTAATCTGTTTAACACTGGGCCTCAAAGAGAGAATTTCTTTTCTTCTGTACTTATTAA GCACCTATTATGTGTTGAGCTTATATATACAAAGGGTTATTATATGCTAATATAGTAATAGTAATGGTGG TTGGTACTATGGTAATTACCATAAAAATTATTATCCTTTTAAAATAAAGCTAATTATTATTGGATCTTTT TTAGTATTCATTTTATGTTTTTTATGTTTTTGATTTTTTAAAAGACAATCTCACCCTGTTACCCAGGCTG GAGTGCAGTGGTGCAATCATAGCTTTCTGCAGTCTTGAACTCCTGGGCTCAAGCAATCCTCCTGCCTTGG CCTCCCAAAGTGTTGGGATACAGTCATGAGCCACTGCATCTGGCCTAGGATCCATTTAGATTAAAATATG CATTTTAAATTTTAAAATAATATGGCTAATTTTTACCTTATGTAATGTGTATACTGGCAATAAATCTAGT TTGCTGCCTAAAGTTTAAAGTGCTTTCCAGTAAGCTTCATGTACGTGAGGGGAGACATTTAAAGTGAAAC AGACAGCCAGGTGTGGTGGCTCACGCCTGTAATCCCAGCACTCTGGGAGGCTGAGGTGGGTGGATCGCTT GAGCCCTGGAGTTCAAGACCAGCCTGAGCAACATGGCAAAACGCTGTTTCTATAACAAAAATTAGCCGGG CATGGTGGCATGTGCCTGTGGTCCCAGCTACTAGGGGGCTGAGGCAGGAGAATCGTTGGAGCCCAGGAGG TCAAGGCTGCACTGAGCAGTGCTTGCGCCACTGCACTCCAGCCTGGGTGACAGGACCAGACCTTGCCTCA AAAAAATAAGAAGAAAAATTAAAAATAAATGGAAACAACTACAAAGAGCTGTTGTCCTAGATGAGCTACT TAGTTAGGCTGATATTTTGGTATTTAACTTTTAAAGTCAGGGTCTGTCACCTGCACTACATTATTAAAAT ATCAATTCTCAATGTATATCCACACAAAGACTGGTACGTGAATGTTCATAGTACCTTTATTCACAAAACC CCAAAGTAGAGACTATCCAAATATCCATCAACAAGTGAACAAATAAACAAAATGTGCTATATCCATGCAA TGGAATACCACCCTGCAGTACAAAGAAGCTACTTGGGGATGAATCCCAAAGTCATGACGCTAAATGAAAG AGTCAGACATGAAGGAGGAGATAATGTATGCCATACGAAATTCTAGAAAATGAAAGTAACTTATAGTTAC AGAAAGCAAATCAGGGCAGGCATAGAGGCTCACACCTGTAATCCCAGCACTTTGAGAGGCCACGTGGGAA GATTGCTAGAACTCAGGAGTTCAAGACCAGCCTGGGCAACACAGTGAAACTCCATTCTCCACAAAAATGG GAAAAAAAGAAAGCAAATCAGTGGTTGTCCTGTGGGGAGGGGAAGGACTGCAAAGAGGGAAGAAGCTCTG GTGGGGTGAGGGTGGTGATTCAGGTTCTGTATCCTGACTGTGGTAGCAGTTTGGGGTGTTTACATCCAAA AATATTCGTAGAATTATGCATCTTAAATGGGTGGAGTTTACTGTATGTAAATTATACCTCAATGTAAGAA AAAATAATGTGTAAGAAAACTTTCAATTCTCTTGCCAGCAAACGTTATTCAAATTCCTGAGCCCTTTACT TCGCAAATTCTCTGCACTTCTGCCCCGTACCATTAGGTGACAGCACTAGCTCCACAAATTGGATAAATGC ATTTCTGGAAAAGACTAGGGACAAAATCCAGGCATCACTTGTGCTTTCATATCAACCATGCTGTACAGCT TGTGTTGCTGTCTGCAGCTGCAATGGGGACTCTTGATTTCTTTAAGGAAACTTGGGTTACCAGAGTATTT CCACAAATGCTATTCAAATTAGTGCTTATGATATGCAAGACACTGTGCTAGGAGCCAGAAAACAAAGAGG AGGAGAAATCAGTCATTATGTGGGAACAACATAGCAAGATATTTAGATCATTTTGACTAGTTAAAAAAGC AGCAGAGTACAAAATCACACATGCAATCAGTATAATCCAAATCATGTAAATATGTGCCTGTAGAAAGACT AGAGGAATAAACACAAGAATCTTAACAGTCATTGTCATTAGACACTAAGTCTAATTATTATTATTAGACA CTATGATATTTGAGATTTAAAAAATCTTTAATATTTTAAAATTTAGAGCTCTTCTATTTTTCCATAGTAT TCAAGTTTGACAATGATCAAGTATTACTCTTTCTTTTTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTTT TGGTCTTGTTGCCCATGCTGGAGTGGAATGGCATGACCATAGCTCACTGCAACCTCCACCTCCTGGGTTC AAGCAAAGCTGTCGCCTCAGCCTCCCGGGTAGATGGGATTACAGGCGCCCACCACCACACTCGGCTAATG TTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAGAGG ATCCACCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGATGTAGGCCACTGCGCCCGGCCAAGTATTGC TCTTATACATTAAAAAACAGGTGTGAGCCACTGCGCCCAGCCAGGTATTGCTCTTATACATTAAAAAATA GGCCGGTGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAAGCCAAGGCGGGCAGAACACCCGAGGT CAGGAGTCCAAGGCCAGCCTGGCCAAGATGGTGAAACCCCGTCTCTATTAAAAATACAAACATTACCTGG GCATGATGGTGGGCGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGGATCCGCGGAGCCTGGCA GATCTGCCTGAGCCTGGGAGGTTGAGGCTACAGTAAGCCAAGATCATGCCAGTATACTTCAGCCTGGGCG ACAAAGTGAGACCGTAACAAAAAAAAAAAAATTTAAAAAAAGAAATTTAGATCAAGATCCAACTGTAAAA AGTGGCCTAAACACCACATTAAAGAGTTTGGAGTTTATTCTGCAGGCAGAAGAGAACCATCAGGGGGTCT TCAGCATGGGAATGGCATGGTGCACCTGGTTTTTGTGAGATCATGGTGGTGACAGTGTGGGGAATGTTAT TTTGGAGGGACTGGAGGCAGACAGACCGGTTAAAAGGCCAGCACAACAGATAAGGAGGAAGAAGATGAGG GCTTGGACCGAAGCAGAGAAGAGCAAACAGGGAAGGTACAAATTCAAGAAATATTGGGGGGTTGAATCA ACACATTTAGATGATTAATTAAATATGAGGACTGAGGAATAAGAAATGAGTCAAGGATGGTTCCAGGCTG CTAGGCTGCTTACCTGAGGTGGCAAAGTCGGGAGGAGTGGCAGTTTAGGACAGGGGGCAGTTGAGGAATA TTGTTTTGATCATTTTGAGTTTGAGGTACAAGTTGGACACTTAGGTAAAGACTGGAGGGGAAATCTGAAT ATACAATTATGGGGACTGAGGAACAAGTTTTTTATTTTTTGTTTCGTTTTCTTGTTGAAGAACAAATTT AATTGTAATCCCAAGTCATCAGCATCTAGAAGACAGTGGCAGGAGGTGACTGTCTTGTGGGTAAGGGTTT GGGGTCCTTGATGAGTATCTCTCAATTGGCCTTAAATATAAGCAGGAAAAGGAGTTTATGATGGATTCCA GGCTCAGCAGGGCTCAGGGAGGGCTCAGGCAGCCAGCAGAGGAAGTCAGAGCATCTTCTTTGGTTTAGCCCC AAGTAATGACTTCCTTAAAAAAGCTGAAGGAAAATCCAGAGTGACCAGATTATAAACTGTACTCTTGCATT TTCTCTCCCTCCTTCACCCACAGCCTCTTGATCGAACCGGAGGAAGTTTCTTTACCAATTCAAAAATGTC CGCTGGGCTAAGGGTCGGCGTGAGACCTACCTGTGCTACGTAGTGAAGAGGCGTGACAGTGCTACATCCT TTTCACTGGACTTTGGTTATCTTCGCAATAAGGTATCAATTAAAGTCGGCTTTGCAAGCAGTTTAATGGT CAACTGTGAGTGCTTTTAGAGCCACCTGCTGATGGTATTACTTCCATCCTTTTTTGGCATTTGTGTCTCT ATCACATTCCTCAAATCCTTTTTTTTATTTCTTTTTCCATGTCCATGCACCCATATTAGACATGGCCCAA AATATGTGATTTAATTCCTCCCCAGTAATGCTGGGCACCCTAATACCACTCCTTCCTTCAGTGCCAAGAA CAACTGCTCCCAAACTGTTTACCAGCTTTCCTCAGCATCTGAATTGCCTTTGAGATTAATTAAGCTAAAA GCATTTTTATATGGGAGAATATTATCAGCTTGTCCAAGCAAAAATTTTAAATGTGAAAAACAAATTGTGT CTTAAGCATTTTTGAAAATTAAGGAAGAAGAATTTGGGAAAAAATTAACGGTGGCTCAATTCTGTCTTCC AAATGATTTCTTTTCCCTCCTACTCACATGGGTCGTAGGCCAGTGAATACATTCAACATGGTGATCCCCA GAAAACTCAGAGAAGCCTCGGCTGATGATTAATTAAATTGATCTTTCGGCTACCCGAGAGAATTACATTT CCAAGAGACTTCTTCACCAAAATCCAGATGGGTTTACATAAACTTCTGCCCACGGGTATCTCCTCTCTCC TAACACGCTGTGACGTCTGGGCTTGGTGGAATCTCAGGGAAGCATCCGTGGGGTGGAAGGTCATCGTCTG GCTCGTTGTTTGATGGTTATATTACCATGCAATTTTCTTTGCCTACATTTGTATTGAATACATCCCAATC TCCTTCCTATTCGGTGACATGACACATTCTATTTCAGAAGGCTTTGATTTTATCAAGCACTTTCATTTAC TTCTCATGGCAGTGCCTATTACTTCTCTTACAATACCCATCTGTCTGCTTTACCAAAATCTATTTCCCCT TTTCAGATCCTCCCAAATGGTCCTCATAAACTGTCCTGCCTCCACCTAGTGGTCCAGGTATATTTCCACA ATGTACATCAACAGGCACTTCTAGCCATTTTCCTTCCAAAAGGTGCAAAAAGCAACTTCATAAACACA AATTAAATCTTCGGTGAGGTAGTGTGATGCTGCTTCCTCCCAACTCAGCGCACTTCGTCTTCCTCATTCC ACAAAAACCCATAGCCTTCCTTCACTCTGCAGGACTAGTGCTGCCAAGGGTTCAGCTCTACCTACTGGTG TGCTCTTTTGAGCAAGTTGCTTAGCCTCTCTGTAACAAGGACAATAGCTGCAAGCATCCCCAAAGATC ATTGCAGGAGACAATGACTAAGGCTACCAGAGCCGCAATAAAAGTCAGTGAATTTTAGCGTGGTCCTCTC TGTCTCTCCAGAACGGCTGCCACGTGGAATTGCTCTTCCTCCGCTACATCTCGGACTGGGACCTAGACCC TGGCCGCTGCTACCGCGTCACCTGGTTCACCTCCTGGAGCCCCTGCTACGACTGTGCCCGACATGTGGCC GACTTTCTGCGAGGGAACCCCAACCTCAGTCTGAGGATCTTCACCGCGCGCCTCTACTTCTGTGAGGACC GCAAGGCTGAGCCCGAGGGGCTGCGGCGGCTGCACCGCGCCGGGTGCAAATAGCCATCATGACCTTCAA AGGTGCGAAAGGGCCTTCCGCGCAGGCGCAGTGCAGCAGCCCGCATTCGGGATTGCGATGCGGAATGAAT GAGTTAGTGGGGAAGCTCGAGGGGAAGAAGTGGGCGGGGATTCTGGTTCACCTCTGGAGCCGAAATTAAA GATTAGAAGCAGAGAAAAGAGTGAATGGCTCAGAGACAAGGCCCCGAGGAAATGAGAAAATGGGGCCAGG GTTGCTTCTTTCCCCTCGATTTGGAACCTGAACTGTCTTCTACCCCCATATCCCCGCCTTTTTTTCCTTT TTTTTTTTTTGAAGATTATTTTTACTGCTGGAATACTTTTGTAGAAAACCACGAAAGAACTTTCAAAGCC TGGGAAGGGCTGCATGAAAATTCAGTTCGTCTCTCCAGACAGCTTCGGCGCATCCTTTTGGTAAGGGGCT TCCTCGCTTTTTAAATTTTCTTTCTTTCTCTACAGTCTTTTTTGGAGTTTCGTATATTTCTTATATTTTC TTATTGTTCAATCACTCTCAGTTTTCATCTGATGAAAACTTTATTTCTCCTCCACATCAGCTTTTTCTTC TGCTGTTTCACCATTCAGAGCCCTCTGCTAAGGTTCCTTTTCCCTCCCTTTTCTTTCTTTTGTTGTTTCA CATCTTTAAATTTCTGTCTCTCCCCAGGGTTGCGTTTCCTTCCTGGTCAGAATTCTTTTCTCCTTTTTTT TTTTTTTTTTTTTTTTTTTTAAACAAACAAACAAAAAACCCAAAAAAACTCTTTCCCAATTTACTTTCTT CCAACATGTTACAAAGCCATCCACTCAGTTTAGAAGACTCTCCGGCCCCACCGACCCCCAACCTCGTTTT GAAGCCATTCACTCAATTTGCTTCTCTCTTTCTCTACAGCCCCTGTATGAGGTTGATGACTTACGAGACG CATTTCGTACTTTGGGACTTTGATAGCAACTTCCAGGAATGTCACACACGATGAAATATCTCTGCTGAAG ACAGTGGATAAAAAAACAGTCCTTCAAGTCTTCTCTGTTTTTATTCTTCAACTCTCACTTTCTTAGAGTTT ACAGAAAAATATTTATATACGACTCTTTAAAAAGATCTATGTCTTGAAAATAGAGAAGGAACACAGGTC TGGCCAGGGACGTGCTGCAATTGGTGCAGTTTTGAATGCAACATTGTCCCCTACTGGGAATAACAGAACT GCAGGACCTGGGAGCATCCTAAAGTGTCAACGTTTTTCTATGACTTTTAGGTAGGATGAGAGCAGAAGGT AGATCCTAAAGCATGGTGAGAGGATCAAATGTTTTTATATCAAACATCCTTTATTATTTGATTCATTTG AGTTAACAGTGGTGTTAGTGATAGATTTTTCTATTCTTTTCCCTTGACGTTTACTTTCAAGTAACACAAA CTCTTCCATCAGGCCATGATCTATAGGACCTCCTAATGAGAGTATCTGGGTGATTGTGACCCCAAACCAT CTCTCCAAAGCATTAATATCCAATCATGGCCTGTAGTTTTAATCAGCAGAAGCATGTTTTTATGTTTGT ACAAAAGAAGATTGTTATGGGTGGGGATGGAGGTATAGACCATGCATGGTCACCTTCAAGCTACTTTAAT AAAGGATCTTAAAATGGGCAGGAGGACTGTGAACAAGACACCCTAATAATGGGTTGATGTCTGAAGTAGC AAATCTTCTGGAAACGCAAACTCTTTTAAGGAAGTCCCTAATTTAGAAACACCCACAAACTTCACATATC ATAATTAGCAAACAATTGGAAGGAAGTTGCTTGAATGTTGGGGAGAGGAAAATCTATTGGCTCTCGTGGG TCTCTTCATCTCAGAAATGCCAATCAGGTCAAGGTTTGCTACATTTTGTGTGTGTGATGCTTCTCCCA AAGGTATATTAACTATATAAGAGTTGTGACAAAACAGAATGATAAAGCTGCGAACCGTGGCACACGCT CATAGTTCTAGCTGCTTGGGAGGTTGAGGAGGGAGGATGGCTTGAACACAGGTGTTCAAGGCCAGCCTGG GCAACATAACAAGATCCTGTCTCTCAAAAAAAAAAAAAAAAAAGAAAGAGAGGGCCGGGCGTGGTG GCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGCCGGGCGGATCACCTGTGGTCAGGAGTTTGAGA CCAGCCTGGCCAACATGGCAAAACCCCGTCTGTACTCAAAATGCAAAAATTAGCCAGGCGTGGTAGCAGG CACCTGTAATCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTTGAACCCAGGAGGTGGAGGTTGCA GTAAGCTGAGATCGTGCCGTTGCACTCCAGCCTGGGCGACAAGAGCAAGACTCTGTCTCAGAAAAAAAAA AAAAAAAGAGAGAGAGAGAAAGAGAACAATTTGGGAGAGAAGGATGGGAAGCATTGCAAGGAAAT TGTGCTTTATCCAACAAAATGTAAGGAGCCAATAAGGGATCCCTATTTGTCTCTTTGGTGTCTATTTGT CCCTAACAACTGTCTTTGACAGTGAGAAAAATATTCAGAATAACCATATCCCTGTGCCGTTATTACCTAG CAACCCTTGCAATGAAGATGAGCAGATCCACAGGAAAACTTGAATGCACAACTGTCTTATTTTAATCTTA TTGTACATAAGTTTGTAAAAGAGTTAAAAATTGTTACTTCATGTATTCATTTATATTTTATATTATTTTG CGTCTAATGATTTTTTATTAACATGATTTCCTTTTCTGATATATTGAAATGGAGTCTCAAAGCTTCATAA ATTTATAACTTTAGAAATGATTCTAATAACAACGTATGTAATTGTAACATTGCAGTAATGGTGCTACGAA GCCATTTCTCTTGATTTTTAGTAAACTTTTATGACAGCAAATTTGCTTCTGGCTCACTTTCAATCAGTTA AATAAATGATAAATAATTTTGGAAGCTGTGAAGATAAAATACCAAATAAAATAATATAAAAGTGATTTAT ATGAAGTTAAAATAAAAAATCAGTATGATGGAATAAACTTG
[0253] Other exemplary deaminases that can be fused to Cas9 according to aspects of the present disclosure are provided below. It should be understood that in some embodiments, domains lacking the activity domain of the respective sequence, such as a localization signal (nuclear export signal, nuclear localization sequence, cytoplasmic localization signal), can be used. Human AID: TIFF0007596259000007.tif31170 (Underline: Nuclear localization sequence, Double underline: Nuclear export signal) Mouse AID: TIFF0007596259000008.tif30170 (Underline: nuclear localization sequence, double underline: nuclear export signal) Dog AID: TIFF0007596259000009.tif31170 (Underline: nuclear localization sequence, double underline: nuclear export signal) Bovine AID: TIFF0007596259000010.tif31170 (Underline: nuclear localization sequence, double underline: nuclear export signal) Rat AID TIFF0007596259000011.tif38170 (Underline: nuclear localization sequence, double underline: nuclear export signal) Mouse APOBEC-3 TIFF0007596259000012.tif59170 (Italics: nucleic acid editing domain) Rat APOBEC-3: TIFF0007596259000013.tif62170 (italics: nucleic acid editing domain) Rhesus macaque APOBEC-3G: TIFF0007596259000014.tif53170 (italics: nucleic acid editing domain, underline: cytoplasmic localization signal) Chimpanzee APOBEC-3G: TIFF0007596259000015.tif53170 (italics: nucleic acid editing domain, underline: cytoplasmic localization signal) Green monkey APOBEC-3G: TIFF0007596259000016.tif53170 (italics: nucleic acid editing domain, underline: cytoplasmic localization signal) Human APOBEC-3G: TIFF0007596259000017.tif55169 (italics: nucleic acid editing domain, underline: cytoplasmic localization signal) Human APOBEC-3F: TIFF0007596259000018.tif53169 (italics: nucleic acid editing domain) Human APOBEC-3B: TIFF0007596259000019.tif53169 (italics: nucleic acid editing domain) Rat APOBEC-3B: MQPQGLGPNAGMGPVCLGCSHRRPYSPIRNPLKKLYQQTFYFHFKNVRYAWGRKNNFLCYEVNGMDCALPVPLRQGVFRKQGHIHAELCFIYWFHDKV LRVLSPMEFKVTWYMSWSPCSKCAEQVARFLAAHRNLSLAIFSSRLYYYLRNPNYQQKLCRLIQEGVHVAAMDLPEFKKCWNKFVDNDGQPFRPWMRL RINFSFYDCKLQEIFSRMNLLREDVFYLQFNNSHRVKPVQNRYYRRKSYLCYQLERANGQEPLKGYLLYKKGEQHVEILFLEKMRSMELSQVRITCYLT WSPCPNCARQLAAFKKDHPDLILRIYTSRLYFWRKKFQKGLCTLWRSGIHVDVMDLPQFADCWTNFVNPQRPFRPWNELEKNSWRIQRRLRRIKESWGL Bovine APOBEC-3B: DGWEVAFRSGTVLKAGVLGVSMTEGWAGSGHPGQGACVWTPGTRNTMNLLREVLFKQQFGNQPRVPAPYYRRKTYLCYQLKQRNDLTLDRGCFRNKKQRHAERFIDKINSLDL NPSQSYKIICYITWSPCPNCANELVNFITRNNHLKLEIFASRLYFHWIKSFKMGLQDLQNAGISVAVMTHTEFEDCWEQFVDNQSRPFQPWDKLEQYSASIRRRLQRILTAPI Chimpanzee APOBEC-3B: MNPQIRNPMEWMYQRTFYYNFENEPILYGRSYTWLCYEVKIRRGHSNLLWDTGVFRGQMYSQPEHHAEMCFLSWFCGNQLSAYKCFQITWFVSWTPCPDCVAKLAKFLAEHPNVTLTISAAR LYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYNEGQPFMPWYKFDDNYAFLHRTLKEIIRHLMDPDTFTFNFNNDPLVLRRHQTYLCYEVERLDNGTWVLMDQHMGFLCNEAKNL LCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGQVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQ ALSGRLRAILQVRASSLCMVPHHRPPPPPQSPGPCLPLCSEPPLGSLLPTGRPAPSLPFLTASFSFPPPASLPPLPSLSLSPGHLPVPSFHSLTSCSIQPPCSSRIRETEGWASVSKEGRDLG Human APOBEC-3C: TIFF0007596259000020.tif30169 (italics: nucleic acid editing domain) Gorilla APOBEC-3C3C TIFF0007596259000021.tif30170 Human APOBEC-3A: TIFF0007596259000022.tif31170 (italics: nucleic acid editing domain) Rhesus macaque APOBEC-3A: TIFF0007596259000023.tif31170 (Italics: nucleic acid editing domain) Bovine APOBEC-3A3A: TIFF0007596259000024.tif31170 (italics: nucleic acid editing domain) Human APOBEC-3H: TIFF0007596259000025.tif30170 (Italics: nucleic acid editing domain) Rhesus macaque APOBEC-3H: MALLTAKTFSLQFNNKRRVNKPYYPRKALLCYQLTPQNGSTPTRGHLKNKKKDHAEIRFINKIKSMGLDETQCYQVTCYLTWSPCPSCAGELVDFIKAHRHLNLRIFASRLYYHWRPNYQEGLLLLGCGSQVPVEVMGLPEFTDCWENFVDHKEPPSFNPSEKLEELDKNSQAIKRRLERIKSRSVDVLENGLRSLQLGPVTPSSSIRNSR Human APOBEC-3D: TIFF0007596259000026.tif52170 (italics: nucleic acid editing domain) Human APOBEC-1: MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKNTTNHVEVNFIKKFTSERDFHPSMSCSIITWFLSWSPCWECSQAIREFLSRHPGVTLVIYVAR LFWHMDQQNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQNHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR Mouse APOBEC-1: MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSVWRHTSQNTSNHVEVNFLEKFTTERYFRPNTRCSITWFLSWSPCGECSRAITEFLSRHPYVTLFI YIARLYHHTDQRNRQGLRDLISSGVTIQIMTEQEYCYCWRNFVNYPPSNEAYWPRYPHLWVKLYVLELYCIILGLPPCLKILRRKQPQLTFFTITLQTCHYQRIPPHLLWATGLK Rat APOBEC-1: MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELRKETCLLYEINWGGRHSIWRHTSQNTNKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTLFI YIARLYHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSPSNEAHWPRYPHLWVRLYVLELYCIILGLPPCLNILRRKQPQLTFFTIALQSCHYQRLPPHILWATGLK Human APOBEC-2: MAQKEEAAVATEAASQNGEDLENLDDPEKLKELIELPPFEIVTGERLPANFFKFQFRNVEYSSGRNKTFLCYVVEAQGKGGQVQASRGYLEDEHAAAHAEEAFFNTILPAFD PALRYNVTWYVSSSPCAACADRIIKTLSKTKNLRLLILVGRLFMWEEPEIQAALKKLKEAGCKLRIMKPQDFEYVWQNFVEQEEGESKAFQPWEDIQENFLYYEEKLADILK Mouse APOBEC-2: MAQKEEAAEAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVNFFKFQFRNVEYSSGRNKTFLCYVVEVQSKGGQAQATQGYLEDEHAGAHAEEAFFNTILPAFDPALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLILVSRLFMWEEPEVQAALKKLKEAGCKLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK Rat APOBEC-2: MAQKEEAAEAAPASQNGDDLENLEDPEKLKELIDLPPFEIVTGVRLPVNFFKFQFRNVEYSSGRNKTFLCYVVEAQSKGGQVQATQGYLEDEHAGAHAEEAFFNTILPAFDPALKYNVTWYVSSSPCAACADRILKTLSKTKNLRLLILVSRLFMWEEPEVQAALKKLKEAGCKLRIMKPQDFEYLWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADILK ウシ APOBEC-2: MAQKEEAAAAAEPASQNGEEVENLEDPEKLKELIELPPFEIVTGERLPAHYFKFQFRNVEYSSGRNKTFLCYVVEAQSKGGQVQASRGYLEDEHATNHAEEAFFNSIMPTFDPALRYMVTWYVSSSPCAACADRIVKTLNKTKNLRLLILVGRLFMWEEPEIQAALRKLKEAGCRLRIMKPQDFEYIWQNFVEQEEGESKAFEPWEDIQENFLYYEEKLADIK Petromyzon marinus CDA1 (pmCDAl) MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNK PQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRG NGHTLKIWACKLYYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQ LNENRWLEKTLKRAEKRRSELSFMIQVKILHTTKSPAV ヒト APOBEC3G D316R D317R MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQ VYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDP KVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKF NYDEFQHCWSKFVYSQ RELFEPWNNLPKYYILLHFMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVER MHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTC FTSWSPCFSCAQEMAKFISK KHVSLCIFTARIYRRQGRCQEGLRTLAEAGAKISF T YSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN ヒト APOBEC3G chain A MDPPTFTFNFNNEPWWGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHG FLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI FTARIYDDQGRCQEGLRTLAEAGAKISF TYSEFKHCWDTFVDHQGCPFQPWDGLD EHSQDLSGRLRAILQ ヒト APOBEC3G chain A D120R D121R MDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHG FLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCI FTARIYRRQGRCQEGLRTLAEAGAKISFMTYSEFKHCWDTFVDHQGCPFQPWDGLDE HSQDLSGRLRAILQ
[0254] Some aspects of the present disclosure are based on the recognition that modulating the catalytic activity of the deaminase domain of any of the fusion proteins described herein (e.g., by creating point mutations in the deaminase domain) affects the processivity of the fusion protein (e.g., a base editor). For example, mutations that reduce, but do not eliminate, the catalytic activity of the deaminase domain in a base editing fusion protein can make it less likely that the deaminase domain will catalyze the deamination of residues adjacent to a targeted residue, thereby narrowing the deamination window. The ability to narrow the deamination window can prevent undesired deamination of residues adjacent to a particular targeted residue, thereby reducing or preventing off-target effects.
[0255] For example, in some embodiments, an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase, where X is any amino acid. In some embodiments, an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
[0256] In some embodiments, the APOBEC deaminase incorporated into the base editor can comprise one or more mutations selected from the group consisting of D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase, where X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprise an APOBEC deaminase that comprises one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
[0257] In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise the H121R and H122R mutations of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase comprising the R126A mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase comprising the R126E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase comprising the R118A mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W90A mutation in rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W90Y mutation in rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the R132E mutation in rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W90Y and R126E mutations in rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the R126E and R132E mutations of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the W90Y and R132E mutations of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the W90Y, R126E, and R132E mutations of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
[0258] In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the D316R and D317R mutations in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase that comprises the R320A mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the R320E mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the R313A mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W285A mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W285Y mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the R326E mutation in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase that comprises the W285Y and R320E mutations in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the R320E and R326E mutations in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the W285Y and R326E mutations in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, an APOBEC deaminase incorporated into a base editor may comprise an APOBEC deaminase that comprises the W285Y, R320E, and R326E mutations in hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
[0259] Several modified cytidine deaminases are commercially available, including, but not limited to, SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, VRER-BE3, YE1-BE3, EE-BE3, YE2-BE3, and YEE-BE3, which are available from Addgene (plasmids 85169, 85170, 85171, 85172, 85173, 85174, 85175, 85176, 85177).
[0260] Other exemplary deaminases that can be fused to Cas9 according to aspects of the present disclosure are provided below. It should be understood that in some embodiments, the active domain of each sequence can be used, for example, a localization signal (nuclear export signal, cytoplasmic localization signal, nuclear localization sequence).
[0261] Details of C to T nucleobase editing proteins are described in International PCT Application No. PCT / US2016 / 058344 (WO 2017 / 070632) and Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" Nature 533, 420-424 (2016), the entire contents of which are incorporated herein by reference.
[0262] Editing A to G In some embodiments, base editors described herein can comprise a deaminase domain comprising an adenosine deaminase. Such an adenosine deaminase domain of a base editor can facilitate editing of an adenine (A) nucleobase to a guanine (G) nucleobase by deaminating the adenine (A) to form inosine (I), which exhibits the base pairing properties of guanine (G). Adenosine deaminase can deaminate (i.e., remove the amino group from) the adenine of deoxyadenosine residues in deoxyribonucleic acid (DNA).
[0263] In some embodiments, nucleobase editors provided herein can be generated by fusing one or more protein domains together to produce a fusion protein. In certain embodiments, the fusion proteins provided herein include one or more features that improve the base editing activity (e.g., efficiency, selectivity, and specificity) of the fusion protein. For example, the fusion proteins provided herein can include a Ca9 domain with reduced nuclease activity. In some embodiments, the fusion proteins provided herein can include a Cas9 domain without nuclease activity (dCas9) or a Cas9 domain termed Cas9 nickase (nCas9) that cleaves one strand of a double-stranded DNA molecule. Without wishing to be bound by any particular theory, the presence of a catalytic residue (e.g., H840) maintains the activity of Cas9 to cleave the unedited (i.e., non-deaminated) strand containing the T opposite the targeted A. Mutation of the catalytic residue of Cas9 (e.g., from D10 to A10) prevents cleavage of the edited strand containing the targeted A residue. Such Cas9 variants can generate a single-stranded DNA break (nick) at a specific position based on the target sequence defined by the gRNA, resulting in repair of the unedited strand and ultimately a T to C change in the unedited strand. In some embodiments, the A to G base editor further comprises an inhibitor of inosine base excision repair, such as a uracil glycosylase inhibitor (UGI) domain or a catalytically inactive inosine-specific nuclease. Without wishing to be bound by any particular theory, the UGI domain or catalytically inactive inosine-specific nuclease can inhibit or prevent base excision repair of deaminated adenosine residues (e.g., inosine), thereby improving the activity or efficiency of the base editor.
[0264] Base editors comprising adenosine deaminase can act on any polynucleotide, including DNA, RNA, or DNA-RNA hybrids. In certain embodiments, base editors comprising adenosine deaminase can deaminate target A in polynucleotides comprising RNA. For example, a base editor may comprise an adenosine deaminase domain capable of deaminating target A in RNA polynucleotides and / or DNA-RNA hybrid polynucleotides. In one embodiment, the adenosine deaminase incorporated into the base editor comprises all or a portion of an adenosine deaminase acting on RNA (ADAR, e.g., ADAR1 or ADAR2). In another embodiment, the adenosine deaminase incorporated into the base editor comprises all or a portion of an adenosine deaminase acting on tRNA (ADAT). Base editors comprising an adenosine deaminase domain can also deaminate A nucleobases in DNA polynucleotides. In one embodiment, the adenosine deaminase domain of a base editor comprises all or a portion of ADAT comprising one or more mutations that allow the ADAT to deaminate a target A in DNA. For example, a base editor may comprise all or a portion of Escherichia coli ADAT (EcTadA) comprising one or more of the following mutations: D108N, A106V, D147Y, E155V, L84F, H123Y, I157F, or a corresponding mutation in another adenosine deaminase.
[0265] The adenosine deaminase can be from any suitable organism. In some embodiments, the adenosine deaminase is from a prokaryote. In some embodiments, the adenosine deaminase is from a bacterium. In some embodiments, the adenosine deaminase is from Escherichia coli, Staphylococcus aureus, Salmonella typhi, Shewanella putrefaciens, Haemophilus influenzae, Caulobacter crescentus, or Bacillus subtilis. In some embodiments, the adenosine deaminase is from E. coli. In some embodiments, the adenosine deaminase is a naturally occurring adenosine deaminase that includes one or more mutations corresponding to any of the mutations provided herein (e.g., mutations in ecTadA). Corresponding residues in any homologous proteins can be identified, for example, by sequence alignment and determination of homologous residues. Thus, mutations in any naturally occurring adenosine deaminase (e.g., having homology to ecTadA) that correspond to any of the mutations described herein (e.g., any of the mutations identified in ecTadA) can be generated.
[0266] TadA In certain embodiments, the TadA is any one of the TadAs described in PCT / US2017 / 045381 (WO 2018 / 027078), which is incorporated by reference in its entirety.
[0267] In one embodiment, a fusion protein of the invention comprises wild-type TadA linked to TadA7.10, where TadA7.10 is linked to a Cas9 nickase. In certain embodiments, the fusion protein comprises a single Tad7.10 domain (e.g., provided as a monomer). In other embodiments, the ABE7.10 editor comprises TadA7.10 and TadA(wt), which can form a heterodimer. The corresponding sequences are as follows: SEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIKAQKKAQSSTD This is referred to as the "TadA reference sequence" or wild-type TadA (TadA(wt)). TadA7.10: SEVEFSHEYW MRHALTLAKR ARDEREVPVG AVLVLNNRVI GEGWNRAIGL HDPTAHAEIM ALRQGGLVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNAKT GAAGSLMDVL HYPGMNHRVE ITEGILADEC AALLCYFFRM PRQVFNAQKK AQSSTD
[0268] In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences described for any of the adenosine deaminases provided herein. It is recognized that the adenosine deaminases provided herein may comprise one or more mutations (e.g., any of the mutations provided herein). The present disclosure provides any deaminase domain having a certain percentage of identity as well as any of the mutations described herein or combinations thereof. In some embodiments, the adenosine deaminase comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to a reference sequence, or any of the adenosine deaminases provided herein. In some embodiments, the adenosine deaminase comprises an amino acid sequence having at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical contiguous amino acid residues compared to any one of the amino acid sequences known in the art or described herein.
[0269] In some embodiments, the TadA deaminase is a full-length E. coli TadA deaminase. For example, in one embodiment, the adenosine deaminase has the amino acid sequence: MRRAFITGVFFLSE...
Claims
1. 1. An in vitro or ex vivo method of editing a MECP2 polynucleotide that contains a single nucleotide polymorphism (SNP) associated with Rett Syndrome (RTT), comprising contacting the MECP2 polynucleotide with a base editor complexed with one or more guide polynucleotides, wherein the base editor comprises: and an adenosine deaminase domain of SpCas9, wherein the napDNAbp domain of SpCas9 has protospacer adjacent motif (PAM) specificity for the nucleic acid sequence 5'-NGT-3', wherein the napDNAbp domain of SpCas9 comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:42 and further comprises the following amino acid substitutions numbered as follows in SEQ ID NO:42: D1135V or D1135L; G1218R or G1218S; E1219F or F1219V; A1322R; R1335V or R1335Q; and T1337F, T1337H, T1337I, T1337K, T1337L, T1337M, T1337N, T1337Q, T1337R, T1337S, or T1337V, wherein one or more of said guide polynucleotides targets said base editor to effect an A.T to G.C modification of said SNP associated with RTT, wherein said SNP associated with RTT is a c.763C>T or a c.916C>T mutation in a MECP2 polynucleotide.
2. The method of claim 1, wherein the SNP results in expression of a Mecp2 protein containing the amino acid modification R255* or R306C.
3. 3. The method of claim 2, wherein the A.T to G.C modification of the SNP associated with RTT changes a cysteine to an arginine or a stop codon to an arginine in the Mecp2 protein.
4. The napDNAbp domain of SpCas9 a) further comprising the amino acid substitution L1111R according to the numbering in SEQ ID NO: 42 and an amino acid substitution selected from the group consisting of D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, and D1332R; or b) the following amino acid substitutions according to numbering in SEQ ID NO:42: D1135L; S1136R; G1218S or G1218R; E1219V or E1219F; A1322R; R1335Q; and T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, or T1337M and further comprising an amino acid substitution selected from the group consisting of D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, and D1332R. The method of claim 1.
5. 5. The method of any one of claims 1 to 4, wherein the adenosine deaminase domain comprises an adenosine deaminase consisting of the following TadA*7.10 amino acid sequence: SEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD.
6. 6. The method of any one of claims 1 to 5, wherein the one or more guide polynucleotides comprise a CRISPR RNA (crRNA) and a transcoding small RNA (tracrRNA), wherein the crRNA comprises a nucleic acid sequence complementary to the MECP2 polynucleotide.
7. A base editor comprising a nucleic acid programmable DNA binding protein (napDNAbp) domain of SpCas9 and an adenosine deaminase domain, wherein the napDNAbp domain of SpCas9 has protospacer adjacent motif (PAM) specificity for the nucleic acid sequence 5'-NGT-3', wherein the napDNAbp domain of SpCas9 comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:42 and further comprises the following amino acid substitutions in the numbering of SEQ ID NO:42: D1135V or D1135L; G1218R or G1218S; E1219F or F1219V; A1322R; R1335V or R1335Q; and T1337F, T1337H, T1337I, T1337K, T1337L, T1337M, T1337N, T1337Q, T1337R, T1337S, or T1337V A base editor, or a polynucleotide encoding the base editor, And one or more guide polynucleotides that target the base editor to result in an A.T to G.C modification of a SNP associated with RTT, wherein the SNP associated with RTT is a c.763C>T or a c.916C>T mutation in a MECP2 polynucleotide. A cell or a precursor thereof, in vitro or ex vivo.
8. The cell of claim 7 , wherein the cell is a neuron that expresses a Mecp2 polypeptide.
9. The cell of claim 7 or 8, wherein the cell is a mammalian cell.
10. The cell according to any one of claims 7 to 9, wherein the SNP results in expression of a Mecp2 protein comprising the amino acid modification R255* or R306C.
11. The cell of claim 10, wherein the A.T to G.C modification of the RTT-associated SNP changes a cysteine to an arginine or a stop codon to an arginine in the Mecp2 protein.
12. The napDNAbp domain of SpCas9 a) the numbering in SEQ ID NO: 42 further comprises the amino acid substitution L1111R and an amino acid substitution selected from the group consisting of D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, and D1332R; or b) the following amino acid substitutions according to numbering in SEQ ID NO:42: D1135L; S1136R; G1218S or G1218R; E1219V or E1219F; A1322R; R1335Q; and T1337L, T1337I, T1337V, T1337F, T1337S, T1337N, T1337K, T1337R, T1337H, T1337Q, or T1337M and further comprising an amino acid substitution selected from the group consisting of D1332A, D1332S, D1332T, D1332V, D1332L, D1332K, and D1332R. The cell described in claim 7.
13. 10. The cell of claim 7, wherein the adenosine deaminase domain comprises an adenosine deaminase consisting of the following TadA*7.10 amino acid sequence: SEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD.
14. 14. The cell of any one of claims 7 to 13, wherein the one or more guide polynucleotides comprise a CRISPR RNA (crRNA) and a transcoding small RNA (tracrRNA), wherein the crRNA comprises a nucleic acid sequence complementary to the MECP2 polynucleotide.
15. 15. A composition comprising a cell according to any one of claims 7 to 14 for use in a method of treating RTT in a subject, said method comprising administering said cell to said subject.
Citation Information
Patent Citations
Adenosine nucleobase editors and uses thereof
WO2018027078A1
